Skin compositions and methods of use thereof

Abstract

The present invention provides a formulation for application to the skin and pharmaceutical uses of the formulations of the invention. The present invention also provides methods of delivering a medicament to a subject and kits for treating a subject having a skin condition.

Description

[0001] This application is a divisional application of Chinese Patent Application No. 201610825596.8, filed August 31, 2011, entitled "Skin Compositions and Methods of Using the Same," which is a divisional application of Chinese Patent Application No. 201180041794.0, filed August 31, 2011, entitled "Skin Compositions and Methods of Using the Same."

[0002] RELATED APPLICATIONS

[0003] This application claims the benefit of U.S. Provisional Patent Application No. 61 / 500,455, filed June 23, 2011; U.S. Provisional Patent Application No. 61 / 499,002, filed June 20, 2011; U.S. Provisional Patent Application No. 61 / 496,420, filed June 13, 2011; U.S. Provisional Patent Application No. 61 / 493,020, filed June 3, 2011; U.S. Provisional Patent Application No. 61 / 489,119, filed May 23, 2011; U.S. Provisional Patent Application No. 61 / 486,643, filed May 16, 2011; U.S. Provisional Patent Application No. 61 / 472,995, filed April 7, 2011; U.S. Provisional Patent Application No. 61 / 446,337, filed February 24, 2011; U.S. Provisional Patent Application No. 61 / 432,458, filed January 13, 2011; U.S. Provisional Patent Application No. 61 / 412,531, filed November 11, 2010; and U.S. Provisional Patent Application No. 61 / 378,504, filed August 31, 2010. The entire contents of the foregoing applications are hereby incorporated by reference. BACKGROUND

[0004] Current methods for reducing the appearance of skin imperfections, such as wrinkles, fine lines, age spots, enlarged pores, or scars, include invasive and non-invasive methods and formulations. Invasive techniques such as surgery, fillers (e.g., Restylane, Juvederm), laser resurfacing, or More permanent effects can be provided and more prominent imperfections can be treated. However, many consumers cannot afford or do not want to undergo such aggressive cosmetic treatments.

[0005] Examples of non-invasive methods include hiding the defect by applying a foundation-type cosmetic to the skin or applying a cosmetic preparation that includes ingredients that can reduce the appearance of the defect over time (e.g., an anti-wrinkle cream). Unfortunately, foundation cosmetics are not durable and cannot reduce the appearance of significant skin defects, such as deep wrinkles or scars, while cosmetic preparations containing ingredients that can reduce the appearance of defects take time to take effect and also cannot reduce the appearance of significant defects. In particular, many current cosmetic preparations do not have the desired mechanical properties to reduce the appearance of significant defects.

[0006] High molecular weight polymers, including proteins and polysaccharides, have been tried for developing anti-aging skin care cosmetic preparations (Jachowicz et al., Skin Res. and Tech., 2008, 14:312-319). While these polymers change the physical properties of the skin (e.g., elasticity and stiffness) when applied to the skin, they do not provide durability to achieve the natural repetition of facial movements that are lost with aging. Currently available polymeric materials for skin care products do not necessarily provide elasticity, environmental resistance, and skin adhesion for long-lasting product properties, and they also do not provide the aesthetic feel and appearance that consumers of cosmetic products desire. SUMMARY

[0007] The present invention provides a non-invasive composition that is durable with a natural appearance that exhibits desired aesthetic characteristics and reduces the appearance of skin and body defects, while providing cosmetic results that are typically achieved by more invasive, dermatologist-administered procedures, if at all.

[0008] In one embodiment, the present invention provides a non-invasive body correction preparation that forms a body correction film upon application to a subject, thereby improving a body defect. The present invention also provides methods of using such body correction preparations. In another embodiment, the present invention provides a cleanser to remove the film.

[0009] Thus, in one embodiment, the present invention is directed, at least in part, to a body correction preparation for application to the skin of a subject: comprising a) a reactive enhancing component; and b) a crosslinking component; wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a body correction film on the skin of the subject and the film has the appearance of natural skin.

[0010] In one embodiment, the present invention is directed, at least in part, to a two-part body correction preparation for application to the skin of a subject: comprising a) a reactive enhancing component; and b) a crosslinking component; wherein the reactive enhancing component and the crosslinking component are prevented from contacting prior to use; and wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a body correction film on the skin of the subject.

[0011] In one embodiment, the present application provides, at least in part, a body correction formulation for application to the skin of a subject comprising a) a reactive enhancing component; and b) a crosslinking component; wherein the reactive enhancing component has a viscosity of about 5,000 to about 1,000,000 cSt or cP at 25°C; and wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a body correction film on the skin of the subject.

[0012] In one embodiment, the present application provides, at least in part, a body correction formulation for application to the skin of a subject comprising a) a reactive enhancing component; and b) a crosslinking component; wherein the reactive enhancing component has a viscosity of about 5,000 to about 1,000,000 cSt or cP at 25°C; and wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a body correction film on the skin of the subject.

[0013] In one embodiment, the present application provides, at least in part, a body correction formulation for application to the skin of a subject comprising a) a reactive enhancing component; and b) a crosslinking component; wherein the reactive enhancing component has a viscosity of about 5,000 to about 1,000,000 cSt or cP at 25°C; and wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a body correction film on the skin of the subject.

[0014] In one embodiment, the present application provides, at least in part, a body correction formulation for application to the skin of a subject comprising a) a reactive enhancing component; and b) a crosslinking component; wherein the reactive enhancing component has a viscosity of about 5,000 to about 1,000,000 cSt or cP at 25°C; and wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a body correction film on the skin of the subject.

[0015] In one embodiment, the present application provides, at least in part, a body correction formulation for application to the skin of a subject comprising a) a reactive enhancing component; and b) a crosslinking component; wherein the reactive enhancing component has a viscosity of about 5,000 to about 1,000,000 cSt or cP at 25°C; and wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a body correction film on the skin of the subject.

[0016] In one embodiment, the present application provides, at least in part, a body correction formulation for application to the skin of a subject comprising a) a reactive enhancing component; and b) a crosslinking component; wherein the reactive enhancing component has a viscosity of about 5,000 to about 1,000,000 cSt or cP at 25°C; and wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a body correction film on the skin of the subject.

[0017] In one embodiment, the present application provides, at least in part, a body correction formulation for application to the skin of a subject comprising a) a reactive enhancing component; and b) a crosslinking component; wherein the reactive enhancing component has a viscosity of about 5,000 to about 1,000,000 cSt or cP at 25°C; and wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a body correction film on the skin of the subject.

[0018] In one embodiment, the present application is directed, at least in part, to a method for delivering a medicament to a subject comprising applying to the skin of the subject a formulation comprising a) a first reactive enhancing component optionally comprising one or more medicaments; and b) a second crosslinking component optionally comprising one or more medicaments; wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a film on the skin, thereby delivering the medicament to the subject.

[0019] In one embodiment, the present application is directed, at least in part, to a body correction formulation for application to the body of a subject comprising at least one preselected functional modulating component, wherein the composition forms a body correction film upon application to the body of the subject.

[0020] In one embodiment, the present application is directed, at least in part, to a body correction formulation for application to the skin of a subject targeting a treatment area on the body of the subject comprising at least one preselected treatment specific component, wherein the composition forms a body correction film upon application to the targeted treatment area on the body of the subject.

[0021] In one embodiment, the present application is directed, at least in part, to a film removal cleanser for removing a body correction film, wherein the film is prepared by a method comprising the steps of applying a reactive enhancing component to the skin; and applying a crosslinking component to the reactive enhancing component, and wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component.

[0022] In another embodiment, the present application is directed, at least in part, to a film removal cleanser comprising a film wetting component, a penetrating component, a film swelling component, and a film removing component.

[0023] In some embodiments, the present application is directed to a formulation for repairing a body correction film for application to the skin, wherein the formulation comprises a) a first reactive enhancing component and b) a second crosslinking component, wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a film on the skin.

[0024] In some embodiments, the present application is directed, at least in part, to a method for repairing a body correction film applied to the skin comprising the steps of a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation for repairing the film, wherein the formulation comprises a first reactive enhancing component and a second crosslinking component, wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a film on the skin, thereby repairing the body correction film.

[0025] In some embodiments, the present application relates at least in part to a kit for repairing a body correction membrane, the kit comprising a formulation comprising a) a first reactive enhancing component and b) a second cross-linking component, wherein the cross-linking component catalyzes in situ cross-linking of the reactive enhancing component to form a membrane on the skin. SUMMARY

[0026] Figure 1 is a graph showing the change in Young's modulus of the skin after application of the formulation of the present application. The change in Young's modulus indicates a decrease in the stiffness of the skin upon application of the formulation.

[0027] Figure 2 is a graph showing the change in retraction time after application of the formulation of the present application. The change in retraction time indicates that the skin is more elastic upon application of the formulation.

[0028] Figure 3 is a graph showing the evaluation of two formulations by a researcher for attributes in a randomized double-blind clinical trial. The formulations are provided in Example 5. The attributes rated include the degree of reduction in shine, pore size, deep wrinkles, and fine wrinkles. For all attributes, the application of both membranes provided an improvement in the 22 subjects evaluated. The four attributes are further detailed by treatment site. These sites are forehead, crows feet, under eye, and bridge of the nose ('number 11'). An improvement in each targeted treatment area was observed.

[0029] Figure 4 is a graph showing the evaluation of two formulations described in Example 5 by an evaluator for attributes in a randomized double-blind clinical trial. The evaluator's evaluation shows an improvement in each of the best attributes rated after the application of the formulations.

[0030] Figure 5 is a graph showing the evaluation of two formulations described in Example 5 by a panelist for attributes in a randomized double-blind clinical trial. The attributes evaluated are youthful appearance, oil control (or reduction in shine), pore size, even skin tone, taut skin appearance, and wrinkling. For each attribute, the panelists on average experienced an improvement in each benefit after treatment with the formulations.

[0031] Figure 6 is a graph showing the decrease in the average age of the panelists as determined by the evaluator. An overall age reduction of 8.7 years and 7.7 years was observed for Formulation 60-140-LX2 and Formulation 60-140-1, respectively.

[0032] Figure 7is a chart showing the average Griffith score results from blinded evaluation of photographs of panelists. The Griffith score is a standardized quantitative measure of the degree of photodamage, where a score of 0 corresponds to no photodamage and a score of 9 indicates severe photodamage. For both examples, the Griffith score decreased by 2.15 points and 1.25 points, respectively, after application of the formulations 60-140-LX2 and 60-140-1. This result is consistent with Figure 4 and 5 where the panelists appeared younger after application of the formulations. DETAILED DESCRIPTION

[0033] In some embodiments, the present application relates at least in part to a body- correcting formulation for application to skin, comprising a) a reactive enhancing component; and b) a crosslinking component; wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a body- correcting film on the skin.

[0034] The phrase "body-correcting formulation" or "formulation" includes a cosmetic composition that forms a film on the body that improves a body defect when applied to the body. The phrase "body defect" includes those portions of a subject's body that the subject perceives as flawed or defective, or where a skilled person, such as a dermatologist, cosmetologist, or plastic surgeon, would perceive as flawed or defective. The phrase "body defect" includes skin defects, as well as sagging of soft body tissue (e.g., sagging skin, sagging breasts, buttocks, abdomen, jaw, neck, etc.). The phrase "skin defect" includes those things on a subject's skin that the subject perceives as a flaw or defect. Examples of skin defects include port wine stains or nevus flammeus (e.g., nevus flammeus nuchae or midline nevus flammeus), melasma, wrinkles, blemishes, acne, moles, scars, tattoos, bruises, skin irregularities, birthmarks, sun damage, age damage, uneven skin tone, sagging skin, skin roughness, hyperpigmentation, enlarged pores, telangiectasia, redness, shine, cellulite, stretch marks, or loss of skin elasticity.

[0035] In one embodiment of the present application, the compositions, formulations, or films of the present application result in a visual and or tactile improvement in the properties of the skin. In certain embodiments, the compositions, formulations, or films of the present application conceal, mask, or camouflage, but do not treat, a skin or body defect of a subject.

[0036] In at least one embodiment, the skin or body defect does not include a wound or a skin condition.

[0037] The phrase "wound" includes a loss of skin where the skin is torn, cut, or punctured. A wound is a break in the skin. In one embodiment, a wound is caused by contact of the skin with a foreign object. The break in the skin can result in external bleeding. Wounds include open wounds, such as abrasions, lacerations, incisions, punctures, tears, or amputations. Wounds also include burn wounds. A burn is a type of injury to living tissue caused by heat, electricity, chemicals, light, radiation, or friction.

[0038] The phrase "skin condition" includes a condition that causes at least one symptom on the skin of a subject in need of medical treatment. In one embodiment, a skin condition is caused by an autoimmune condition. In another embodiment, a skin condition is caused by an environmental factor, such as an allergen or a chemical. Examples of symptoms of a skin condition in need of treatment are skin inflammation, skin itch, dry skin, crusting, blistering or breaking skin, skin swelling, or skin lesion formation. Skin conditions include, but are not limited to, chronic simple lichen, cutaneous lupus (e.g., acute cutaneous lupus, subacute cutaneous lupus, chronic cutaneous lupus, chilblain lupus, discoid lupus, lupus erythematosus-lichen planus overlap syndrome, lupus erythematosus panniculitis, tumid lupus erythematosus, and wart-like lupus erythematosus), psoriasis (e.g., psoriasis vulgaris, psoriasis erythrodemica, pustular psoriasis, drug-induced psoriasis, pustulosis palmoplantaris, seborrheic psoriasis, and guttate psoriasis), eczema (e.g., atopic eczema, atopic dermatitis, contact dermatitis, asteatotic eczema, seborrheic dermatitis, dyshidrotic eczema, discoid eczema, venous eczema, nummular eczema, neurodermatitis, and autoeczematization), or chronic dry skin.

[0039] In some embodiments, the body correction formulation is a skin correction formulation. The phrase "skin correction formulation" includes a cosmetic composition that forms a film on the skin that improves a skin defect when applied to the skin. In some embodiments, the improvement is a complete improvement or a partial improvement. One of skill in the art will be able to determine the extent of improvement of one or more body defects by using the method described in Example 6.

[0040] In some embodiments, the body correction formulation is a body shaping formulation. A body shaping formulation includes a cosmetic composition that forms a body shaping film on the skin of a subject when applied to the skin.

[0041] In some embodiments, the body correction formulation is a skin protection formulation. A skin protection formulation includes a cosmetic composition that forms a protective film on the skin of a subject when applied to the skin.

[0042] In some embodiments, the body correction formulation can deliver a cosmetic or therapeutic agent to a subject in need thereof.

[0043] In some embodiments, the body correction formulation is used to repair a body correction film.

[0044] In one embodiment, the body-correcting formulation includes a reactive enhancing component and a crosslinking component. The term "reactive enhancing component" includes a component that forms the basis of a body-correcting film when applied to the skin as a first component, the body-correcting film being formed upon application of the crosslinking component to the reactive enhancing component. In one embodiment, the reactive enhancing component includes at least one reactive ingredient and at least one enhancing ingredient.

[0045] The term "reactive component" includes one or more components of a reactive enhancing component that provides a reactive film-forming element for the formulation. In some embodiments, the reactive component includes at least one polysiloxane, polyethylene oxide, polypropylene oxide, polyurea, polyurethane, polyester (including polylactic acid-glycolic acid copolymer, polycaprolactone, polylactic acid, polyglycolic acid and polyhydroxybutyrate, polyamide or polysulfone). In another embodiment, the reactive component is a compound of formula I:

[0046]

[0047] in

[0048] W is R 1 R 2 R 3 SiO-、-OR 4 -NR 5 R 6 -CR 7 R 8 R 9 Or C 5-10 Aryl;

[0049] X is -R 11 R 12 Si-O-、-OCONR 13 -、-NR 14 CONR 15 -、-CO-、-NR 16 CO-, -SO2-, -O-, -S-, or -NR 17 -;

[0050] V does not exist, or C 1-20 Alkyl, C 2-20 alkenyl, C 5-10 Aryl, -O-, -NR 10 -or-S-;

[0051] Y is -R 18 R 19 Si-O-、-OCONR 20 -、-NR 21 CONR 22 -、-CO-、-NR23 CO-, -SO2-, -O-, -S-, or -NR 24 ;

[0052] Z is -SiR 25 R 26 R 27 , -OR 28 , -NR 29 R 30 , -CR 31 R 32 R 33 or C 5-10 aryl;

[0053] R 1 , R 2 , R 3 , R 7 , R 8 , R 9 , R 11 , R 12 , R 18 , R 19 , R 25 , R 26 , R 27 , R 31 , R 32 and R 33 are each independently hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl, or C 1-20 alkoxy;

[0054] R 4 , R 5 , R 6 , R 13 , R 14 , R 15 , R 16 , R 17 , R 20 , R 21 , R 22 , R 23 , R 24 , R 28 , R 29 and R 30 are each independently hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl; and

[0055] s and t are each independently an integer from about 0 to about 6000.

[0056] X and Y of Formula I represent independent "monomer units". The number of X and Y monomer units present in Formula I is provided by the values of s and t, respectively. Representative monomer units include:

[0057]

[0058] where R is as defined above for R 1 , R 2 , R 3 , etc.

[0059] It is understood that when more than one X (or Y) monomer unit is present (e.g., s (or t) is greater than 1), the value of R s for each individual monomer unit described by -[X] t - (or -[Y] 11 ) is independently selected. For example, if the value of monomer unit X is -R 12 , the value of R 13 , the value of R 14 , the value of R 15 , the value of R 16 , the value of R 17 , the value of R 18 , the value of R 19 , the value of R 20 , the value of R 21 , the value of R 22 , the value of R 23 , and the value of R 24 is independently selected. For example, if the value of monomer unit X is -R 11 R 12 Si-O- and the value of s is 3, then -[X] s - is

[0060] -[R 11 R 12 Si-O-R 11 R 12 Si-O-R 11 R 12 Si-O]-.

[0061] In this example, it is understood that the three R 11 groups present can be the same or different from one another, e.g., one R 11 may be hydrogen and the other two R 11 groups can be methyl.

[0062] W and Z of Formula I represent independent endcaps, each at one end of Formula I. For example, endcaps include:

[0063] where represents attachment to a monomer unit and where R is as defined above for R 1 , R 2 , R 3as defined above.

[0064] In one embodiment,

[0065] W is R 1 R 2 R 3 SiO-, -OR 4 , -NR 5 R 6 , -CR 7 R 8 R 9 or C 5-10 aryl;

[0066] X is -R 11 R 12 Si-O- or -NR 14 CONR 15 -;

[0067] V is absent, or C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, -O-, -NR 10 - or -S-;

[0068] Y is -R 18 R 19 Si-O- or -NR 21 CONR 22 -;

[0069] Z is -SiR 25 R 26 R 27 , -OR 28 , -NR 29 R 30 , -CR 31 R 32 R 33 or C 5-10 aryl;

[0070] R 1 , R 2 , R 3 , R 7 , R 8 , R 9 , R 11 , R 12 , R 18 , R 19 , R 25 , R 26 , R 27 , R 31 , R 32 and R 33 are each independently hydrogen, C 1-20alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxy, or C 1-20 alkoxy;

[0071] R 4 , R 5 , R 6 , R 14 , R 15 , R 21 , R 22 , R 28 , R 29 , and R 30 are each independently hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl; and

[0072] s and t are each independently an integer from about 0 to about 6000, wherein the sum of s and t is not 0.

[0073] In one embodiment,

[0074] W is R 1 R 2 R 3 SiO-, -CR 7 R 8 R 9 or C 5-10 aryl;

[0075] X is -R 11 R 12 Si-O- or -NR 14 CONR 15 -;

[0076] V is absent, or C 1-20 alkyl, C 2-20 alkenyl, or C 5-10 aryl;

[0077] Y is -R 18 R 19 Si-O- or -NR 21 CONR 22 -;

[0078] Z is -SiR 25 R 26 R 27 , -CR 31 R 32 R 33 or C 5-10 aryl;

[0079] R 1 , R 2 , R3 R 7 R 8 R 9 R 11 R 12 R 18 R 19 R 25 R 26 R 27 R 31 R 32 and R 33 Each is independently hydrogen, C 1-20 Alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 Alkoxy;

[0080] R 14 R 15 R 21 and R 22 Each is independently hydrogen, C 1-20 Alkyl, C 2-20 alkenyl, C 5-10 Aryl; and

[0081] s and t are each independent integers from approximately 0 to approximately 6000, where the sum of s and t is not 0.

[0082] In one implementation scheme, V does not exist, and W is R. 1 R 2 R 3 SiO-; X is -R 11 R 12 Si-O-; Y is -R 18 R 19 Si-O-; Z is -SiR 25 R 26 R 27 And R 1 R 2 R 3 R 11 R 12 R 18 R 19 R 25 R 26 and R 27 Each was independently selected from C 1-20 Alkyl (e.g., C1 alkyl, such as methyl) or C 2-20 Alkenyl (e.g., C2-alkenyl, such as vinyl). In one embodiment, R 1 R 2 R 3 R 11 R12 R 18 R 19 R 25 R 26 and R 27 At least one of them is C 2-20 Alkenyl, for example, C2-alkenyl (e.g., vinyl). In another embodiment, R 1 R 2 R 3 R 11 R 12 R 18 R 19 R 25 R 26 and R 27 At least two of them are C 2-20 Alkenyl, for example, C2-alkenyl (e.g., vinyl). In some embodiments, R 1 R 2 R 3 R 25 R 26 and R 27 At least one of them is C 2-20 Alkenyl, for example, C2 alkenyl (e.g., vinyl).

[0083] In one implementation scheme, V does not exist, and W is R. 1 R 2 R 3 SiO-; X is -R 11 R 12 Si-O-; Y is -R 18 R 19 Si-O-; Z is -SiR 25 R 26 R 27 And R 1 R 2 R 3 R 25 R 26 and R 27 Each was independently selected from C 1-20 Alkyl (e.g., C1 alkyl, such as methyl) or C 2-20 Alkenyl (e.g., C2-alkenyl, such as vinyl); and R 11 R 12 R 18 and R 19 Each was independently selected from C 1-20 Alkyl (e.g., C1 alkyl, such as methyl). In one embodiment, R 1 R 2 R 3 At least one of them and R25 R 26 and R 27 At least one of them is C 2-20 Alkenyl, for example, C2-alkenyl (e.g., vinyl). In one embodiment, R 1 R 2 R 3 One of them is C2-alkenyl (e.g., vinyl) while the others are C2-alkenyl. 1-20 Alkyl (e.g., C1 alkyl, such as methyl), and R 25 R 26 and R 27 At least one of them is C 2-20 Alkenyl groups, for example, C2 alkenyl groups (e.g., vinyl groups), while others are C... 1-20 Alkyl (e.g., C1 alkyl, such as methyl). In one embodiment, for at least one monomer unit, R 11 or R 12 At least one of them and R 18 or R 19 At least one of them is C 2-20 Alkenyl, for example, C2-alkenyl (e.g., vinyl). In one embodiment, for at least one monomer unit, R 11 or R 12 One is C2-alkenyl (e.g., vinyl) while the others are C... 1-20 Alkyl (e.g., C1 alkyl, such as methyl), and R 18 or R 19 At least one of them is C 2-20 Alkenyl groups, for example, C2 alkenyl groups (e.g., vinyl groups), while others are C... 1-20 Alkyl (e.g., C1 alkyl, such as methyl).

[0084] In some embodiments, the organopolysiloxane includes a vinyl portion only at the end caps of the polymer. In some embodiments, the organopolysiloxane includes a vinyl portion only in the monomer units of the polymer, and not at the end caps of the polymer. In other embodiments, the organopolysiloxane includes vinyl portions at both end caps of the polymer or in the monomer units of the polymer. In one embodiment, the polymer includes two vinyl portions located at the end caps or within the monomer units, or a combination thereof.

[0085] In one embodiment, an average of at least two vinyl moieties are present in the polymer. In a specific embodiment, at least two vinyl moieties are present in the polymer and at least two vinyl moieties are present on both end caps of the polymer. In a specific embodiment, only two vinyl moieties are present in the polymer. In a specific embodiment, only two vinyl moieties are present in the polymer and are located on each end cap. In a specific embodiment, an average of at least two vinyl moieties are present in the polymer and at least two vinyl moieties are present in one or more monomeric units of the polymer. In a specific embodiment, an average of at least two vinyl moieties are present anywhere in the polymer but are spaced from another vinyl moiety by about 2000 monomeric units, for example, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 monomeric units. In a specific embodiment, an average of at least two vinyl moieties are present anywhere in the polymer but are spaced from another vinyl moiety by about 850 monomeric units, for example, 350, 450, 550, 650, 750, 850, 950, 1050, 1150, 1250, or 1350 monomeric units. In a specific embodiment, an average of more than two vinyl moieties are present anywhere in the polymer but are spaced from another vinyl moiety by about 40 monomeric units, for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or 80 monomeric units. In a specific embodiment, one or more Si-H units are present in addition to the vinyl moieties. Alternatively, in one embodiment, if a vinyl moiety is present, then a Si-H is not present.

[0086] In one embodiment, V is absent, W is R 1 R 2 R 3 SiO-; X is -R 11 R 12 Si-O-; Y is -R 18 R 19 Si-O-; Z is -SiR 25 R 26 R 27 ; R 1 , R 2 , R 3 , R 11 , R 12 , R 18 , R 19 , R 25 , R 26 and R 27 are each independently selected from hydrogen or C 1-20alkyl (e.g., C1alkyl, such as methyl). In one embodiment, for at least one monomer unit, R 1 , R 2 , R 3 , R 25 , R 26 , and R 27 are each independently selected from C 1-20 alkyl (e.g., C1alkyl, such as methyl); and R 11 , R 12 , R 18 , and R 19 are each independently selected from hydrogen or C 1-20 alkyl (e.g., C1alkyl, such as methyl), wherein at least one of R 11 , R 12 , R 18 , and R 19 is hydrogen. In one embodiment, an average of more than two Si-H units (e.g., one or more of R 11 , R 12 , R 18 , and R 19 is hydrogen) are present in the polymer, such as 3-15 Si-H units can be present. In a specific embodiment, 8 Si-H units are present. In one embodiment, one or more Si-H units (e.g., one or more of R 11 , R 12 , R 18 , and R 19 is hydrogen) are present in the polymer. In one embodiment, at least two monomer units include a -Si-H unit (e.g., one or more of R 11 , R 12 , R 18 , and R 19 is hydrogen). In one embodiment, at least 3 monomer units include a -Si-H unit (e.g., one or more of R 11 , R 12 , R 18 , and R 19 is hydrogen). In one embodiment, at least 4 monomer units include a -Si-H unit (e.g., one or more of R 11 , R 12 , R 18 , and R 19 is hydrogen). In one embodiment, at least 5 monomer units include a -Si-H unit (e.g., one or more of R 11 , R 12 , R 18 , and R 19 is hydrogen). In one embodiment, at least 6 monomer units include a -Si-H unit (e.g., one or more of R11 one or more of R 12 one or more of R 18 and R 19 is hydrogen). In one embodiment, at least 7 monomer units include -Si-H units (e.g., R 11 one or more of R 12 one or more of R 18 and R 19 is hydrogen). In one embodiment, at least 8 monomer units include -Si-H units (e.g., R 11 one or more of R 12 one or more of R 18 and R 19 is hydrogen). In one embodiment, Si-H units can be present in one or both endcaps in addition to being present in monomer units as described above. In specific embodiments, Si-(alkyl) or Si-(vinyl) units can also be present in the polymer. In specific embodiments, only Si-CH3and Si-H units are present. In specific embodiments, for non-Si-H positions of the polymer, the monomer units or endcaps include C1-C 20 alkyl groups, especially methyl groups.

[0087] In specific embodiments, an average of at least two Si-H units are present in the polymer. In specific embodiments, an average of at least two Si-H moieties are present anywhere in the polymer but are spaced from another Si-H moiety by about 2000 monomer units, e.g., 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 monomer units. In specific embodiments, an average of at least two Si-H units are present anywhere in the polymer but are spaced from another Si-H moiety by about 850 monomer units, e.g., 350, 450, 550, 650, 750, 800, 850, 950, 1050, 1150, 1250, or 1350 monomer units. In specific embodiments, an average of more than two Si-H units are present anywhere in the polymer but are spaced from another Si-H moiety by about 40 monomer units, e.g., 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or 80 monomer units.

[0088] In one aspect of any of the above embodiments, the sum of s and t is from about 1000 to about 8000; from about 1300 to about 2700; from about 1500 to about 2700; from about 1600 to about 2600; from about 1600 to about 2500; from about 1700 to about 2500; from about 1800 to about 2400; from about 1800 to about 2300; from about 1900 to about 2300; from about 2000 to about 2200; from about 2050 to about 2150; an integer from about 2100.

[0089] In one aspect of any of the above embodiments, the sum of s and t is from about 200 to about 1100; from about 600 to about 1100; from about 700 to about 1000; from about 800 to about 900; from about 825 to about 875; about 850; from about 200 to about 800; from about 225 to about 700; from about 250 to about 600; from about 275 to about 500; from about 300 to about 400; from about 350 to about 400; an integer from about 375. In particular embodiments, the sum of s and t is an integer from about 850.

[0090] In one aspect of any of the above embodiments, the sum of s and t is from about 5 to about 1300; from about 10 to about 1100; from about 10 to about 600; from about 15 to about 500; from about 15 to about 400; from about 20 to about 300; from about 20 to about 200; from about 25 to about 100; from about 25 to about 75; from about 30 to about 50; an integer from about 40.

[0091] In some embodiments, the reactive component comprises at least one organopolysiloxane. The term "organopolysiloxane" includes compounds of Formula II:

[0092]

[0093] wherein R 1a , R 2a , R 3a , R 4a , R 5a , R 6a , R 7a , R 8a , R 9a and R 10a are each independently selected from hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl, or C 1-20 alkoxy and p and q are each independently an integer from 10 to about 6000.

[0094] In some embodiments, the organopolysiloxane is a compound of Formula IIa:

[0095]

[0096] wherein R 1a’ , R 3a’ , R 4a’ , R 5a’ , R 6a’ , R 8a’ , R 9a’ and R 10a’ are each independently selected from hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl, or C 1-20 alkoxy and p and q are each independently integers from 10 to about 6000. In one embodiment, R 1a’ , R 3a’ , R 4a’ , R 5a’ , R 6a’ , R 8a’ , R 9a’ and R 10a’ are alkyl (e.g., C1alkyl, such as methyl).

[0097] The term "alkyl" includes both branched and straight chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. The term "C 1-20 alkyl" includes both branched and straight chain aliphatic groups having from 1 to 20 carbons. Examples of alkyl moieties include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, n-hexyl, i-propyl, i-butyl, s-butyl, t-butyl, i-pentyl, and s-pentyl. Also, the term alkyl includes "unsubstituted alkyl" and "substituted alkyl", the latter referring to alkyl moieties having a substituent replacing a hydrogen on one or more carbons of the hydrocarbon backbone (e.g., F, Cl, Br, I, NO2, CN, alkyl, aryl, hydroxyl, alkoxy, COCH3, etc.).

[0098] The term "alkenyl" includes both straight chain and branched chain configurations having one or more sites of unsaturation in the chain, which can occur at any stable point along the chain, for example, ethenyl and propenyl. The term "C 2-20 alkenyl" includes both straight chain and branched chain hydrocarbon groups having from 1 to 20 carbons and one or more sites of unsaturation. Also, the term "alkenyl" includes "unsubstituted alkenyl" and "substituted alkenyl", the latter referring to alkenyl moieties having a substituent replacing a hydrogen on one or more carbons of the hydrocarbon backbone (e.g., F, Cl, Br, I, NO2, CN, alkyl, aryl, hydroxyl, alkoxy, COCH3, etc.).

[0099] The term "aryl" includes 5-10 membered monocyclic, bicyclic, or tricyclic, wherein at least one ring (if more than 1 exists) is aromatic. The term "aryl" also includes "heteroaryl" moieties, wherein one heteroatom (e.g., N, O, or S) replaces one or more carbons in a monocyclic, bicyclic, or tricyclic ring. The term "aryl" also includes "unsubstituted aryl" and "substituted aryl," the latter referring to aryl moieties having substituents replacing hydrogens on one or more carbon aromatic rings (e.g., F, Cl, Br, I, NO2, CN, alkyl, hydroxyl, alkoxy, COCH3, etc.).

[0100] The term "hydroxyl" includes -OH.

[0101] The term "alkoxy" includes where O is covalently bonded to a C 1-20 alkyl group.

[0102] In some embodiments, the organopolysiloxane is vinyl-terminated. The expression "vinyl-terminated organopolysiloxane" includes organopolysiloxanes of Formula II, wherein R 2a and one or both of R 7a is substituted with a C2alkyl moiety, such as a vinyl moiety (e.g., -CH=CH2). In particular embodiments, "vinyl-terminated organopolysiloxane" includes organopolysiloxanes of Formula II, wherein R 2a and one or both of R 7a is substituted with a C2alkyl moiety, such as a vinyl moiety (e.g., -CH=CH2) and R 1a , R 3a , R 4a , R 5a , R 6a , R 8a , R 9a , and R 10a are independently selected from C 1-20 alkyl groups, such as methyl groups.

[0103] In other embodiments, the organopolysiloxane is selected from the group consisting of: a vinyl terminated polydimethylsiloxane; a vinyl terminated diphenylsiloxane- dimethylsiloxane copolymer; a vinyl terminated polyphenylmethylsiloxane, a vinyl phenylmethyl terminated vinyl phenylsiloxane-phenylmethylsiloxane copolymer; a vinyl terminated trifluoropropylmethylsiloxane-dimethylsiloxane copolymer; a vinyl terminated diethylsiloxane-dimethylsiloxane copolymer; a trimethylsiloxy terminated vinyl methylsiloxane-dimethylsiloxane copolymer; a silanol terminated vinyl methylsiloxane-dimethylsiloxane copolymer; a vinyl terminated vinyl methylsiloxane-dimethylsiloxane copolymer; a vinyl gum; a vinyl methylsiloxane homopolymer; a vinyl T-structured polymer; a monovinyl terminated polydimethylsiloxane; a vinyl methylsiloxane terpolymer; a vinyl methoxysilane homopolymer; and combinations thereof.

[0104] In some embodiments, the organopolysiloxane is a high viscosity organopolysiloxane, a low viscosity organopolysiloxane, or a combination thereof.

[0105] When the organopolysiloxane is a combination of high and low viscosity organopolysiloxanes, the combination of high and low viscosity vinyl organosiloxanes provides a bimodal distribution of organosiloxane molecular weight. In at least one embodiment, the organopolysiloxane is a combination of high and low viscosity vinyl-terminated organopolysiloxanes that provides a bimodal distribution of vinyl-terminated organopolysiloxanes. In one embodiment, the organopolysiloxane is a combination of Formulas I, II, Ila, lib, and lie that provides a bimodal distribution of vinyl-terminated organopolysiloxanes, especially a combination of Formulas Ila, lib, and / or lie, or more especially a combination of Formulas lib and lie. In one embodiment, the bimodal distribution of polymer molecular weight is represented by the ratio of the high viscosity organopolysiloxane molecular weight to the low viscosity organopolysiloxane molecular weight (e.g., the sum of s and t). In one embodiment, the ratio is 2 to 3. In a particular embodiment, the ratio is 2.5.

[0106] The term "viscosity" refers to a measure of the resistance of a fluid which is deforming by either shear or tensile stress. One of skill in the art will be able to determine how to measure the viscosity of a fluid without undue experimentation, for example, using a viscometer or a rheometer. Representative methods include measuring viscosity using a capillary viscometer, a rotational viscometer, or a rheometer at the instrument-specific strain. A particular method for determining the viscosity of a fluid is shown in Example 8.

[0107] The phrase "high viscosity organopolysiloxane" includes organopolysiloxanes having a viscosity of about 100,000 to about 500,000 cSt or cP at 25 °C, for example, about 110,000 to about 450,000 cSt or cP, about 120,000 to about 400,000 cSt or cP, about 125,000 to about 350,000 cSt or cP, about 130,000 to about 300,000 cSt or cP, about 135,000 to about 250,000 cSt or cP, about 140,000 to about 200,000 cSt or cP, about 145,000 to about 190,000 cSt or cP, about 150,000 to about 185,000 cSt or cP, about 155,000 to about 175,000 cSt or cP, or about 160,000 to about 170,000 cSt or cP. In some embodiments, the high viscosity organopolysiloxane has a viscosity of about 140,000 to about 200,000 cSt or cP at 25 °C. In one embodiment, the high viscosity organopolysiloxane has a viscosity of about 165,000 cSt or cP at 25 °C.

[0108] In one embodiment, the high viscosity organopolysiloxane has an average molecular weight of about 100,000 to about 200,000 Da, for example, about 115,000 to about 195,000 Da, about 120,000 to about 190,000 Da, about 125,000 to about 185,000 Da, about 130,000 to about 180,000 Da, about 135,000 to about 175,000 Da, about 140,000 to about 170,000 Da, about 145,000 to about 165,000 Da, or about 150,000 to about 160,000 Da. In one embodiment, the high viscosity organopolysiloxane has an average molecular weight of about 155,000 Da.

[0109] In some embodiments, the high viscosity organopolysiloxane has Formula II, wherein R 2a and R 7a is C 2-20 alkenyl, for example, C2 alkenyl (e.g., ethenyl) and R 1a , R 3a , R 4a , R 5a , R 6a , R 8a , R 9a and R 10a are each C 1-20 alkyl, for example, C1 alkyl (e.g., methyl). In some embodiments, the high viscosity organopolysiloxane is vinyl-terminated. In other embodiments, the high viscosity organopolysiloxane is a vinyl-terminated polydimethylsiloxane.

[0110] In some embodiments, the high viscosity organopolysiloxane has a vinyl weight percent of about 0.010 to about 0.100, for example, about 0.015 to about 0.080, about 0.020 to about 0.075, about 0.025 to about 0.060, or about 0.030 to about 0.050. In one embodiment, the high viscosity organopolysiloxane has a vinyl weight percent of about 0.030 to about 0.040.

[0111] In other embodiments, the high viscosity organopolysiloxane has a vinyl equivalent per kilogram of about 0.0100 to about 0.0200, for example, about 0.0110 to about 0.0190, about 0.0115 to about 0.0180, about 0.0120 to about 0.0170, about 0.0125 to about 0.0165, or about 0.013 to about 0.016.

[0112] In one embodiment, the high viscosity organopolysiloxane has an average of at least two vinyl units per high viscosity organopolysiloxane. In one embodiment, the monomeric units comprising the vinyl moieties are spaced throughout the polymer. In one embodiment, the monomeric unit containing a vinyl group is spaced about 2000 monomeric units from another monomeric unit containing a vinyl group or a terminal cap containing a vinyl group. For example, the vinyl units in the high viscosity organopolysiloxane are spaced 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 monomeric units.

[0113] In some embodiments, the high viscosity organopolysiloxane is selected from the group consisting of: a vinyl terminated polydimethylsiloxane; a vinyl terminated diphenylsiloxane-dimethylsiloxane copolymer; a vinyl terminated polyphenylmethylsiloxane, a vinylphenylmethyl terminated vinylphenylsiloxane-phenylmethylsiloxane copolymer; a vinyl terminated trifluoropropylmethylsiloxane-dimethylsiloxane copolymer; a vinyl terminated diethylsiloxane-dimethylsiloxane copolymer; a trimethylsiloxy terminated vinylmethylsiloxane-dimethylsiloxane copolymer; a silanol terminated vinylmethylsiloxane-dimethylsiloxane copolymer; a vinyl terminated vinylmethylsiloxane-dimethylsiloxane copolymer; a vinyl gum; a vinylmethylsiloxane homopolymer; a vinyl T-structure polymer; a monovinyl terminated polydimethylsiloxane; a vinylmethylsiloxane terpolymer; a vinylmethoxysilane homopolymer; and combinations thereof.

[0114] The phrase "low viscosity organopolysiloxane" includes organopolysiloxanes having a viscosity of about 500 to about 50,000 cSt or cP at 25 °C, for example, about 1,000 to about 45,000 cSt or cP, about 1,500 to about 40,000 cSt or cP, about 2,000 to about 35,000 cSt or cP, about 2,500 to about 30,000 cSt or cP, about 3,000 to about 25,000 cSt or cP, about 3,500 to about 20,000 cSt or cP, about 4,000 to about 15,000 cSt or cP, or about 4,000 to about 12,000 cSt or cP. In some embodiments, the low viscosity organopolysiloxane includes an organopolysiloxane having a viscosity of about 100 to about 5,000 cSt or cP at 25 °C, for example, about 200 to about 4000 cSt or cP, about 300 to about 3000 cSt or cP, about 400 to about 2000 cSt or cP, or about 750 to about 1500 cSt or cP. In one embodiment, the low viscosity organopolysiloxane has a viscosity of about 10,000 cSt or cP at 25 °C. In some embodiments, the low viscosity organopolysiloxane has a viscosity of about 1000 cSt or cP at 25 °C.

[0115] In some embodiments, the low viscosity organopolysiloxane has an average molecular weight of about 20,000 to about 80,000 Da, for example, about 50,000 to about 75,000 Da, about 55,000 to about 70,000 Da, about 60,000 to about 65,000 Da, or 62,000 to about 63,000 Da. In one embodiment, the low viscosity organopolysiloxane has an average molecular weight of about 62,700 Da. In one embodiment, the low viscosity organopolysiloxane has an average molecular weight of about 28,000 Da.

[0116] In some embodiments, the low viscosity organopolysiloxane has Formula II, wherein R 2a and R 7a is a C 2-20 alkenyl, for example, a C2 alkenyl (e.g., vinyl) and R 1a , R 3a , R 4a , R 5a , R 6a , R 8a , R 9a , and R 10a are each a C 1-20 alkyl, for example, a C1 alkyl (e.g., methyl). In some embodiments, the low viscosity organopolysiloxane is vinyl-terminated. In other embodiments, the low viscosity organopolysiloxane is a vinyl-terminated polydimethylsiloxane.

[0117] In some embodiments, the low viscosity organopolysiloxane has a vinyl weight percent of from about 0.010 to about 0.30, for example, from about 0.020 to about 0.29, from about 0.030 to about 0.28, from about 0.040 to about 0.27, from about 0.050 to about 0.26, from about 0.060 to about 0.25, from about 0.070 to about 0.24, from about 0.080 to about 0.23, or from about 0.090 to about 0.22. In some embodiments, the low viscosity organopolysiloxane has a vinyl weight percent of from about 0.18 to about 0.26.

[0118] In other embodiments, the low viscosity organopolysiloxane has a vinyl equivalent per kilogram of from about 0.010 to about 0.100, for example, from about 0.015 to about 0.090, from about 0.020 to about 0.080, from about 0.025 to about 0.070, from about 0.030 to about 0.060, or from about 0.040 to about 0.050. In some embodiments, the low viscosity organopolysiloxane has a vinyl equivalent per kilogram of from about 0.030 to about 0.040.

[0119] In other embodiments, the low viscosity organopolysiloxane has an average of at least two vinyl units per low viscosity organopolysiloxane. In one embodiment, the monomeric units comprising the vinyl moieties are spaced throughout the polymer. In one embodiment, the monomeric unit containing a vinyl group is spaced from another monomeric unit containing a vinyl group or a vinyl containing end cap by about 800 monomeric units. For example, the vinyl units in the low viscosity organopolysiloxane are spaced by 450, 550, 650, 750, 800, 850, 950, 1050, 1150, 1250, or 1350 monomeric units.

[0120] In some embodiments, the low viscosity organopolysiloxane is selected from the group consisting of: a vinyl terminated polydimethylsiloxane; a vinyl terminated diphenylsiloxane-dimethylsiloxane copolymer; a vinyl terminated polyphenylmethylsiloxane, a vinyl phenylmethyl terminated vinyl phenylsiloxane-phenylmethylsiloxane copolymer; a vinyl terminated trifluoropropylmethylsiloxane-dimethylsiloxane copolymer; a vinyl terminated diethylsiloxane-dimethylsiloxane copolymer; a trimethylsiloxy terminated vinylmethylsiloxane-dimethylsiloxane copolymer; a silanol terminated vinylmethylsiloxane-dimethylsiloxane copolymer; a vinyl terminated vinylmethylsiloxane-dimethylsiloxane copolymer; a vinyl gum; a vinylmethylsiloxane homopolymer; a vinyl T-structure polymer; a monovinyl terminated polydimethylsiloxane; a vinylmethylsiloxane terpolymer; a vinylmethoxysilane homopolymer; and combinations thereof.

[0121] In some embodiments, the organopolysiloxane is a compound of Formula IIb:

[0122]

[0123] wherein R 1c , R 3c , R 4c , R 5c , R 6c , R 8c , R 9c and R 10c are each independently selected from hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl, or C 1-20 alkoxy and e and f are each independently integers from 10 to about 6000. In one embodiment, R 1c , R 3c , R 4c , R 5c , R 6c , R 8c , R 9c and R 10c are alkyl (e.g., C1alkyl, such as methyl). In some embodiments, the sum of e and f is from about 1000 to about 8000; from about 1300 to about 2700; from about 1500 to about 2700; from about 1600 to about 2600; from about 1600 to about 2500; from about 1700 to about 2500; from about 1800 to about 2400; from about 1800 to about 2300; from about 1900 to about 2300; from about 2000 to about 2200; from about 2050 to about 2150; integers from about 2100.

[0124] In some embodiments, the organopolysiloxane is a compound of Formula IIc:

[0125]

[0126] wherein R 1d , R 3d , R 4d , R 5d , R 6d , R 8d , R 9d and R 10d are each independently selected from hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl, or C 1-20 alkoxy and g and j are each independently integers from 10 to about 6000. In one embodiment, R 1d , R 3d , R 4d , R 5d , R 6dR 8d R 9d and R 10d are alkyl groups (e.g., C1alkyl groups, such as methyl groups). In some embodiments, the sum of g and j is from about 200 to about 1100; from about 600 to about 1100; from about 700 to about 1000; from about 800 to about 900; from about 825 to about 875; about 850; from about 200 to about 800; from about 225 to about 700; from about 250 to about 600; from about 275 to about 500; from about 300 to about 400; from about 350 to about 400; an integer from about 375. In some embodiments, the sum of g and j is an integer from about 850.

[0127] In some embodiments, the reactive component comprises at least one hydride-functionalized polysiloxane. The expression "hydride-functionalized polysiloxane" includes compounds of Formula III:

[0128]

[0129] wherein R 1b R 2b R 3b R 4b R 5b R 6b R 7b R 8b R 9b and R 10b are each independently selected from hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl, or C 1-20 alkoxy and m and n are each independently integers from 10 to about 6000, provided that at least one of R 1b R 2b R 3b R 4b R 5b R 6b R 7b R 8b R 9b and R 10b is hydrogen. In some embodiments, at least one of R 1b R 2b R 3b R 4b R 5b R 6b R 7b R 8b R 9b and R 10b is hydrogen and the rest are C 1-20 alkyl groups. In some embodiments, R1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b , and R 10b are hydrogen (e.g., two Si-H units per functional hydride polysiloxane molecule). In other embodiments, at least three of R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b , and R 10b are hydrogen (e.g., three Si-H units per functional hydride polysiloxane molecule). In some embodiments, at least two of R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b , and R 10b are hydrogen (e.g., two Si-H units per functional hydride polysiloxane molecule) and the remainder are C 1-20 alkyl groups. In other embodiments, at least three of R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b , and R 10b are hydrogen (e.g., three Si-H units per functional hydride polysiloxane molecule) and the remainder are C 1-20 alkyl groups. In some embodiments, at least two of R 4b , R 5b , R 9b , and R 10b are hydrogen (e.g., two Si-H units per functional hydride polysiloxane molecule) and the remainder are C 1-20 alkyl groups. In other embodiments, at least three of R 4b , R 5b , R 9b , and R 10bAt least three of them are hydrogen (e.g., three Si-H units / functionalized hydride polysiloxane molecules) and the rest are C. 1-20 alkyl.

[0130] In one embodiment, at least two of the monomer units of Formula III include -Si-H units (e.g., R...). 11 R 12 R 18 and R 19 One or more of them are hydrogen). For example, the average 2 to 15 monomer units of Formula III include Si-H units. In one embodiment, at least two monomer units of Formula III include -Si-H units (e.g., R...). 11 R 12 R 18 and R 19 One or more of them are hydrogen). In one embodiment, at least three monomer units of Formula III include -Si-H units (e.g., R...). 11 R 12 R 18 and R 19 One or more of them are hydrogen). In one embodiment, at least four monomer units of Formula III include -Si-H units (e.g., R... 11 R 12 R 18 and R 19 One or more of them are hydrogen). In one embodiment, at least five monomer units of Formula III include -Si-H units (e.g., R... 11 R 12 R 18 and R 19 One or more of them are hydrogen). In one embodiment, at least six monomer units of Formula III include -Si-H units (e.g., R... 11 R 12 R 18 and R 19 One or more of them are hydrogen). In one embodiment, at least seven monomer units of Formula III include -Si-H units (e.g., R... 11 R 12 R 18 and R 19 One or more of them are hydrogen). In one embodiment, at least eight monomer units of Formula III include -Si-H units (e.g., R... 11 R 12 R 18 and R 19One or more of them are hydrogen. In a specific embodiment, the non-Si-H positions may include Si-(alkyl) or Si-(vinyl) units. In a specific embodiment, the non-Si-H positions are Si-CH3. In one embodiment, the Si-H units in the hydride-functionalized organopolysiloxane are spaced 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 65, 70, 75, 80, 85, 90, 100, 125, 150, or 200 monomer units.

[0131] In any of the above embodiments, the sum of m and n is approximately 10 to approximately 1300; approximately 10 to approximately 1100; approximately 10 to approximately 600; approximately 15 to approximately 500; approximately 15 to approximately 400; approximately 20 to approximately 300; approximately 20 to approximately 200; approximately 25 to approximately 100; approximately 25 to approximately 75; approximately 30 to approximately 50; an integer starting from approximately 40.

[0132] In some embodiments, the hydride-functionalized polysiloxane comprises Si-H units only at the end caps of the polymer. In some embodiments, the polysiloxane comprises Si-H units only in the monomer units of the polymer, and not at the end caps of the polymer. In other embodiments, the polysiloxane comprises Si-H units at both end caps of the polymer or in the monomer units of the polymer. In one embodiment, the polysiloxane comprises 2-12 Si-H units located at the end caps, within the monomer units, or a combination thereof. In one embodiment, the polysiloxane comprises 4-15 Si-H units located at the end caps, within the monomer units, or a combination thereof. In one embodiment, the polysiloxane comprises 8 Si-H units located at the end caps, within the monomer units, or a combination thereof.

[0133] In some embodiments, the hydrogenated functionalized polysiloxane has a viscosity of about 5 to about 11,000 cSt or cP at 25°C, for example, about 10 to about 10,000 cSt or cP, about 15 to about 5,000 cSt or cP, about 20 to about 1,000 cSt or cP, about 25 to about 500 cSt or cP, about 30 to about 100 cSt or cP, and about 40 to about 50 cSt or cP. In one embodiment, the hydrogenated functionalized polysiloxane has a viscosity of about 45 cSt or cP at 25°C.

[0134] In some embodiments, the average molecular weight of the hydride-functionalized polysiloxane is about 900 to about 60,000 Da, for example, about 1000 to about 50,000 Da, about 1200 to about 25,000 Da, about 1400 to about 20,000 Da, about 1600 to about 15,000 Da, about 1800 to about 10,000 Da, about 2000 to about 5000 Da, about 2200 to about 4000 Da, and 2300 to about 2500 Da. In one embodiment, the average molecular weight of the hydride-functionalized polysiloxane is about 2400 Da.

[0135] In some embodiments, the percent SiH content of the hydride-functionalized polysiloxane is about 3 to about 45%, for example, about 5 to about 40%, about 10 to about 35%, about 20 to about 30%, or about 26 to 27%. In some embodiments, the percent SiH content of the hydride-functionalized polysiloxane is about 26%.

[0136] In some embodiments, the SiH content of the hydride-functionalized polysiloxane is about 0.500 mmol / g to about 10.00 mmol / g, for example, about 1.00 mmol / g to about 9.00 mmol / g, about 2.00 to about 8.00 mmol / g, about 3.00 mmol / g to about 7.00 mmol / g, and about 4.00 mmol / g to about 6.00 mmol / g. In one embodiment, the SiH content of the hydride-functionalized polysiloxane is about 4.00 to about 5.00 mmol / g, for example, 4.35 mmol / g.

[0137] In other embodiments, the hydride-functionalized polysiloxane is alkyl-terminated. The expression "alkyl-terminated" includes hydride-functionalized polysiloxanes of Formula III, wherein one or both of R 2b and R 7b are C 1-20 alkyl. In some embodiments, "alkyl-terminated" includes hydride-functionalized polysiloxanes of Formula III, wherein one, two, three, four, five, or six of R 1b , R 2b , R 3b , R 6b , R 7b , and R 8b are C 1-20 alkyl. In one embodiment, R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , and R 10bEach is C 1-20 Alkyl groups, such as C1 alkyl groups (e.g., methyl groups) and R 9b It is hydrogen. In one implementation, R 1b R 2b R 3b R 4b R 5b R 6b R 7b R 8b and R 9b Each is C 1-20 Alkyl groups, such as C1 alkyl groups (e.g., methyl groups) and R 10b It is hydrogen.

[0138] In some embodiments, the hydride-functionalized polysiloxane is selected from the group consisting of: hydride-terminated polydimethylsiloxane; hydride-terminated polyphenyl-(dimethylhydrosiloxy)siloxane; hydride-terminated methylhydrosiloxane-phenylmethylsiloxane copolymer; trimethylsiloxy-terminated methylhydrosiloxane-dimethylsiloxane copolymer; trimethylsiloxy-terminated polymethylhydrosiloxane; polyethylhydrosiloxane, triethylsiloxane, methylhydrosiloxane-phenyloctylmethylsiloxane copolymer; methylhydrosiloxane-phenyloctylmethylsiloxane terpolymer and combinations thereof.

[0139] In some embodiments, the reactive component comprises a combination of polymers of formulas I, II, IIa, IIb, IIc, IId, and / or III. In specific embodiments, the reactive component comprises a combination of polymers of formulas IIa, IIb, IIc, and / or III. In specific embodiments, the reactive component comprises a combination of polymers of formulas IIb, IIc, and III.

[0140] In some embodiments, the reactive component comprises a combination of high molecular weight vinyl organopolysiloxanes, low molecular weight vinyl organopolysiloxanes, and / or hydride-functionalized organopolysiloxanes. In one embodiment, each of the high and low molecular weight organopolysiloxanes comprises an average of at least two vinyl moieties / polymers. In a specific embodiment, each vinyl organopolysiloxane comprises exactly two vinyl moieties. In one embodiment, the ratio of the high molecular weight organopolysiloxane to the low molecular weight organopolysiloxane is 2 to 3, for example, 2, 2.5, or 3. The ratio can be selected to adjust the chemical and physical properties of the membrane to suit a particular method or body part. In one embodiment, the hydride-functionalized organic polymer comprises an average of more than two Si-H units in the polymer. In a specific embodiment, there are 8 Si-H units / hydride-functionalized organopolysiloxanes.

[0141] In some embodiments, the reactive component comprises a combination of a high molecular weight hydride-functionalized organopolysiloxane, a low molecular weight hydride-functionalized organopolysiloxane, and / or a vinyl organopolysiloxane. In one embodiment, each of the high and low molecular weight organopolysiloxanes includes an average of at least two Si-H units per polymer. In particular embodiments, each hydride-functionalized organopolysiloxane includes exactly two Si-H moieties. In one embodiment, the ratio of high molecular weight organopolysiloxane to low molecular weight organopolysiloxane is 2 to 3, such as 2, 2.5, or 3. The ratio can be selected so as to adjust the chemical and physical properties of the film to suit a particular method or body part. In one embodiment, the vinyl organopolymers include an average of at least more than two vinyl units per polymer. In particular embodiments, there are 8 vinyl units per vinyl organopolysiloxane.

[0142] The phrase "reinforcing component" includes one or more components of the reactive reinforcing component that provide a desired physical property of the film resulting from the in-situ reaction between the reactive reinforcing component and the crosslinking component. Such physical properties include, for example, mechanical elements (e.g., elasticity, durability, strain at break, tensile strength, etc.), biocompatibility (e.g., selectivity of permeability, adhesion, etc.), optical effects (e.g., reflectivity, color, etc.), and surface conditioning (e.g., texture, chemistry, etc.). Examples of reinforcing components include clay (e.g., AI2O3, SiO2), chalk, talc, calcite (e.g., CaCO3), mica, barium sulfate, zirconium dioxide, zinc sulfide, zinc oxide, titanium dioxide, aluminum oxide, aluminosilicate, calcium silicate, or optionally surface-treated silica (e.g., fumed silica, hydrated silica, or anhydrous silica). In some embodiments, the reinforcing component is silica, such as surface-treated silica, such as silica treated with hexamethyldisilazane.

[0143] In some embodiments, the reinforcing component has a surface area of about 100 to about 300 m 2 / g, such as about 110 to about 250 m 2 / g, about 120 to about 225 m 2 / g, about 130 to about 200 m 2 / g, about 135 to about 185 m 2 / g, about 160 to about 170 m 2 / g, and about 164 to about 166 m 2 / g. In one embodiment, the reinforcing component has a surface area of about 160 ± 25 m 2 / g.

[0144] In some embodiments, the reinforcing component has an average particle size of about 1 to about 20 μιη.

[0145] In some embodiments, the reinforcing ingredient is mixed with a low viscosity and / or high viscosity organopolysiloxane.

[0146] In some embodiments, the reactive ingredient and the reinforcing ingredient comprise about 20 to about 90% of the reactive reinforcing component, for example, about 40% to about 60% of the reactive reinforcing component. In some embodiments, the reactive ingredient and the reinforcing ingredient comprise about 45.0 to about 61.0% of the reactive reinforcing component, for example, about 45.0%, about 45.5%, about 46.0%, about 46.5%, about 47.0%, about 47.5%, about 48.5%, about 49.0%, about 49.5%, about 50.0%, about 50.5%, about 51.0%, about 51.5%, about 52.0%, about 52.5%, about 53.0%, about 53.5%, about 54.0%, about 54.5%, about 55.0%, about 55.5%, about 56.0%, about 56.5%, about 57.0%, about 58.0%, about 58.5%, about 59.0%, about 59.5%, about 60.0%, or about 60.5% of the reactive reinforcing component. In some embodiments, the reactive ingredient and the reinforcing ingredient comprise about 45% of the reactive reinforcing component. In one embodiment, the reactive ingredient and the reinforcing ingredient comprise about 48.0% of the reactive reinforcing component. In some embodiments, the reactive ingredient and the reinforcing ingredient comprise about 50.0% of the reactive reinforcing component. In another embodiment, the reactive ingredient and the reinforcing ingredient comprise about 51.0% of the reactive reinforcing component. In some embodiments, the reactive ingredient and the reinforcing ingredient comprise about 51.5% of the reactive reinforcing component. In another embodiment, the reactive ingredient and the reinforcing ingredient comprise about 54.5% of the reactive reinforcing component. In another embodiment, the reactive ingredient and the reinforcing ingredient comprise about 55.0% of the reactive reinforcing component. In some embodiments, the reactive ingredient and the reinforcing ingredient comprise about 59.5% of the reactive reinforcing component. In another embodiment, the reactive ingredient and the reinforcing ingredient comprise about 60.5% of the reactive reinforcing component. In some embodiments, the reactive ingredient and the reinforcing ingredient comprise about 30.0 to about 40.0% of the reactive reinforcing component, for example, about 30.0%, about 30.5%, about 31.0%, about 31.5%, about 32.0%, about 32.5%, about 33.0, about 33.5%, about 34.0%, about 34.5%, about 35.0%, about 35.5%, about 36.0%, about 36.5%, about 37.0%, about 37.5%, about 38.0%, about 38.5%, about 39.0%, about 39.5%, about 40.0%. In some embodiments, the reactive ingredient and the reinforcing ingredient comprise about 33.0 to about 40.0% of the reactive reinforcing component.

[0147] In one embodiment, the enhancing ingredient comprises about 8.0 to about 13.0% of the reactive enhancing component, for example, about 8.5%, about 9.0%, about 9.5%, about 10.0%, about 10.5%, about 11.0%, about 11.5%, about 12.0%, or about 12.5%. In some embodiments, the enhancing ingredient comprises about 8.5% of the reactive enhancing component. In one embodiment, the enhancing ingredient comprises about 9.0% of the reactive enhancing component. In another embodiment, the enhancing ingredient comprises about 9.5% of the reactive enhancing component. In some embodiments, the enhancing ingredient comprises about 10.0% of the reactive enhancing component. In some embodiments, the enhancing ingredient comprises about 10.5% of the reactive enhancing component. In another embodiment, the enhancing ingredient comprises about 11.0% of the reactive enhancing component. In another embodiment, the enhancing ingredient comprises about 12.0% of the reactive enhancing component. In another embodiment, the enhancing ingredient comprises about 13.0% of the reactive enhancing component.

[0148] In another embodiment, the reactive ingredient comprises about 30.0 to about 60.0% of the reactive enhancing component, for example, about 30.5%, about 31.0%, about 32.0%, about 33.0%, about 34%, about 35.0%, about 36.0%, about 37.0%, about 38.0%, about 39.0%, about 40.0%, about 41.0%, about 42.0%, about 43.0%, about 44.0%, about 45.0%, about 46.0%, about 47.0%, about 48.0%, about 49.0%, about 50.0%, about 51.0%, about 52.0%, about 53.0%, about 54.0%, about 55.0%, about 56.0%, about 57.0%, about 58.0%, or about 59.0%.

[0149] In some embodiments, the reactive enhancement component has a viscosity of about 5,000 to 1,000,000 cSt or cP at 25°C. In some embodiments, the reactive enhancement component has a viscosity of about 10,000 to 10,000,000 cSt or cP at 25°C, for example, about 10,000,000, about 9,000,000, about 8,000,000, about 7,000,000, about 6,000,000, about 5,000,000, about 4,000,000, about 3,000,000, or about 2,000,000, about 1,000,000, about 900,000, about 800,000, about 700,000, about 600,000, about 500,000, about 400,000, about 300,000, about 200,000, about 100,000, about 90,000, about 80,000, about 70,000, about 60,000, about 50,000, about 40,000, about 30,000, about 20,000, about 10,000 cSt. In one embodiment, the reactive enhancement component has a viscosity of about 1,000,000 cSt.

[0150] In some embodiments, the reactive enhancement component has a vinyl to functional hydride (e.g., -CH=CH2 of the one or more organopolysiloxanes to Si-H of the hydride-functional polysiloxane) ratio of about 1 : 10 to about 1 : 100, for example, about 1 : 15 to about 1 : 90, about 1 : 20 to about 1 : 80, about 1 : 25 to about 1 : 70, about 1 : 30 to about 1 : 60, about 1 : 35 to about 1 : 50. In one embodiment, the reactive enhancement component has a vinyl to functional hydride ratio of about 1 : 40. In another embodiment, the reactive enhancement component has a vinyl to functional hydride ratio of about 1 : 20. In some embodiments, the reactive enhancement component has a vinyl to functional hydride ratio of about 1 : 15.

[0151] The phrase "crosslinking component" includes a component that catalyzes the in situ formation of a body correction film when applied to the reactive enhancement component.

[0152] The term "catalyzes the in situ formation of a body correction film" includes causing a reaction to occur between the reactive components of the reactive enhancement component to form a body correction film on the skin. Without being bound by theory, the crosslinking component induces a reaction between the one or more organopolysiloxanes and the hydride-functional polysiloxane of the reactive enhancement component, resulting in condensation of these components to form a film on the skin.

[0153] In some embodiments, the crosslinking component comprises a metal catalyst, such as a platinum catalyst, a rhodium catalyst, or a tin catalyst. Examples of platinum catalysts include, for example, platinum carbonyl cyclovinylmethyl siloxane complex, platinum divinyltetramethyldisiloxane complex, platinum cyclovinylmethyl siloxane complex, platinum octanoic aldehyde / octanol complex, and combinations thereof. Examples of rhodium catalysts include tris(dibutylsulfide)trichlororhodium. Examples of tin catalysts include tin II octoate, tin II neodecanoate, diisooctyl dibutyl tin maleate, di-n-butyl bis(2,4-pentanedionate)tin, di-n-butyl butoxychlorotinane, dibutyl dilaurate, dimethyl tin di-neodecanoate, dimethyl hydroxy (oleic acid) tin, and tin II oleate.

[0154] In some embodiments, the crosslinking component further comprises a vinyl-terminated organopolysiloxane (e.g., a compound of Formula I, II, Ha, lib, or lie). In some embodiments, the amount of vinyl-terminated polysiloxane is a stabilizing amount of vinyl-terminated polysiloxane. The phrase "stabilizing amount" includes an amount that prevents degradation of the catalyst and / or the crosslinking component and / or the orthotic film. In some embodiments, the stabilizing amount of vinyl-terminated polysiloxane is less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%, less than about 5%, or less than about 2%. In some embodiments, the stabilizing amount of vinyl-terminated polysiloxane is about 1%.

[0155] In some embodiments, the crosslinking component has a viscosity of about 1,000 to about 50,000 cSt or cP at 25 °C.

[0156] In some embodiments, the catalyst is added in solution and the solution comprises about 1.0 to about 5.0% of the crosslinking component, for example, about 1.5%, about 2.0%, about 2.5%, about 3.0%, about 3.5%, about 4.0%, or about 4.5%. In one embodiment, the catalyst is about 2.0% of the crosslinking component.

[0157] In some embodiments, the catalyst comprises about 0.005 to about 0.04% of the crosslinking component, for example, about 0.005%, about 0.010%, about 0.015%, about 0.020%, about 0.025%, about 0.030%, or about 0.035%, or about 0.040%. In one embodiment, the catalyst is about 0.02% of the crosslinking component.

[0158] In some embodiments, the catalyst is present in the crosslinking component in an amount of about 100 ppm to about 500 ppm.

[0159] In some embodiments, the reactive-enhancing component and the crosslinking component are prevented from contacting prior to use. The reactive-enhancing component and the crosslinking component can be kept from contacting prior to use by conventional means known to those skilled in the art. In one embodiment, the skin correction formulation is a two-part formulation, wherein the reactive-enhancing component and the crosslinking component are packaged in separate containers and mixed prior to use. In another embodiment, the reactive-enhancing component is applied to the skin first, and the crosslinking component is applied over the reactive-enhancing component. In yet another embodiment, the crosslinking component is applied to the skin first and the reactive-enhancing component is applied over the crosslinking component. In a further embodiment, the reactive-enhancing component and the crosslinking component are packaged together in the same container with a barrier between the two components, and mixed when the components are removed from the container.

[0160] The term "body" includes any portion of a subject's body that can benefit from the formulations disclosed herein. Examples of a subject's body include skin, neck, eyebrow, jaw, eye, hand, foot, face, cheek, chest, abdomen, hip, thigh, back, leg, ankle, fat mass, adipose deposit, and the like.

[0161] The term "skin" includes the epidermis of a subject's skin, which is the outer layer of the skin and includes a stratified squamous epithelium composed of proliferative basal keratinocytes and differentiated suprabasal keratinocytes.

[0162] The term "subject" includes a subject in which the formulations disclosed herein would be suitable for use. In one example, the subject is a mammal, such as a human. In another embodiment, the subject is suffering from a skin defect, a body defect, or has recently undergone a cosmetic procedure. In another embodiment, the subject desires to appear more youthful or wishes to enhance their body.

[0163] In one embodiment, the body correction formulation further comprises one or more of a slip agent, a tackiness modifier, a spreadability enhancer, a diluent, a viscosity modifier, an optical modifier, a particulate, a volatile silicone, an emulsifier, an emollient, a surfactant, a thickener, a solvent, a film former, a humectant, a preservative, a pigment, a cosmetic agent, or a therapeutic agent. In other embodiments, the reactive-enhancing component and / or the crosslinking component further comprises one or more of a slip agent, a tackiness modifier, a spreadability enhancer, a diluent, a viscosity modifier, an optical modifier, a particulate, a volatile silicone, an emulsifier, an emollient, a surfactant, a thickener, a solvent, a film former, a humectant, a preservative, a pigment, a cosmetic agent, or a therapeutic agent. One of skill in the art can readily determine more appropriate additives based on the INCI dictionary, incorporated by reference in its entirety herein.

[0164] Examples of cosmetic or therapeutic agents include sunscreen agents (e.g., ultraviolet light protectants), anti-aging agents, anti-acne agents, anti-wrinkle agents, spot reducers, moisturizers, antioxidants, vitamins.

[0165] In some embodiments, the emulsifier is SIMULGEL TM 400.

[0166] In some embodiments, the composition or film is applied first, followed by one or more other cosmetic or therapeutic agents. In some embodiments, the composition or film is applied after one or more other cosmetic or therapeutic agents. In some embodiments, the film and one or more other cosmetic or therapeutic agents are applied substantially simultaneously. In some embodiments, the composition or film is used to deliver one or more other cosmetic or therapeutic agents.

[0167] In some embodiments, a finishing formulation can be applied to the body to correct the formulation at or after the film is formed on the body. The term "finishing formulation" includes a composition comprising components that provide a desired tactile feel or a desired aesthetic appearance to the film after formation. For example, a finishing formulation can provide a silky, soft, and / or smooth tactile feel or a wet, fresh, matte, shiny, or luminous aesthetic appearance after application to the film.

[0168] In some embodiments, the finishing formulation comprises one or more of an oil, an ester, or an ether, e.g., a triglyceride, PPG-3 benzyl ether myristate, Schercemol DISD ester, or a particulate, e.g., a nylon, a silica, and a silicone elastomeric bead. In some embodiments, one or more of these components comprises about 0.5% to about 100% of the finishing formulation.

[0169] In some embodiments, the finishing formulation is a cream, a spray, a foam, a paste, a serum, a gel, or a powder.

[0170] In some embodiments, the finishing formulation further comprises one or more of a slip agent, a tackiness modifier, a spreadability enhancer, a diluent, a viscosity modifier, an optical modifier, a particulate, a volatile siloxane, an emulsifier, an emollient, a surfactant, a thickener, a solvent, a film former, a humectant, a preservative, a pigment, a dye (e.g., a fluorescent dye), a cosmetic agent, or a therapeutic agent.

[0171] In some embodiments, the films and formulations described herein comprise one or more pigments. This includes natural or non-natural colorants or dyes. In one embodiment, the pigment is a fluorescent dye.

[0172] In some embodiments, the membrane and formulation further comprise a pigment dispersion formulation. The term "pigment dispersion formulation" includes a formulation capable of providing one or more pigments as a separate component of the formulation or membrane to the membrane or formulation. In some embodiments, the pigment dispersion formulation allows for uniform distribution of the pigment within the membrane and formulation. In some embodiments, the pigment dispersion formulation comprises at least one reactive component. In some embodiments, the pigment dispersion formulation comprises at least one reinforcing component. In some embodiments, the pigment dispersion formulation comprises one or more of the following: slip agents, adhesion modifiers, spreadability enhancers, diluents, viscosity modifiers, optical modifiers, particles, volatile siloxanes, emulsifiers, emollients, surfactants, thickeners, solvents, film-forming agents, wetting agents, preservatives, pigments, cosmetics, or therapeutic agents. In other embodiments, the reactive enhancing component and / or crosslinking component further comprises one or more of the following: slip agent, adhesion modifier, spreadability enhancer, diluent, viscosity modifier, optical modifier, particulate, volatile siloxane, emulsifier, emollient, surfactant, thickener, solvent, film-forming agent, wetting agent, preservative, pigment, cosmetic or therapeutic agent.

[0173] In some embodiments, the pigment dispersion is applied when the reactive enhancing component is applied to the skin. In some embodiments, the pigment dispersion is applied when the crosslinking component is applied to the skin. In some embodiments, the pigment dispersion is applied between the application of the reactive enhancing component to the skin and the application of the crosslinking component to the skin.

[0174] In some implementations, the pigment dispersion formulation may be applied to skin that has not yet been treated with a body orthopedic formulation or film. For example, a subject may apply the pigment dispersion formulation to the area around the body orthopedic film or formulation on the skin, or the subject may apply the pigment formulation to the skin instead of applying a body orthopedic film or formulation.

[0175] The term "application" includes methods of applying the formulations disclosed herein to a subject's body, such as application using fingers, brushes, cotton balls, pads, sprayers, sponges, swabs, roll-on applicators, etc. Those skilled in the art can readily determine appropriate methods for applying the formulations disclosed herein.

[0176] In some embodiments, the present invention relates at least in part to a kit comprising a body-correcting agent containing a reactivity-enhancing component and a crosslinking component. In some embodiments, the kit is a multi-compartment kit comprising at least two compartments, one compartment containing the reactivity-enhancing component and the second compartment containing the crosslinking component. In some embodiments, the kit further includes instructions for using the kit, one or more brushes, one or more swabs, a film-removing cleaner, or a mirror. In some embodiments, the kit further includes one or more finishing agents.

[0177] In some embodiments, the present application relates at least in part to a body correction film prepared by a method comprising: applying a reactive enhancing component to the body; and applying a crosslinking component to the reactive enhancing component, wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component.

[0178] In some embodiments, the present application relates at least in part to a body correction film prepared by a method comprising: applying a crosslinking component to the body; and applying a reactive enhancing component to the crosslinking component, wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component.

[0179] The phrase "body correction film" includes a film that forms after the reaction of a reactive enhancing component and a crosslinking component and that improves one or more body imperfections after formation. In some embodiments, the body correction film is a skin correction film (e.g., a film that improves one or more body imperfections).

[0180] In some embodiments, the body correction film has the appearance of natural skin after application to the skin. The phrase "appearance of natural skin" includes the perception that the body correction film has the appearance, feel, and texture of real skin when applied to the skin and that the skin treated with the film has the physical properties (e.g., elasticity and stiffness) of real (e.g., fresh) skin. A trained observer and / or technician will be able to determine whether the film has the appearance of natural skin when applied to the body. For example, a trained observer will be able to determine whether the film appears overly shiny when applied to the body, as described in Example 3, or whether the film appears to not move with the muscle tissue underneath the skin, for example, in response to disruption, yielding, or deformation of the film in response to natural skin movement.

[0181] A technician will be able to determine whether the film has the appearance of natural skin after application to the body. For example, the elasticity and stiffness of the skin (with or without a body correction film applied thereto) can be assessed by a variety of methods (Agache et al. Arch. Dermatol. Rev., 269 (1980) 221, the teachings of which are incorporated herein by reference). For example, the DermaLab suction cup instrument provides one commonly used method to assess the mechanical properties of the skin and has previously been shown that younger skin is less stiff and more elastic than older skin (Grahame et al. Clinical Science 39 (1970) 223-238, the teachings of which are incorporated herein by reference). With this method, the stiffness of the skin is indicated by the Young's modulus, a measure calculated by the instrument based on the pressure required to suck the skin up a predetermined distance.

[0182] In some embodiments, the Young's modulus of the skin treated with the body- correcting formulation is reduced by about 5% to about 70%, such as about 30% to about 60%, or about 40% to about 50%, as compared to untreated skin. In some embodiments, the Young's modulus of the skin treated with the body- correcting formulation is reduced by about 5% to about 25%, as compared to untreated skin.

[0183] Elasticity of the skin is determined by the skin retraction time. The retraction time is obtained by measuring the time it takes for the skin to fall a predetermined distance toward its natural position after removal of suction pressure. In some embodiments, the retraction time of the skin treated with the body- correcting formulation is reduced by about 5% to about 75%, such as about 30% to about 60%, or about 50% to about 65%, as compared to untreated skin. In some embodiments, the retraction time of the skin treated with the body- correcting formulation is reduced by about 5% to about 10%, as compared to untreated skin. In some embodiments, the retraction time of the skin treated with the film is approximately the retraction time of the film alone.

[0184] The bicep and hand skin was evaluated before and after application of the body- correcting treatment, as shown in Figure 1 and 2 The DermaLab results demonstrate that the skin is less stiff Figure 1 and more elastic Figure 2 after product application. The observed decrease in stiffness and increase in skin elasticity are consistent with younger skin.

[0185] In some embodiments, the body- correcting film has the appearance and physical properties of young, flawless, natural skin after application to the skin. The phrase "young skin" includes skin that has little or no damage, as measured by Griffith score. The Griffith score (GS) as shown below is a quantitative measure of the amount of skin damage a subject has.

[0186] 0-1 : No damage

[0187] 2-3 : Mild damage

[0188] 4-5 : Moderate damage

[0189] 6-7 : Moderate to severe damage

[0190] 8-9 : Severe damage

[0191] In some embodiments, young skin includes skin having a Griffith score of about 0 to about 3.

[0192] In some embodiments, the subject has a negative change in Griffith score (AGS) of about 1, about 2, about 3, about 4, about 5, about 6, about 7, or about 8 after applying the body- correcting formulation. In some embodiments, the subject has a AGS of about -0.5 to about -3.0 after applying the body- correcting formulation. In one embodiment, the subject has a AGS of about -1 to about -1.5, about -1.2 to about -1.3 (e.g., about -1.25) after applying the body- correcting formulation. In another embodiment, the subject has a AGS of about -2.0 to about -3.0, e.g., about -2.0 to about -2.5, or about -2.1 to about -2.2 (e.g., about -2.15) after applying the body- correcting formulation.

[0193] One skilled in the art will be able to determine whether the film has the appearance of young, flawless, natural skin after being applied to the body by the method disclosed in Example 6.

[0194] In other embodiments, the film provides stiffness and elasticity after being applied to the skin such that the skin treated with the film appears substantially more like young skin than untreated skin. The term "elasticity" includes the tendency of the skin to return to its original shape once deformed. The phrase "substantially like the elasticity of young skin" includes the ability of the skin to return to its original shape once deformed in a manner similar to young skin. The term "stiffness" includes the resistance of the skin to deformation. The phrase "substantially like the stiffness of young skin" includes the ability of the skin to resist deformation in a manner similar to young skin. One skilled in the art will also be able to determine whether the film has the foregoing physical properties of young, flawless, natural skin after being applied to the body by the techniques described above (e.g., using the Dermalab suction cup instrument).

[0195] In some embodiments, the subject and / or an observer of the subject perceives a reduction in age after applying the body- correcting formulation. In some embodiments, the perceived reduction in age is about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, about 10 years, about 11 years, about 12 years, about 13 years, about 14 years, or about 15 years less than the actual age of the subject. In some embodiments, the perceived reduction in age is about 7.5 years less than the actual age of the subject after applying the body- correcting formulation. In other embodiments, the perceived reduction in age is about 8.5 years less than the actual age of the subject after applying the body- correcting formulation.

[0196] The phrases "forming a film" and "film formation" include the result of a polymerization reaction that occurs upon the interaction of the reactive-enhancing component and the crosslinking component. Without being bound by theory, film formation is characterized by a phase change from a viscous sol state of the mixture to a continuous, interconnected polymer state of the film.

[0197] A skilled artisan can determine when a film is formed on the body by using conventional methods. For example, rheological measurements using small amplitude oscillatory shear can continuously determine the continuous evolution of the viscoelastic properties of the reaction mixture, such as the elastic modulus (G'), the viscous modulus (G"), and the loss tangent (tan delta) through the film formation process. In some embodiments, a rheometer can be used to determine the intersection between G' and G" over time and the time at which delta becomes frequency independent, which is a measure of film formation. In some embodiments, the film is formed in at least about five minutes, such as in about one minute, about two minutes, about three minutes, or about four minutes. In some embodiments, the film is formed in at least about 10 seconds to about 3 minutes.

[0198] In some embodiments, the skin or body correction film has a Young's modulus (e.g., tensile strength) of about 0.01 to about 1 MPa, as shown in Example 1.

[0199] In some embodiments, the skin or body correction film has a strain at break with a strain at break of at least about 150%, as measured by Example 1.

[0200] In some embodiments, the skin or body correction film has a leather adhesion greater than about 20 N / mm, such as greater than about 25 N / mm, greater than about 30 N / mm, greater than about 35 N / mm, greater than about 40 N / mm, greater than about 45 N / mm, greater than about 50 N / mm, greater than about 55 N / mm, greater than about 60 N / mm, greater than about 65 N / mm, greater than about 70 N / mm, greater than about 75 N / mm, or greater than about 80 N / mm, as determined by the leather adhesion test shown in Example 2. In one embodiment, the leather adhesion is about 50 to about 80 N / mm, as determined by the leather adhesion test shown in Example 2.

[0201] In some embodiments, the skin or body correction film has a hysteresis of less than about 10%, such as less than about 9%, less than about 8%, less than about 7%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than 1%, or about 0%.

[0202] In some embodiments, the skin or body correction film has a thickness of about 10 μm to about 1500 μm, such as about 50 μm to about 500 μm. In some embodiments, the film has a thickness of less than about 100 μm. The film thickness can be measured by methods known to one skilled in the art, such as by a combination of calipers and a calibrated microscope. The film thickness can also be measured digitally from photomicrographs of the film cross-section. Microscope calibration allows the conversion of the measured pixel distance into a unit of distance.

[0203] In some embodiments, the skin or body correction film shrinks by less than about 1 to 30%, for example, about 1 to about 15%. The amount of shrinkage can be determined by methods known to one of skill in the art, for example, by the Croll method (Croll, S. G. J. Coatings Tech. 52 (1980) 35, the teachings of which are incorporated herein by reference). In this method, a film is used to cover one side of a thin flexible substrate. The amount of bowing that develops in the substrate as a result of shrinkage of the coating is used to calculate the magnitude of the coating shrinkage (Francis et al., J Mater Sci 2002; 37:4717-31, the teachings of which are incorporated herein by reference).

[0204] In some embodiments, the body correction film is physiologically stable. The phrase "physiologically stable" includes the durability of the film upon exposure to normal skin conditions, such as humidity, tears, sweat, or sebum. Physiological stability can be determined by methods commonly used by one of skill in the art, such as an uptake test, which measures the weight change of the film upon exposure to physiological factors. For example, the uptake test can employ a formulation that mimics sweat (e.g., IX phosphate buffered saline solution) or sebum (e.g., 25% wax monoesters, 41% triglycerides, 16% free fatty acids, and 12% squalene). In some embodiments, the weight of the film increases by less than about 10%, for example, less than about 9%, less than about 8%, less than about 7%, less than about 6%, less than about 5%, less than 4%, less than 3%, less than 2%, less than 1%, or shows no increase upon exposure to humidity, tears, sweat, or sebum.

[0205] In some embodiments, the present application relates at least in part to a method for correcting a body defect in a subject, comprising applying to the subject a formulation comprising a) a first reactive enhancement component; and a second crosslinking component; wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancement component to form a film on the skin, thereby correcting the body defect. The phrase "correcting a body defect" includes improving (e.g., partially or completely) one or more body defects permanently or temporarily (e.g., for the duration of time that the film remains on the skin). One of skill in the art will be able to determine whether a body defect is partially or completely corrected upon application of a body correction formulation to the body by the techniques described in Example 6.

[0206] In some embodiments, the phrase "correcting a physical defect" includes reducing the appearance of a physical defect in a subject, which includes applying a formulation to the subject, the formulation comprising a) a first reactive enhancing component; and b) a second crosslinking component; wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a film on the skin, thereby reducing the appearance of the skin or physical defect. The phrase "reducing the appearance of a physical defect" includes diminishing one or more outward aspects of one or more physical defects. In some embodiments, the appearance of the physical defect is reduced by about 100%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 10%, or about 5% after applying the physical correction formulation to the subject as compared to the untreated subject.

[0207] In some embodiments, the phrase "correcting a physical defect" includes concealing a physical defect in a subject, which includes applying a formulation to the subject, the formulation comprising a) a first reactive enhancing component; and b) a second crosslinking component; wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a film on the skin, thereby concealing the appearance of the physical defect. The phrase "concealing a physical defect" includes partially or completely masking or hiding one or more physical defects from view. In some embodiments, the method provides for concealing a physical defect in a subject after a cosmetic procedure, which includes applying a formulation to the skin that has undergone a cosmetic procedure, the formulation comprising a) a first reactive enhancing component; and b) a second crosslinking component; wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a film on the skin, thereby concealing the appearance of the physical defect. Examples of cosmetic procedures include, for example, a cosmetic surgery (e.g., an eye lift, a face lift, a tummy tuck, etc.) or a cosmetic procedure (e.g., a Botox® injection). In some embodiments, the cosmetic procedure is a Botox® injection. In some embodiments, the skin defect is concealed. In some embodiments, the physical defect is concealed by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% after applying the physical correction formulation as compared to the untreated physical defect.

[0208] In some embodiments, the phrase "correcting a physical imperfection" includes improving the appearance of a subject's body, which includes applying a formulation to the subject, the formulation comprising a) a first reactive enhancement component; and b) a second crosslinking component; wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancement component to form a film on the skin, thereby improving the appearance of the body. The phrase "improving the appearance of a subject's body" includes enhancing the outward appearance of the body. Examples of improving the appearance of the body include reducing or masking the appearance of a port wine stain or a nevus flammeus (e.g., a nape nevus flammeus or a median nevus flammeus), melasma, wrinkles, scars, moles, acne, scars, skin deformities, birthmarks, burn wounds, blemishes, or pores, evening out skin tone, reducing or masking shine, lifting sagging skin, or reducing or masking fatty bulges or stretch marks. In some embodiments, the appearance of the subject's skin is improved.

[0209] In some embodiments, the phrase "correcting a physical imperfection" includes enhancing a subject's body, which includes applying a formulation to the subject's skin, the formulation comprising a) a first reactive enhancement compound; and b) a second crosslinking component; wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancement component to form a film on the skin, thereby enhancing the subject's body. The phrase "enhancing the body" includes increasing or intensifying a characteristic of the subject's body to make the subject's appearance more attractive. For example, the subject's body can be enhanced by adding a colorant, glitter, or the like. In some embodiments, the appearance of the subject's skin is enhanced.

[0210] In some embodiments, the present application is directed, at least in part, to a method of reducing the appearance of a subject's age, which includes applying a formulation to the subject, the formulation comprising a) a first reactive enhancement component; and b) a second crosslinking component; wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancement component to form a film on the skin, thereby reducing the appearance of the subject's age. The phrase "reducing the appearance of a subject's age" includes the perception by the subject or those observing the subject that the subject appears younger after applying the body-correcting film to the subject. In some embodiments, the subject appears about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, about 10 years, about 11 years, about 12 years, about 13 years, about 14 years, about 15 years, about 16 years, about 17 years, about 18 years, about 19 years, or about 20 years younger after applying the body-correcting film.

[0211] In some embodiments, the present application relates at least in part to a method for protecting a subject's body comprising applying a formulation to a subject, the formulation comprising a) a first reactive enhancing component; and b) a second cross-linking component; wherein the cross-linking component catalyzes in situ cross-linking of the reactive enhancing component to form a film on the skin, thereby protecting the body. The phrase "protecting a subject's body" includes preventing or shielding the subject's skin or body from environmental elements, such as damage from sunlight, wind, rain, or environmental toxins. In some embodiments, the subject's skin is protected.

[0212] In some embodiments, the present application relates at least in part to a method for shaping a subject's body comprising applying a formulation to a subject, the formulation comprising: a) a first reactive enhancing component; and b) a second cross-linking component; wherein the cross-linking component catalyzes in situ cross-linking of the reactive enhancing component to form a film on the skin, thereby shaping the body. The phrase "shaping a subject's body" includes altering the subject's body, such as by providing support to soft body tissue and preventing sagging of soft body tissue. Examples of soft body tissue include the abdomen, hips, thighs, neck, eyebrows, jaw, chest, skin under the arms, and skin around the eyes. In some embodiments, the subject's skin is shaped.

[0213] In some embodiments, the phrase "shaping a subject's body" includes altering a structure by, for example, repositioning a portion of the subject's body, including applying a formulation to the subject, the formulation comprising a) a first reactive enhancing component; and b) a second crosslinking component; wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a film on the skin, thereby shaping the body. In some embodiments, a portion of the subject's body is repositioned, for example, the chest, the skin, the buttocks, etc. The phrase "repositioning a subject's body" includes lifting a subject's body, for example, in a manner similar to a surgical cosmetic procedure (e.g., a facelift, an eye lift, a breast lift, etc.). In some embodiments, the subject's skin is repositioned. In some embodiments, the skin is facial skin (e.g., skin around the eyes, skin over the eyebrows, or skin around the lips) or neck skin. In some embodiments, the body is repositioned by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, or about 50% after applying the body correction formulation to the body as compared to the subject's body without treatment. In some embodiments, the body is repositioned by about 1 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 9 mm, about 1 cm, about 1.5 cm, about 2.0 cm, about 2.5 cm, about 3.0 cm, about 3.5 cm, about 4.0 cm, about 4.5 cm, about 5.0 cm, about 5.5 cm, about 6.0 cm, about 6.5 cm, about 7.0 cm, about 7.5 cm, about 8.0 cm, about 8.5 cm, about 9.0 cm, about 9.5 cm, or about 10 cm after applying the body correction formulation to the body.

[0214] In some embodiments, the present application is directed, at least in part, to a method for delivering an agent to a subject, comprising applying a formulation to the subject's skin, the formulation comprising a) a first reactive enhancing component optionally comprising one or more agents; and b) a second crosslinking component optionally comprising one or more agents; wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a film on the skin, thereby delivering the agent to the subject. The phrase "delivering an agent" includes releasing an agent (e.g., a cosmetic or therapeutic agent) to the subject's skin after forming a film on the subject's skin. In some embodiments, the agent is delivered once or the agent is formulated to be delivered in a time-release manner. Examples of agents include cosmetic agents and therapeutic agents.

[0215] In some embodiments, the present application is directed, at least in part, to a body correction formulation for application to a subject's body, comprising at least one preselected functional modulating component, wherein the composition forms a body correction film upon application to the subject's body.

[0216] The term "preselected" includes components that are selected prior to the preparation of the formulation. For example, components can be selected during the manufacturing process to produce a unique formulation. Alternatively, components can be selected by the subject prior to application of the formulation.

[0217] The phrase "function regulating component" includes components that allow the body- correcting formulation to selectively adjust for the particular use of the film (e.g., to reduce the appearance of wrinkles, to reduce shine, to conceal pores, etc.). The function regulating component or components can be selected based on the physical properties of the film necessary for effective application for the particular use of the film. For example, if the formulation is to be used to reduce shine, the value of the modulus relative to other physical properties of the resulting film should be lower.

[0218] In some embodiments, the present application relates at least in part to a body- correcting formulation targeted to a treatment area on the body of a subject, comprising at least one preselected treatment-specific component, wherein the composition forms a body- correcting film upon application to the targeted treatment area on the body of the subject.

[0219] The phrase "targeted treatment area" includes the body area to which the formulation is applied.

[0220] The phrase "treatment-specific component" includes components that allow the body- correcting formulation to selectively adjust for the targeted treatment area on the body (e.g., under the eyes, forehead, lips, buttocks, neck, etc.). The treatment-specific component or components can be selected based on the physical properties of the film produced by the formulation necessary for effective application to the targeted treatment area, as shown in Table 1. For example, if the targeted treatment area is under the eyes, the value of the modulus relative to other physical properties of the resulting film should be lower.

[0221] Table 1

[0222]

[0223] Examples of function regulating components and treatment-specific components include stiffness components, elasticity components, elongation components, and adhesion components, matte components, and texture components.

[0224] The phrase "stiffness component" includes components that adjust the flexibility of the resulting film, as determined by measuring the Young's modulus of the film (see Example 2). Examples of stiffness components include reactive ingredients (e.g., organopolysiloxanes and / or hydride-functionalized polysiloxanes) and reinforcing ingredients.

[0225] The phrase "elasticity component" includes components that adjust the recoil force of the resulting film, as determined by measuring hysteresis, and includes, for example, reinforcing ingredients.

[0226] The phrase "elongation component" includes components that adjust the stretch of the resulting film, as determined by measuring the percent elongation at yield. Examples of elongation components include reactive ingredients (e.g., organopolysiloxanes and / or hydride-functionalized polysiloxanes) and reinforcing ingredients.

[0227] The phrase "adhesion component" includes components that adjust the adhesion of the resulting film, as measured by the leather adhesion test (see Example 2). Examples of adhesion components include reactive ingredients (e.g., organopolysiloxanes and / or hydride-functionalized polysiloxanes) and reinforcing ingredients.

[0228] The phrase "matt component" includes components that adjust the color of the resulting film, as measured by determining the color of the resulting film (see Example 3). Examples of matt components include reinforcing ingredients and light-scattering particles.

[0229] The phrase "texture component" includes components that adjust the texture of the film to give the resulting film the appearance and feel of natural skin, and is measured by determining the friction of the film. One skilled in the art can readily determine a method of measuring the friction of a film, for example, by pressing into and dragging a cantilever across a surface, and recording the resistance force. Higher friction corresponds to higher recorded force and rougher surfaces tend to have higher friction.

[0230] In some embodiments, the present application relates at least in part to a film-removing cleanser for removing a body correction film, wherein the film is prepared by a method comprising: a) applying a reactive reinforcing component to the skin; and b) applying a crosslinking component to the reactive reinforcing component, wherein the crosslinking component catalyzes in situ crosslinking of the reactive reinforcing component.

[0231] In other embodiments, the present application relates at least in part to a film-removing cleanser comprising a film-wetting component, a film-penetrating component, a film-swelling component, and a film-removing component.

[0232] The phrase "film-removing cleanser" includes cosmetic formulations that break down a body correction film when applied to the film to allow the film to be removed from the body. In some embodiments, the film-removing cleanser removes the film by wetting the film, penetrating the film, swelling the film, and removing the film from the skin.

[0233] The phrase "film-wetting component" includes those components of a cleanser that allow the film to absorb liquid. In some embodiments, the film-wetting component comprises caprylyl methicone, ethyl trisiloxane, or a combination thereof.

[0234] The phrase "film-penetrating component" includes those components of a cleanser that allow the cleanser to penetrate the film. Examples of film-penetrating components include siloxane emulsifiers, caprylyl methicone, ethyl trisiloxane, or a combination thereof.

[0235] The phrase "film swelling component" includes a component of the cleansing agent that swells the film. Examples of film swelling components include caprylyl methicone, ethyl trisiloxane, isododecane, or combinations thereof.

[0236] The phrase "film release component" includes a component of the cleansing agent that causes the film to not adhere to the skin or body of a subject to which the film is applied. Film release components include glycols, water, or combinations thereof.

[0237] In some embodiments, the cleansing agent disrupts the mechanical integrity of the film. The phrase "disrupts the mechanical integrity of the film" includes a disordering of the mechanical characteristics that provide the film its unique properties (e.g., stiffness, elasticity, elongation, adhesion, etc.).

[0238] In some embodiments, the cleansing agent comprises a silicone phase, an emulsifier phase, and an aqueous phase. The phrase "silicone phase" includes a component of the cleansing agent that comprises one or more silicones (e.g., caprylyl methicone and ethyl trisiloxane). In some embodiments, the silicone phase also includes isododecane and Aerogel VM2270 (Dow Corning). The phrase "emulsifier phase" includes a component of the cleansing agent that comprises one or more emulsifiers (e.g., silicone emulsifiers such as lauryl PEG-9 polydiethylsiloxane ethyl dimethicone, PEG-35 castor oil, or isododecane and lauryl dimethicone / polyglyceryl-3 crosspolymer). The phrase "aqueous phase" includes a component of the cleansing agent that is dissolved in water (e.g., water, propylene glycol, butylene glycol, glycerin, or combinations thereof). In some embodiments, the aqueous phase includes MP diol glycol, a preservative (e.g., neolone PE), an optical particle (e.g., silica and DMPA / iso phthalate / SMDI copolymer & Green 5), and a structural particle (e.g., nylon-12).

[0239] In some embodiments, the silicone phase is about 50% of the cleansing agent, the emulsifier phase is about 8% of the cleansing agent, and the aqueous phase is about 42% of the cleansing agent.

[0240] In some embodiments, the present application is directed, at least in part, to a method of cleaning a body surface having a body correction film applied thereto, comprising applying an effective amount of a film-dissolving cleansing agent to the film to dissolve the film. In some embodiments, the body surface is skin.

[0241] In some embodiments, the present application is directed, at least in part, to a formulation for repairing a body correction film applied to skin, wherein the formulation comprises a) a first reactive enhancement component and b) a second crosslinking component; wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancement component to form a film on the skin.

[0242] The term "repair" includes improving the body-corrective film after the film is formed on the skin. In some embodiments, the term "repair" includes patching or patching up a tear, gap, or break in the film. In some embodiments, the term "repair" includes replacing a portion of the film that can be removed from the skin. In some embodiments, the term "repair" includes reattaching or reattaching a portion of the film that can be unattached from the skin (e.g., delaminated from the skin). In some embodiments, the term "repair" includes swelling the edges of a tear, gap, or break in the film to make the film more malleable so that the film can be reshaped.

[0243] In some embodiments, the present application is directed, at least in part, to a method for repairing a body-corrective film applied to the skin by: a) identifying an area of the film in need of repair; b) optionally smoothing the edges of the film; and c) applying a formulation to repair the film, wherein the formulation comprises a first reactive-enhancing component and a second crosslinking component; wherein the crosslinking component catalyzes in situ crosslinking of the reactive-enhancing component to form a film on the skin, thereby repairing the body-corrective film.

[0244] The phrase "smoothing the edges of the film" includes removing, scrubbing, swelling, brushing, or abrading the edges of the film in the area in need of repair so that uneven or non-uniform portions of the film are removed.

[0245] In some embodiments, the present application is directed to a kit comprising a first reactive-enhancing component and a second crosslinking component, wherein the crosslinking component catalyzes in situ crosslinking of the reactive-enhancing component to form a film on the skin. In some embodiments, the present application is directed, at least in part, to a kit for repairing a body-corrective film, wherein the kit comprises a formulation comprising a) a first reactive-enhancing component and b) a second crosslinking component wherein the crosslinking component catalyzes in situ crosslinking of the reactive-enhancing component to form a film on the skin.

[0246] In some embodiments, the kit is a multi-compartment kit that includes at least two compartments. In some embodiments, the reactive-enhancing component is in one compartment and the crosslinking component is in a second compartment. In some embodiments, the kit further comprises one or more brushes, one or more swabs, a film-removing cleanser, instructions for use, or a mirror. In some embodiments, the kit further comprises a pigment-dispersing formulation. EXAMPLE

[0247] Example I. Cycle Test and Extension Traction Test

[0248] Sample Preparation:To perform the batch mechanical property determination, the target material was cast in a dumbbell shaped mold. The neck portion of the mold was 20 mm long, 5 mm wide, and 1.5 mm deep. The "handle" of the mold was 20 mm x 15 mm and provided sufficient area to ensure secure, non-slip gripping of the sample during testing. The mold dimensions were consistent with the ASTM D638 guidelines.

[0249] Once the poured samples were fully cured and dry, the formed samples were removed from their respective molds by means of a spatula and measured with digital and dial calipers to determine the exact dimensions.

[0250] Mechanical Testing: The mechanical characterization of the samples was performed in an Instron 3342 (Instron, Norwood MA) equipped with a 100 N load cell (Instron #2519-103). The dumbbell shaped samples were mounted on the instrument via a modified Instron 2710-101 grip which ensured that the samples did not slip or move within the grip during testing. Two types of tests were performed on each sample, first a cycle test, and then an extension pull test. It was noted that the results of the first test (e.g., cycle test) had a negligible effect on the results of the second test (e.g., extension pull test). Each test was pre-programmed into the Bluehill Lite Software used to operate the instrument. The parameters and data associated with each of the two tests are described below.

[0251] Cycle Test: To determine the elasticity of the material, a cycle test was designed. The cycle test was used to determine the most elastic (e.g., spring-like) material and the Instant Residual Strain (I.R.S.) was obtained from this test, as described below. In general, the higher the elasticity of a material, the faster it returns to its original shape after deformation. For materials with the best elasticity, the I.R.S. and the cycle test area are close to zero, so the lower the value the better.

[0252] Prior to starting the test, the sample was mounted on the instrument so that the rectangular handle portion of the sample, and no sample neck, was secured within the instrument grips. The instrument grip distance was adjusted so that the sample was in neutral tension, as indicated by the instrument force close to zero (±0.01 N). Subsequently, a cyclic extension was performed at 1 mm / s to reach a maximum extension of 15% of the initial sample length. A total of 15 cycles were performed and recorded. The stress-strain data recorded by the instrument was exported into Excel, where the reported mechanical properties were calculated.

[0253] Multiple parameters were automatically extracted using an Excel template. The cyclic Young's modulus was calculated as the linear slope of the stress-strain curve for the first cycle, from 1% to 4%. The R-squared value of the linear fit was higher than 0.99 or the Young's modulus was discarded. The instantaneous residual strain (I.R.S.) for each cycle was calculated as the difference in strain between the loading curve and the unloading curve at half of the maximum stress reached during the 1st cycle. The I.R.S. for the 1st cycle was recorded, as well as the average I.R.S. for the 4th to 14th cycles. The area bounded by the loading curve and the unloading curve for each cycle was also calculated. A good consistency between the I.R.S. and the calculated cycle area was observed.

[0254] Most of the materials evaluated had enough flexibility and elasticity to enable repeated cycle tests on the same sample without significant changes in the calculated properties. This indicates that the test does not cause permanent changes in the material being tested.

[0255] Extension Traction Test: An extensional traction test was used to determine the stiffness and extensibility of the materials by measuring the Young's modulus and the ultimate strain. The Young's modulus was used as a measure of the material stiffness, while the ultimate strain was used as a measure of the material flexibility. In order to develop films with a skin-like appearance, the Young's modulus should fall within a target range (e.g., 0.1-1.0 MPa), while the breaking strain (as measured by the ultimate strain) should be high enough (e.g., greater than about 150%) so that the film does not break when deformed by skin motion.

[0256] The sample was placed on the instrument so that the rectangular handle portion of the sample, as well as the sample neck, were secured within the instrument grips. The instrument grip distance was adjusted so that the sample was in neutral tension, as indicated by the instrument force approaching zero (±0.01 N). Then, extension was performed at 10 mm / s until the sample failed. The stress-strain data recorded by the instrument during the extension was exported into Excel, where the reported mechanical properties were calculated.

[0257] Multiple parameters were automatically extracted from the data generated by the instrument using an Excel template. The extensional Young's modulus (YM) was calculated as the linear slope of the stress-strain curve, from 6% to 11%. The R-squared value of the linear fit was higher than 0.99 or the Young's modulus was calculated from the more linear 5% strain range on the stress-strain curve. The shear modulus (G) was determined from the same strain range as the YM. G was calculated as the slope of the best linear fit between the recorded stress and a-a-2, where a is 1 + instantaneous strain. The yield strain was determined as the strain at which the difference between the measured stress and the Neo-Hookean stress: G multiplied by (a-a-2) was more than 10%. The ultimate stress was calculated as the maximum stress recorded during the experiment. The mechanical property calculations shown herein are consistent with ASTM D412.

[0258] Example 2: Leather T-Peel Adhesion Test: To determine the adhesion of the target material, a small piece of soft, flexible leather (25.4 mm wide and 76.2 mm long) was spread with the material. The leather used as the test substrate was a light weight upholstery leather (AD1100 from Leather Unlimited, Belgium WI). Immediately after spreading the material on the first piece of leather, a comparable second piece of leather was placed on top to sandwich the thin layer of material between the two pieces. The two pieces of leather were squeezed together to leave a uniform thin layer of material on the surface of both leather substrates. The edges were wiped to remove the material that entered and the material was cured and dried to form the test sample.

[0259] The adhesion test sample was manually peeled apart at one end portion to separate the two leather substrates enough for effective clamping by the Instron 3342 base plate. Each leather substrate was secured in its own instrument clamp and an extension test was performed at a rate of 10 mm / s to peel the two substrates apart from each other. Force vs. time data was recorded by the instrument during the extension and exported to Excel where the reported adhesion force was calculated.

[0260] An Excel template was used to automatically extract the adhesion parameters from the data generated by the instrument. The average adhesion force of the sample was calculated by averaging the instantaneous forces measured by the instrument during the experiment normalized to the same width (25.4 mm). This test method was developed according to ASTM D1876. The minimum acceptable adhesion force depends on the stiffness of the material and the area of the film placed, which is about greater than 25 N / mm.

[0261] Example 3. Image Analysis Measurements

[0262] Shine:To measure shine in vitro or in vivo, a light box with a light source placed at a 45° angle relative to the site to be measured is used to produce shine, and a camera is used to photograph the site placed so that the angle formed by the line drawn from the lens to the area to be measured is 45°. The white balance, F-stop, and ISO of the camera are manually set to get adequate exposure and good color temperature. One photograph is taken without any diffusing element between the light source and the site to capture the shine. Then, a diffusing element is placed between the light source and the site and another photograph is taken (the shutter speed is changed so that the exposure is similar or equal to the first photograph). This photograph captures the surface without any shine, but the first photograph captures the maximum amount of shine due to the specular reflectance. The photographs are overlaid and cropped to the relevant sample area, and then the diffused photograph is subtracted from the maximum shine photograph to produce a photograph with only the strongest areas of shine present. The overall subtracted photograph is then outlined by finding the average gray value along with the standard deviation. This average gray value is recorded as the shine value and is used to compare the amount of specular reflectance present in each sample. For each sample, the camera settings are identical for each scenario (with and without diffuser).

[0263] Photo Creation Capture: To ensure maximum repeatability of each photograph taken for product performance evaluation in the panelist layout, a Head Positioning System (HPS) was established. The HPS has two configurations: forehead-only evaluation and full-face evaluation. In both configurations, a Model 819 Series bench-mounted chin rest from Applied Science Laboratories (ASL) was used as a base to mount the two different configurations onto a bench. Two cameras were used to capture the subject from two different angles. The first camera (normal shot) was placed on the face so that the line through the lens of the camera was placed at an angle of about 90° relative to the plane of the subject's face. The second camera (45° shot) was placed to the left of the subject so that the line through the lens of the camera was placed at an angle of about 45° relative to the plane of the subject's face, primarily capturing the left side of the subject's face. The position of the cameras relative to the chin rest remained constant.

[0264] In the first configuration, the ASL cheek rest (819-2155) was mounted at the ASL chin rest. In this setup, the panelist's head was positioned so that the line from the center of the camera lens to the area of evaluation was perpendicular to the area of evaluation on the forehead. In the second configuration, the ASL forehead rest (819-2150) was attached to the chin rest. In this setup, the chin rest cup was positioned so that the horizontal bar on the forehead rest was at the level of the panelist's hairline, maximizing the area of evaluation in each photograph.

[0265] Photography lighting consisted of two Calumet Quattro fluorescent lights (CF0003) with four Calumet 35 Watt 5500K daylight color temperature daylight lamps (OL2003) placed in front of and angled directly at the panelist on either side. A glare block polarizing filter from Visual Pursuits, Inc. was also placed in front of each fluorescent light. The daylight lamps were warmed up for at least 10 minutes prior to taking any photographs. In addition to the lighting, a circular polarizing filter was used on each camera lens to control the type of light in each photograph.

[0266] For each evaluation, two sets of photographs were taken with a regular still camera. In the first setting, the circular polarizing filter of the camera was set so that its polarization was similar to that of the daylight lamps, giving photographs that accentuated highlights and fine wrinkles, pores, and skin texture. In the first setting, the circular polarizing filter was set so that the polarization was perpendicular (or crossed) to that of the fluorescent lights, resulting in a washout of all highlights and showing underlying skin color, discolorations, and deep wrinkles. For each evaluation, the 45° still camera was set so that the circular polarizing filter of the camera was set so that its polarization was similar to that of the daylight lamps, giving photographs that accentuated highlights and fine wrinkles, pores, and skin texture.

[0267] Eyebrow-Lift Measurement of Photo: To measure the eyebrow height of the photographs, the photographs were obtained using the previously described method of photograph capture. A "canthus line" was then drawn on the photograph from the medial canthus to the lateral canthus of each eye. This canthus line served as the baseline for measuring eyebrow height. The eyebrows were separated from the image by applying image operations of valley detection, edge detection, and thresholding of the image. Within an experiment, the parameters of the valley and edge detection and thresholding were constant so that the same portion of the eyebrow from each image series was the same. To accurately separate the eyebrows, these parameters were varied to account for differences in photographic exposure from experiment to experiment and skin and eyebrow color from panelist to panelist. From these methods, a binary mask was produced, which was then further manipulated to ensure that only the eyebrow was separated in the photograph. For the total height change measurement, the centroid of each eyebrow was determined from its binary mask. The parameters of the binary manipulation and centroid determination were always kept constant. The height of each eyebrow was the normal to its centroid to its respective canthus line. This method measured the total height change but did not capture the magnitude of the change for a severely arched or angular manipulation (where part of the eyebrow was raised and part was lowered). For this case, instead of measuring the centroid of the eyebrow, the height of the eyebrow at its left and right edges and at its center perpendicular to the canthus line was determined from its binary mask.

[0268] Reduction in Redness Photo Measurement:Photos of panelists were obtained using the photographic setup described previously. The redness comparison was only performed on photos taken within the same experiment, as exposure, as well as light and face positioning, were constant only within a single experiment. After taking a series of photos in an experiment, the cross-polarized photos were covered to keep the area to be evaluated for redness reduction constant between each image. Using image manipulation software, the L*a*b* channels in the CIELAB color space were established for each image in the series. The L* value represents the luminosity, while a* and b* define the chromaticity. Specifically, a* represents the degree of redness (+ values) or greenness (- values). The subsequent images were then normalized using the intensity of the red square on the color chart of the a* channel of the baseline photo by adjusting the intensity of the a* channel of the subsequent images until the a* value within the red square on the color chart of those images equaled the baseline value. The area to be evaluated was then cropped from the photo. The redness reduction was then determined by subtracting the a* value of the area of the 'before' photo from the a* value of the 'after' photo. Negative values from this subtraction indicate a reduction in redness, while positive values indicate an increase.

[0269] Example 4: Stress Test Method

[0270] Artificial eyebrow lifts were formed by applying one of the following methods of pre-tensioning the skin during product application to evaluate the mechanical durability of the material. These pre-tensioning methods were used to exert pressure on the skin surface and to pull the eyebrows to the lifted position:

[0271] • "Eyebrow orthogonal push", in which a stress is applied that originates at the eyebrow hair and is previously oriented away from the eyebrow at an angle of 80° to 100° relative to the eyebrow line,

[0272] • "Corner hairline diagonal pull", in which a stress is applied that originates at the most forward and lateral points on the panelist's hairline and is previously oriented away from the eyebrow at an angle of 10° to 80° relative to the eyebrow line,

[0273] • "Corner hairline orthogonal pull", in which a stress is applied that originates at the most forward and lateral points on the panelist's hairline and is previously oriented away from the eyebrow at an angle of 80° to 100° relative to the eyebrow line,

[0274] • "Lateral hairline orthogonal push", in which a stress is applied that originates at the most forward point of the hairline at or above eye level and is previously oriented away from the eyebrow at an angle of 80° to 100° relative to the eyebrow line,

[0275] While the eyebrow is held elevated by one of these stresses, the product is applied to the area of skin over which the tension is applied. Once the film is cured, the stress is removed and the mechanical durability of the film's ability to retain tension in the skin is evaluated. The degree of eyebrow elevation is measured by using the aforementioned method and this evaluation is accomplished after the product is applied. The durability of the effect is measured by time, normal and exaggerated facial expressions, and environmental stresses such as water, sweat, heat, sebum production, and surface contact to interact with the film. The amount of elevation is tracked at regular intervals to determine how long the film is able to retain the mechanical benefit. If the film is able to resist the stresses mentioned previously and retain the eyebrow elevated at the level initially achieved immediately after application, the film is determined to have mechanical durability.

[0276] Example 5. Formulations

[0277] Examples of formulations that illustrate the two-step application method are provided below. The reactive boost component first step (e.g., treatment) includes Formulations 60-140-1, 60-140-1B, 60-140-HP2, SK 87 / 2, 60-140-LX2, SK 87 / 1, 48-196, 48-199, 60-211, 60-200-1N, 60-208, 66-166-F, 66-167-E, 66-166-C, 66-169-3, 66-170, 79-23, 79-24b, 79-45, 79-46, 79-41, 88-30-1, 83-16, 79-55a, 79-55b, 79-55c, 79-55d, 79-55e, 79-55f, 79-55g, 83-54, 79-55h, 81-18, 81-19, 81-20, 81-21, 79-74, 80-23, 79-88, 79-88-3A, 79-74-RD, 79-90-B, 88-70, 88-72, 88-75-2, 88-75-3, 88-80, 88-85-1, 88-85-2, 88-83-V2, 88-83-V3, and 83-54 shown below.

[0278] The components of the formulations are commercially available. The following table provides the non-proprietary names for any trade names used throughout this application.

[0279]

[0280]

[0281]

[0282]

[0283]

[0284]

[0285]

[0286] Formulation 60-140-1

[0287]

[0288]

[0289] Procedure:

[0290] Components 1-4 were hand mixed in a graduated 4-oz jar until the mixture was free of white specks. Subsequently, components 5-8 were added and the mixture was confirmed to be homogeneous (Mixture A). In a separate container, components 9 and 10 were hand mixed until homogeneous (Mixture B). Mixture B was added to Mixture A under vigorous agitation provided by a 4-blade, 40 mm impeller at 550 rpm, then component 11 was added and the mixing speed was set to 1000 rpm, and mixed for 5 minutes. The mixture was confirmed to be homogeneous.

[0291] Formulation 60-140-1B

[0292] Component Number Component Formulation Percent (%) 1 DMS-V41 22.60 2 Aerosil 8200 8.94 3 PS123-KG 11.30 4 UCT-PS448.5 5.30 5 Velvesil 125 3.42 6 Gransil EP-LS 3.42 7 Soft Beads B 1.20 8 Sepiplus 400 1.20 9 Water 25.66 10 Granhydrogel O 6.36 11 Granpowder Nylon 5.60 12 Cetiol OE 5.00

[0293] Procedure:

[0294] Components 1-4 were hand mixed in a graduated 4-oz jar and the mixture was confirmed to be free of white specks. Subsequently, components 5-8 were added and the mixture was confirmed to be homogeneous (Mixture A). In a separate container, components 9 and 10 were hand mixed until homogeneous (Mixture B). Mixture B was added to Mixture A under vigorous agitation provided by a 4-blade, 40 mm impeller at 550 rpm, then components 11 and 12 were added and the mixing speed was increased to 1000 rpm, and mixed for 5 minutes. The mixture was confirmed to be homogeneous.

[0295] Formulation 60-140-HP2

[0296] Component Number Component Formulation Percent (%) 1 UCT-PS448.5 32.97 2 Aerosil 8200 12.82 3 PS123-KG 14.65 4 Velvesil 125 4.40 5 Gransil EP-LS 4.40 6 Soft Beads B 1.47 7 Sepiplus 400 1.47 8 Granhydrogel O 20.63 9 Granpowder Nylon 7.20

[0297] Procedure:

[0298] Components 1-3 were mixed by hand in a graduated 4-oz jar and the mixture was confirmed to be free of white specks. Subsequently, components 4-7 were added and the mixture was confirmed to be homogeneous (Mixture A). In a separate container, components 8 were mixed by hand until homogeneous (Mixture B). Mixture B was added to Mixture A under vigorous agitation provided by a 4-blade, 40 mm impeller at 550 rpm, then component 9 was added and the mixing speed was increased to 1000 rpm, mixing for 5 minutes. The mixture was confirmed to be homogeneous.

[0299] Formulation SK 87 / 2

[0300]

[0301]

[0302] Procedure:

[0303] Components 1-3 were mixed by hand in a graduated 4-oz jar and the mixture was confirmed to be free of white specks. Subsequently, components 4 and 5 were added and the mixture was confirmed to be homogeneous (Mixture A). In a separate container, components 6 and 7 were mixed by hand until homogeneous (Mixture B). Mixture B was added to Mixture A under vigorous agitation provided by a 4-blade, 40 mm impeller at 550 rpm, then components 8-10 were added and the mixing speed was increased to 1000 rpm, mixing for 5 minutes. The mixture was confirmed to be homogeneous.

[0304] Formulation 60-140-LX2

[0305] Component Number Component Formulation Percent (%) 1 DMS V41 27.51 2 Aerosil 8200 10.87 3 PS123-KG 3.47 4 UCT-PS448.5 13.41 5 Velvesil 125 4.16 6 Gransil EP-LS 4.16 7 Soft Bead B 1.39 8 Sepiplus 400 1.39 9 Water 21.45 10 Granhydrogel O 5.38 11 Granpowder Nylon 6.82

[0306] Procedure:

[0307] Components 1-4 were mixed by hand in a graduated 4-oz jar and the mixture was confirmed to be free of white specks. Subsequently, components 5-8 were added and the mixture was confirmed to be homogeneous (Mixture A). In a separate container, components 9 and 10 were mixed by hand until homogeneous (Mixture B). Mixture B was added to Mixture A under vigorous agitation provided by a 4-blade, 40 mm impeller at 550 rpm, then component 11 was added and the mixing speed was increased to 1000 rpm, mixing for 5 minutes. The mixture was confirmed to be homogeneous.

[0308] Formulation SK 87 / 1

[0309] Component Number Component Formulation Percent (%) 1 DMS V41 36.90 2 Aerosil 8200 12.30 3 PS123-KG 5.50 4 Velvesil 125 11.60 5 Gransil EP-LS 9.10 6 Water 7.10 7 Polyvinyl Alcohol 2.00 8 Granhydrogel O 9.10 9 Granpowder Nylon 6.40

[0310] Procedure:

[0311] Components 1-3 were mixed in a graduated 4-oz jar by hand and the mixture was confirmed to be free of white particulates. Subsequently, components 4 and 5 were added and the mixture was confirmed to be homogeneous (Mixture A). In a separate container, components 6 and 7 were mixed by hand until homogeneous (Mixture B). Mixture B was added to Mixture A under vigorous agitation provided by a 4-blade, 40 mm impeller at 550 rpm, then components 8 and 9 were added and the mixing speed was increased to 1000 rpm, and mixed for 5 minutes. The mixture was confirmed to be homogeneous.

[0312] Formulation 48-196

[0313]

[0314]

[0315] Procedure:

[0316] Components 1-3 were mixed in a graduated 4-oz jar by hand with a 4-blade impeller at 1000 RPM until homogeneous (Mixture A) and the mixture was confirmed to be homogeneous. In a separate container, components 4-8 were mixed by a 4-blade impeller at 750 RPM until homogeneous (Mixture B). In another container, components 9-11 were mixed by a 4-blade impeller at 750 RPM until homogeneous (Mixture C). Mixture B was added to Mixture C under vigorous agitation provided by a 4-blade, 40 mm impeller at 750 rpm, then Mixture A was added drop-wise to the combined Mixtures B and C. Finally, components 12 and 13 were added and the mixing speed was increased to 1000 RPM, and mixed for 10 minutes. The mixture was confirmed to be homogeneous.

[0317] Formulation 48-199

[0318]

[0319]

[0320] Procedure:

[0321] Mix ingredients 1-3 in a graduated 4-oz jar with a 4-bladed impeller at 1000 RPM until homogeneous (mixture A). In a separate container, mix ingredients 4-8 with a 4-bladed impeller at 750 RPM until homogeneous (mixture B). In another container, mix ingredients 9-11 with a 4-bladed impeller at 750 RPM until homogeneous (mixture C). With vigorous agitation provided by a 4-bladed, 40 mm impeller at 750 rpm, add mixture B to mixture C, then add mixture A dropwise to the combined mixture B and C. Finally, add ingredients 12 and 13 and increase the mixing speed to 1000 RPM and mix for 10 minutes. The mixture is confirmed to be homogeneous.

[0322] Formulation 60-211

[0323]

[0324]

[0325] Procedure:

[0326] Mix ingredients 1-7 in a graduated 4-oz jar with a 4-bladed impeller at 2000 rpm until homogeneous (mixture A). In a separate container, mix ingredients 8-11 with a 4-bladed impeller at 750 RPM until homogeneous (mixture B). Slowly add mixture B to mixture A with vigorous agitation provided by a 4-bladed impeller at 2000 RPM. Add ingredients 12 and 13 and increase the mixing speed to 2000 RPM for 5 minutes. The mixture is confirmed to be homogeneous.

[0327] Formulation 60-200-1N

[0328] Component Number Component Formulation Percent (%) 1 Andisil C1000 33.88 2 Andisil C1300 7.65 3 Andisil XL-11 18.03 4 SR 1000 Resin 10.93 5 Iris 2.19 6 Dri-Flow Elite BN 10.93 7 Barium Sulfate HL 4.37 8 Gransil EP-LS 8.74 9 Sepiplus 400 2.19 10 Neolone PE 0.55 11 Tint 0.54

[0329] Procedure:

[0330] Mix ingredients 1-5 in a graduated 4-oz jar with a 4-bladed impeller at 2000 rpm until homogeneous (mixture A). Then add ingredients 6-9 and mix with a 4-bladed impeller at 2000 RPM until homogeneous. Add ingredients 10 and 11 and mix at 2000 RPM until homogeneous.

[0331] Formulation 60-208

[0332]

[0333]

[0334] Procedure:

[0335] Mix ingredients 1-5 in a graduated 4-oz jar with a 4-blade propeller at 2000 rpm until homogeneous (mixture A). Then add ingredients 6-9 and mix with a 4-blade propeller at 2000 RPM until homogeneous. Add ingredients 10 and 11 and mix at 2000 RPM until homogeneous.

[0336] Formulation 66-166-F

[0337]

[0338]

[0339] Procedure:

[0340] Mix ingredients 1-3 together as silicone phase A. Mix ingredients 4-8 in silicone phase B. Combine ingredients 9-11 as the water phase. Slowly add the water phase to silicone phase B and mix until homogeneous. Slowly add phase A dropwise to the new phase. Once all silicone phase A is added, add ingredients 12-19 to the formulation and mix until homogeneous.

[0341] Formulation 66-167-E

[0342]

[0343]

[0344] Procedure:

[0345] Mix ingredients 1-3 together as silicone phase A. Add ingredients 4-8 to silicone phase B. Combine ingredients 9-11 as the water phase. Slowly add the water phase to silicone phase B and mix until homogeneous. Slowly add phase A dropwise to the new phase. Once all silicone phase A is added, add ingredients 12-21 to the formulation and mix until homogeneous.

[0346] Formulation 66-166-C

[0347]

[0348]

[0349] Procedure:

[0350] Mix components 1-3 together as silicone phase A. Add components 4-8 to silicone phase B. Combine components 9-11 as the water phase. Slowly add the water phase to silicone phase B and mix until homogeneous. Add phase A drop by drop very slowly to this new phase. Once all silicone phase A is added, add components 12-19 to the formulation and mix until homogeneous.

[0351] Formulation 66-169-3

[0352]

[0353]

[0354] Procedure:

[0355] Mix components 1-8 together and homogenize at 26,000 RPM for 10 minutes. After 10 minutes, add component 9 and homogenize again at 26,000 RPM for 10 minutes. Add components 10-15 to this homogenized mixture and mix with an overhead stirrer at 2,000 RPM until homogeneous in appearance (this is the silicone phase). In a separate container, mix components 16-19 until homogeneous to form the water phase. Slowly add the water phase to the silicone phase with continuous stirring at 2,000 RPM. Once the water phase is fully mixed, add components 20 and 21 to the formulation and mix at 2,000 RPM until homogeneous.

[0356] Formulation 66-170

[0357]

[0358]

[0359] Procedure:

[0360] Mix components 1-10 together to produce the silicone phase A. Next, mix components 11-14 to produce silicone phase B. The water phase is produced by mixing components 15-20. Slowly add the water phase to silicone phase B while mixing at 2,000 RPM to produce phase C. Finally, mix phase C into silicone phase A until homogeneous.

[0361] Formulation 79-23

[0362]

[0363]

[0364] Procedure:

[0365] Components 1-5 were combined and mixed at 2500 RPM in a dual asymmetric centrifugal mixer (mixture A), confirming that the mixture was free of white particles. Components 6-15 were added to mixture A and mixed in a dual asymmetric centrifugal mixer. Mixture A was confirmed to be homogeneous. In a separate container, components 16 and 20 were mixed at 550 rpm using a 4-blade, 40 mm propeller until homogeneous (mixture B). Mixture B was added dropwise to mixture A while mixing at 2000 rpm using a 4-blade, 40 mm propeller, and the mixture was confirmed to be homogeneous. Component 21 was added to the product of mixtures A and B and mixed at 1000 rpm using a 4-blade, 40 mm propeller until homogeneous.

[0366] Formulation 79-24b

[0367]

[0368]

[0369] Procedure:

[0370] Combine components 4, 8, and 9 and homogenize at 20,000 RPM until smooth. Add components 1-3, 6-7, and 10-12 and mix at 2,500 RPM for 6 minutes using a dual asymmetric centrifuge until no particles are visible (mixture A). In a separate container, mix components 13-17 at 550 rpm using a 4-blade, 40 mm agitator until homogeneous (mixture B). Add mixture B dropwise to mixture A while mixing at 2,000 rpm using a 4-blade, 40 mm agitator until the mixture is confirmed to be homogeneous. Add component 18 to the product of mixtures A and B and mix at 1,000 rpm using a 4-blade, 40 mm agitator until homogeneous.

[0371] Formulation 79-45

[0372] Mix the 2:1 blend of formulations 60-211 and 79-24b together for 2 minutes at 2000 rpm using a 4-blade 40mm propeller.

[0373] Formulation 79-46

[0374] Mix the 1:2 blend of formulations 60-211 and 79-24b together for 2 minutes at 2000 rpm using a 4-blade 40mm propeller.

[0375] Formulation 79-41

[0376] Mix the 1:5 blend of formulations 60-211 and 79-24b together for 2 minutes at 2000 rpm using a 4-blade 40mm propeller.

[0377] Formulation 88-30-1

[0378]

[0379]

[0380] Procedure:

[0381] Ingredients 1 through 7 were mixed at 275 RPM using a propeller blade to make Phase A. In a separate container, ingredients 8 through 10 were mixed at 275 RPM using a propeller blade to make Phase B. Phase B was mixed into Phase A at 275 RPM until the emulsion was uniform. The amount of 0.01% iron oxide was added to the final formulation to impart color. Formulations 83-49 and 83-50 are emulsions of VS 165,000 vinyl silicone and XL-11 hydride functional silicone containing 65% silicone, 8% oleth-10 surfactant, and balanced water, respectively.

[0382] Formulation 83-16

[0383]

[0384]

[0385] Procedure:

[0386] Combine ingredients 1 and 2 and homogenize at 20000 RPM until smooth (mixture A). Add ingredients 3 through 9 and mix with a dual asymmetric centrifugal mixer at 2500 RPM for 6 minutes until no more particulates are visible (mixture B). Combine mixture A and mixture B and centrifugal mix at 2500 RPM for 6 minutes (mixture A+B). In a separate container, mix ingredients 10 through 13 with a 4-blade, 40mm propeller at 550 rpm until homogenous (mixture C). Add mixture C dropwise to mixture A+B while mixing with a 4-blade, 40mm propeller at 400 rpm and mixture is confirmed to be homogenous. Add ingredient 14 to the product of mixture A+B and mixture C and mix with a 4-blade, 40mm propeller at 1000 rpm until homogenous.

[0387] Formulation 79-55a

[0388] Component Number Component Formulation Percent (%) 1 Gransil EP-LS TM ]]> 3.50 2 Andisil XL-11 TM ]]> 8.17 3 Andisil VS 1,000 TM ]]> 32.59 4 Andisil VS 165,000 TM ]]> 6.52 5 Andisil XL-11 TM ]]> 3.04 6 Aerosil R8200 TM ]]> 13.04 7 Sepiplus 400 TM ]]> 1.14 8 Water 21.76 9 Granhydrogel O TM ]]> 6.40 10 Jeechem BUGL TM ]]> 3.20 11 Sodium Chloride 0.32 12 Neolone PE TM ]]> 0.32 13 Iron Oxide Tint Mixture 0.01

[0389] Procedure:

[0390] Combine components 1 and 2 and homogenize at 20000 RPM until smooth (mixture A). Add components 3 to 7 and mix with dual asymmetric centrifugal mixer at 2500 RPM for 6 minutes until no more particulates are visible (mixture B). Combine mixture A and mixture B and centrifuge mix for 6 minutes at 2500 RPM (mixture A+B). In a separate container, mix components 8 to 12 with a 4-blade, 40 mm impeller at 550 rpm until homogenous (mixture C). Add mixture C drop wise to mixture A+B while mixing with a 4-blade 40 mm impeller at 400 rpm and mixture is confirmed to be homogenous. Add component 13 to the product of mixture A+B and mixture C and mix with a 4-blade 40 mm impeller at 1000 rpm until homogenous.

[0391] Formulation 79-55a

[0392]

[0393] Procedure:

[0394] Combine components 1 and 2 and homogenize at 20000 RPM until smooth (mixture A). Add components 3 to 7 and mix with dual asymmetric centrifugal mixer at 2500 RPM for 6 minutes until no more particulates are visible (mixture B). Combine mixture A and mixture B and centrifuge mix for 6 minutes at 2500 RPM (mixture A+B). In a separate container, mix components 8 to 12 with a 4-blade, 40 mm impeller at 550 rpm until homogenous (mixture C). Add mixture C drop wise to mixture A+B while mixing with a 4-blade 40 mm impeller at 400 rpm and mixture is confirmed to be homogenous. Add component 13 to the product of mixture A+B and mixture C and mix with a 4-blade 40 mm impeller at 1000 rpm until homogenous.

[0395] Formulation 79-55c

[0396] Component Number Component Formulation Percent (%) 1 Gransil EP-LS TM ]] 3.50 2 Andisil XL-1B TM ]] 8.17 3 Andisil VS 500 TM ]]> 0.84 4 Andisil MV 2,000 TM ]]> 1.29 5 Andisil VS 65,000 TM ]]> 21.04 6 Andisil XL-1B TM ]] 17.82 7 Aerosil R8200 TM ]]> 14.20 8 Sepiplus 400 TM ]]> 1.14 9 Water 21.76 10 Granhydrogel O TM ]]> 6.40 11 Jeechem BUGL TM ]]> 3.20 12 Sodium Chloride 0.32 13 Neolone PE TM ]]> 0.32 14 Iron Oxide Tint Mixture 0.01

[0397] Procedure:

[0398] Combine components 1 and 2 and homogenize at 20000 RPM until smooth (mixture A). Add components 3 to 8 and mix with a dual asymmetric centrifugal mixer at 2500 RPM for 6 minutes until no more particulates are visible (mixture B). Combine mixture A and mixture B and centrifuge mix for 6 minutes at 2500 RPM (mixture A+B). In a separate container, mix components 9 to 13 with a 4-blade, 40 mm impeller at 550 rpm until homogenous (mixture C). Add mixture C drop wise to mixture A+B while mixing with a 4-blade 40 mm impeller at 400 rpm and mixture is confirmed to be homogenous. Add component 14 to the product of mixture A+B and mixture C and mix with a 4-blade 40 mm impeller at 1000 rpm until homogenous.

[0399] Formulation 79-55d

[0400] Component Number Component Formulation Percent (%) 1 Gransil EP-LS TM ]]> 3.50 2 Andisil XL-1B TM ]]> 8.17 3 Andisil VS 250 TM ]]> 1.29 4 Andisil MV 2,000 TM ]] 1.94 5 Andisil VS 20,000 TM ]] 24.52 6 Andisil CE-4 TM ]]> 1.94 7 Andisil XL-1B TM ]]> 0.33 8 Andisil XL-11 TM ]]> 10.97 9 Aerosil R8200 TM ]]> 14.20 10 Sepiplus 400 TM ]]> 1.14 11 Water 21.76 12 Granhydrogel O TM ]]> 6.40 13 Jeechem BUGL TM ]]> 3.20 14 Sodium Chloride 0.32 15 Neolone PE TM ]]> 0.32 16 Iron Oxide Tint Mixture 0.01

[0401] Procedure:

[0402] Combine components 1 and 2 and homogenize at 20000 RPM until smooth (mixture A). Add components 3 to 10 and mix with a dual asymmetric centrifugal mixer at 2500 RPM for 6 minutes until no more particulates are visible (mixture B). Combine mixture A and mixture B and centrifuge mix for 6 minutes at 2500 RPM (mixture A+B). In a separate container, mix components 11 to 15 with a 4-blade, 40 mm impeller at 550 rpm until homogenous (mixture C). Add mixture C drop wise to mixture A+B while mixing with a 4-blade 40 mm impeller at 400 rpm and mixture is confirmed to be homogenous. Add component 16 to the product of mixture A+B and mixture C and mix with a 4-blade 40 mm impeller at 1000 rpm until homogenous.

[0403] Formulation 79-55e

[0404] Component Number Component Formulation Percent (%) 1 Gransil EP-LS TM ]]> 3.50 2 Andisil XL-1B TM ]]> 8.17 3 Andisil VS 250 TM ]]> 1.29 4 Andisil MV 2,000 TM ]]> 1.94 5 Andisil VS 65,000 TM ]]> 22.91 6 Andisil XL-1B TM ]]> 6.78 7 Andisil XL-11 TM ]]> 8.07 8 Aerosil R8200 TM ]]> 14.20 9 Sepiplus 400 TM ]]> 1.14 10 Water 21.76 11 Granhydrogel O TM ]]> 6.40 12 Jeechem BUGL TM ]]> 3.20 13 Sodium Chloride 0.32 14 Neolone PE TM ]]> 0.32 15 Iron Oxide Tint Mixture 0.01

[0405] Procedure:

[0406] Combine components 1 and 2 and homogenize at 20000 RPM until smooth (mixture A). Add components 3 to 9 and mix with a dual asymmetric centrifugal mixer at 2500 RPM for 6 minutes until no more particulates are visible (mixture B). Combine mixture A and mixture B and centrifuge mix for 6 minutes at 2500 RPM (mixture A+B). In a separate container, mix components 10 to 14 with a 4-blade, 40 mm impeller at 550 rpm until homogenous (mixture C). Add mixture C drop wise to mixture A+B while mixing with a 4-blade 40 mm impeller at 400 rpm and mixture is confirmed to be homogenous. Add component 15 to the product of mixture A+B and mixture C and mix with a 4-blade 40 mm impeller at 1000 rpm until homogenous.

[0407] Formulation 79-55f

[0408] Component No. Component Formulation Percentage (%) 1 Gransil EP-LS TM ]]> 3.50 2 Andisil XL-1B TM ]]> 8.17 3 Andisil VS 250 TM ]]> 1.34 4 Andisil VS 65,000 TM ]]> 23.74 5 Andisil XL-1B TM ]]> 7.03 6 Andisil XL-11 TM ]]> 8.36 7 Aerosil R8200 TM ]]> 14.71 8 Sepiplus 400 TM ]]> 1.14 9 Water 21.76 10 Granhydrogel O TM ]]> 6.40 11 Jeechem BUGL TM ]]> 3.20 12 Sodium Chloride 0.32 13 Neolone PE TM ]]> 0.32 14 Iron Oxide Tint Mixture 0.01

[0409] Procedure:

[0410] Combine components 1 and 2 and homogenize at 20000 RPM until smooth (mixture A). Add components 3 to 8 and mix with a dual asymmetric centrifugal mixer at 2500 RPM for 6 minutes until no more particulates are visible (mixture B). Combine mixture A and mixture B and centrifuge mix for 6 minutes at 2500 RPM (mixture A+B). In a separate container, mix components 9 to 13 with a 4-blade, 40 mm impeller at 550 rpm until homogenous (mixture C). Add mixture C drop wise to mixture A+B while mixing with a 4-blade 40 mm impeller at 400 rpm and mixture is confirmed to be homogenous. Add component 14 to the product of mixture A+B and mixture C and mix with a 4-blade 40 mm impeller at 1000 rpm until homogenous.

[0411] Formulation 79-55g

[0412]

[0413]

[0414] Procedure:

[0415] Combine components 1 and 2 and homogenize at 20000 RPM until smooth (mixture A). Add components 3 to 9 and mix with a dual asymmetric centrifugal mixer at 2500 RPM for 6 minutes until no more particulates are visible (mixture B). Combine mixture A and mixture B and centrifugal mix at 2500 RPM for 6 minutes (mixture A+B). In a separate container, mix components 10 to 14 with a 4-blade, 40 mm impeller at 550 rpm until homogenous (mixture C). Add mixture C dropwise to mixture A+B while mixing with a 4-blade 40 mm impeller at 400 rpm and the mixture is confirmed to be homogenous. Add component 15 to the product of mixture A+B and mixture C and mix with a 4-blade 40 mm impeller at 1000 rpm until homogenous.

[0416] Formulation 83-54

[0417]

[0418]

[0419] Procedure:

[0420] Add components 1 to 7 and mix with a dual asymmetric centrifugal mixer at 2500 RPM for 6 minutes until no more particulates are visible (mixture A). In a separate container, mix components 8 to 12 with a 4-blade, 40 mm impeller at 550 rpm until homogenous (mixture B). Add mixture B dropwise to mixture A while mixing with a 4-blade 40 mm impeller at 400 rpm and the mixture is confirmed to be homogenous. Add component 13 to the product of mixture A and mixture B and mix with a 4-blade 40 mm impeller at 1000 rpm until homogenous.

[0421] Formulation 79-55h

[0422]

[0423]

[0424] Procedure:

[0425] Combine components 1 and 2 and homogenize at 20000 RPM until smooth (mixture A). Add components 3 to 10 and mix with a dual asymmetric centrifugal mixer at 2500 RPM for 6 minutes until no more particulates are visible (mixture B). Combine mixture A and mixture B and centrifugal mix at 2500 RPM for 6 minutes (mixture A+B). In a separate container, mix components 11 to 15 with a 4-blade, 40 mm impeller at 550 rpm until homogenous (mixture C). Add mixture C drop-wise to mixture A+B while mixing with a 4-blade, 40 mm impeller at 400 rpm and the mixture is confirmed to be homogenous. Add component 15 to the product of mixture A+B and mixture C and mix with a 4-blade, 40 mm impeller at 1000 rpm until homogenous.

[0426] Formulation 81-18

[0427]

[0428]

[0429] Procedure:

[0430] Mix components 1-5 in a glass beaker with a 4-blade, 40 mm impeller at 2000 rpm for 2 minutes until the mixture is homogenous (mixture A). Separately, mix components 6-12 until homogenous (mixture B). Add mixture B to mixture A under vigorous agitation provided by a 4-blade, 40 mm impeller at 2000 rpm until homogenous. Further homogenize the final formulation for 2 minutes.

[0431] Formulation 81-19

[0432] Component No. Component Formulation Percentage (%) 1 Dow 9011 Elastomer Blend 10.45 2 Dow 9045 Elastomer Blend 10.45 3 Dow 245 Fluid 8.4 4 Jeensilc CPS-312 2.09 5 PT-50175F 1.00 6 Water 29.83 7 Plantacare 818 UP 0.55 8 Neolone PE 0.21 9 Propylene Glycol 20.87 10 Glycerin 4.16 11 Jeechem BUGL 10.44 12 Sodium Chloride 1.05 13 Nylon 10-12 0.5

[0433] Procedure:

[0434] Mix components 1-5 in a glass beaker with a 4-blade, 40 mm impeller at 2000 rpm for 2 minutes until the mixture is homogenous (mixture A). Separately, mix components 6-12 until homogenous (mixture B). Add mixture B to mixture A under vigorous agitation provided by a 4-blade, 40 mm impeller at 2000 rpm until homogenous. Then add component 13 and homogenize the resulting mixture for 2 minutes.

[0435] Formulation 81-20

[0436] Component No. Component Formulation Percentage (%) 1 Dow 9011 Elastomer Blend 10.45 2 Dow 9045 Elastomer Blend 10.45 3 Dow 245 Fluid 8.4 4 Jeensilc CPS-312 2.09 5 PT-50175F 1.00 6 Water 29.33 7 Plantacare 818 UP 0.55 8 Neolone PE 0.21 9 Propylene Glycol 20.87 10 Glycerin 4.16 11 Jeechem BUGL 10.44 12 Sodium Chloride 1.05 13 Nylon 10-12 1.0

[0437] Procedure:

[0438] Components 1-5 were mixed in a glass beaker with a 4-bladed, 40 mm impeller at 2000 rpm for 2 minutes until the mixture was homogeneous (mixture A). Separately, components 6-12 were mixed until homogeneous (mixture B). Mixture B was added to mixture A under vigorous agitation provided by a 4-bladed, 40 mm impeller at 2000 rpm until homogeneous. Component 13 was then added and the resulting mixture was homogenized for 2 minutes.

[0439] Formulation 81-21

[0440]

[0441]

[0442] Procedure:

[0443] Components 1-5 were mixed in a glass beaker with a 4-bladed, 40 mm impeller at 2000 rpm for 2 minutes until the mixture was homogeneous (mixture A). Separately, components 6-12 were mixed until homogeneous (mixture B). Mixture B was added to mixture A under vigorous agitation provided by a 4-bladed, 40 mm impeller at 2000 rpm until homogeneous. Component 13 was then added and the resulting mixture was homogenized for 2 minutes.

[0444] Formulation 79-74

[0445] Component No. Component Formulation Percentage (%) 1 Andisil VS 10,000 TM ]]> 27.58 2 Andisil VS 165,000 TM ]] 6.46 5 Andisil XL-11 TM ]]> 13.50 6 Aerosil R8200 TM ]]> 17.50 7 Schercemol TM 318Ester]]> 3.00 7 Sepiplus 400 TM ]]> 1.44 8 Water 29.29 9 Plantacare 818UP TM ]]> 0.50 11 Sodium Chloride 0.36 12 Neolone PE TM ]]> 0.36 13 Iron Oxide Tint Mixture 0.01

[0446] Procedure:

[0447] Components 1-7 were added and mixed with a dual asymmetric centrifugal mixer at 2500 RPM for 6 minutes until no more particulates were visible (mixture A). In a separate container, components 8-12 were mixed with a 4-bladed, 40 mm impeller at 550 rpm until homogeneous (mixture B). Mixture B was added dropwise to mixture A while mixing with a 4-bladed, 40 mm impeller at 400 rpm and the mixture was confirmed to be homogeneous. Component 13 was added to the product of mixture A and mixture B and mixed with a 4-bladed, 40 mm impeller at 1000 rpm until homogeneous.

[0448] Pigment dispersion formulation 80-23

[0449] Component No. Component Formulation Percentage (%) 1 Dow 9011 Elastomer Blend 10 2 Dow 9045 Elastomer Blend 10 3 Dow 245 Fluid 10 4 Water 27 5 Plantacare 818 UP 0.5 6 Neolone PE 0.5 7 Propylene Glycol 20 8 Glycerin 4 9 Jeechem BUGL 10 10 Sodium Chloride 1 11 Nylon 4.5 12 Tint 2.5

[0450] Procedure:

[0451] Mix components 1-3 in a glass beaker at 2000 rpm for 2 minutes until homogeneous (mixture A) using a 4-blade 40mm propeller. Separately, mix components 5-10 until homogeneous (mixture B). Add mixture B to mixture A with vigorous stirring provided by a 4-blade 40mm propeller at 2000 rpm until homogeneous. Then add components 11 and 12 and mix at 200 rpm until homogeneous. Then homogenize the final mixture for 2 minutes.

[0452] Formulation 79-88

[0453] Component No. Component Formulation Percentage (%) 1 Andisil VS 10,000 TM ]]> 27.59 2 Andisil VS 165,000 TM ]]> 6.46 3 Andisil XL-11 TM ]]> 13.50 4 Aerosil R8200 TM ]]> 17.50 5 Labrafac CC TM ]]> 3.00 6 Sepiplus 400 TM ]]> 1.44 7 Water 29.29 8 Plantacare 818UP TM ]]> 0.50 9 Sodium Chloride 0.36 10 Neolone PE TM ]]> 0.36

[0454] Procedure:

[0455] Combine components 1 through 4 and mix using a KitchenAid mixer for 5 hours. Then, vacuum the mixture overnight. Next, add components 5 and 6 and homogenize the mixture in a dual asymmetric centrifuge at 2500 RPM. In a separate container, mix components 7 through 10 using a 4-blade, 40 mm propeller at 550 rpm until homogeneous (mixture B). Add mixture B dropwise to mixture A while mixing using a 4-blade, 40 mm propeller at 500 rpm until the mixture is confirmed to be homogeneous.

[0456] Formulation 79-88-3A

[0457]

[0458]

[0459] Procedure:

[0460] Combine components 1 through 4 and mix using a KitchenAid mixer for 5 hours. Then, vacuum the mixture overnight. Next, add components 5 and 6 and homogenize the mixture in a dual asymmetric centrifuge at 2500 RPM. In a separate container, mix components 7 through 10 using a 4-blade, 40 mm propeller at 550 rpm until homogeneous (mixture B). Add mixture B dropwise to mixture A while mixing using a 4-blade, 40 mm propeller at 500 rpm until the mixture is confirmed to be homogeneous.

[0461] Formulation 79-74-RD

[0462] Component No. Component Formulation Percentage (%) 1 Andisil VS 500 TM ]]> 0.52 2 Andisil MV 2000 TM ]]> 0.80 3 Andisil VS 65,000 TM ]]> 13.04 4 Andisil XL-1B TM ]]> 16.84 5 Aerosil R8200 TM ]]> 8.80 6 Water 50.00 7 Veegum Pro 4.00 8 Solagum AX 1.00 9 Dow Corning 5329 5.00

[0463] Procedure:

[0464] Combine components 1 to 5 and vacuum mix (mixture A). In a separate container, mix components 6 to 7 with a 4-bladed, 40 mm impeller at 550 rpm until the mixture is homogeneous and the granules are fully wetted (mixture B). Add component 8 to mixture B and mix with a 4-bladed, 40 mm impeller at 500 rpm until the mixture thickens and becomes homogeneous. Add component 9 to mixture B and mix with a 4-bladed, 40 mm impeller at 500 rpm for 10 minutes. Slowly add mixture A to mixture B with continuous mixing at 500 rpm. Homogenize the product at 10,000 rpm for 5 minutes.

[0465] Formulation 79-90-B

[0466]

[0467]

[0468] Procedure:

[0469] Combine components 1 to 5 and vacuum mix (mixture A). In a separate container, mix components 6 to 7 with a 4-bladed, 40 mm impeller at 550 rpm until the mixture is homogeneous and the granules are fully wetted (mixture B). Add component 8 to mixture B and mix with a 4-bladed, 40 mm impeller at 500 rpm until the mixture thickens and becomes homogeneous. Add component 9 to mixture B and mix with a 4-bladed, 40 mm impeller at 500 rpm for 10 minutes. Slowly add mixture A to mixture B with continuous mixing at 500 rpm. Homogenize the product at 10,000 rpm for 5 minutes.

[0470] Formulation 88-70

[0471]

[0472]

[0473] Procedure:

[0474] Components 1-8 (part A) and components 9-11 (part B). Introduce part B to part A while mixing part A with a flat impeller blade at 500 RPM. Mix the resulting solution until a uniform emulsion is formed. Subsequently add component 12 to the emulsion.

[0475] Formulation 88-72

[0476] Component No. Component Formulation Percentage (%) 1 Andisil VS10,000 28.60％ 2 Andisil VS165,000 6.69％ 3 Andisil XL-11 13.99％ 5 Aerosil R8200 18.16％ 6 KF6013 2.08％ 7 TMF 1.5 2.25％ 8 USG 102 2.35％ 9 Pink tint mix 0.02％ 10 Deionized water 22.25％ 11 Glycerin 1.16％ 12 Jeen BUGL 1.24％ 13 Veegum Ultra Granules 0.11％ 14 Kaolin USP BC2747 0.10％ 15 Jeecide Cap-5 1.00％

[0477] Procedure:

[0478] Components 1-9 were mixed (Phase A) separately from components 10-14 (Phase B). Phase B was added to Phase A while mixing with 4 paddle propeller blades at 500 RPM, then homogenized with a Silverson homogenizer at 3000 to 5000 RPM for 1 hour. Subsequently, component 15 was added using mixing blades at 200 rpm.

[0479] Formulation 88-75-2

[0480]

[0481]

[0482] Procedure:

[0483] Components 1-4 were mixed (Phase A). Separately, components 5-9 were also mixed (Phase B) until a uniform dispersion was formed. Separately, components 10-12 were also mixed (Phase C). Phase C was slowly introduced into Phase B while mixing with a 4-blade propeller bar at 700 RPM to produce a uniform emulsion (Phase D). Phase D was slowly introduced into Phase A at 700 RPM until uniform and the resulting formulation was mixed for 5 minutes. Component 13 was added and mixed for 2 minutes.

[0484] Formulation 88-75-3

[0485]

[0486]

[0487] Procedure:

[0488] Components 1-4 were mixed (Phase A). Separately from Phase A, components 5-9 were mixed (Phase B) until a uniform dispersion was formed. Separately from Phase A and Phase B, components 10-12 were also mixed (Phase C). Phase C was slowly introduced into Phase B while mixing with a 4-blade propeller bar at 700 RPM to produce a uniform emulsion (Phase D). Phase D was slowly introduced into Phase A at 700 RPM until uniform and mixed for 5 minutes. Component 13 was then introduced to the resulting formulation and mixed for 2 minutes, then homogenized at 5000 RPM for 15 minutes.

[0489] Formulation 88-80

[0490]

[0491]

[0492] Procedure:

[0493] Mix components 1-4 (Phase A). Separately from Phase A, mix components 5-9 (Phase B) until a uniform dispersion is formed. Separately from Phase A and Phase B, also mix components 10-12 (Phase C). Slowly introduce Phase C into Phase B while mixing with a 4-bladed impeller bar at 700 RPM to produce a uniform emulsion (Phase D). Add component 13 to Phase D and mix for 2 minutes. Slowly introduce the resulting emulsion into Phase A at 700 RPM until uniform and mix for 5 minutes, then homogenize at 9000 RPM for 7 minutes.

[0494] Formulation 88-85-1

[0495] Component No. Component Formulation Percentage (%) 1 RM 2051 3.28％ 2 FZ 3196 4.92％ 3 USG 102 12.11％ 4 Water 48.83％ 5 Jeecide CAP-5 0.87％ 6 Andisil VS10,000 12.72％ 7 Andisil VS165,000 2.98％ 8 Andisil XL-11 6.23％ 9 Aerosil R8200 8.08％

[0496] Procedure:

[0497] Mix components 1-3 (Phase A). Add component 4 while mixing Phase A until a white emulsion is formed. Mix components 6-9 (Phase B) and subsequently add Phase B to the emulsion and mix at 1300 RPM for 5 minutes. Homogenize the resulting formulation (Silverson) for 5 minutes and add component 5, then mix with an impeller blade at 700 RPM for 2 minutes.

[0498] Formulation 88-85-2

[0499]

[0500]

[0501] Procedure:

[0502] Mix components 1-3 (Phase A). Mix component 4 while mixing Phase A until a white emulsion is formed. Separately mix components 6-9 (Phase B) and subsequently add to the emulsion while mixing at 1300 RPM for 5 minutes. Homogenize the mixture (Silverson) for 5 minutes. Add component 5 and mix the resulting formulation with an impeller blade at 700 RPM for 2 minutes.

[0503] Formulation 88-83-V2

[0504] Component No. Component Formulation Percentage (%) 1 RM 2051 3.3％ 2 FZ 3196 3.3％ 3 DC 2-1184 Fluid 10.0％ 4 USG 102 3.3％ 5 Water 46.3％ 6 Jeecide CAP-5 0.3％ 7 Andisil VS 10,000 14.1％ 8 Andisil VS 165,000 3.3％ 9 Andisil XL-11 6.9％ 10 Aerosil R8200 9.0％

[0505] Procedure:

[0506] Mix components 1-4 (Phase A), subsequently add component 5 until a white emulsion is formed. Add component 6 to the emulsion and mix for 5 minutes (emulsion base). Separately mix components 7-10 (Phase B) and add to the emulsion base at 1300 RPM, then mix for 5 minutes and homogenize (Silverson) for 10 minutes.

[0507] Formulation 88-83-V3

[0508] Component No. Component Formulation Percent (%) 1 RM 2051 3.3％ 2 DC 2-1184 fluid 13.3％ 3 Water 49.7％ 4 Jeecide CAP-5 0.3％ 5 Andisil VS 10,000 14.1％ 6 Andisil VS 165,000 3.3％ 7 Andisil XL-11 6.9％ 8 Aerosil R8200 9.0％

[0509] Procedure:

[0510] Mix components 1 and 2 (Phase A), then add component 3 until a white emulsion is formed. Add component 4 to the emulsion and mix for 5 minutes (emulsion base). Separately mix components 5-8 (Phase B) and add to the emulsion base at 1300 RPM, then mix for 5 minutes and homogenize (Silverson) for 10 minutes.

[0511] Formulation 83-54

[0512] Reactive ingredient and enhancer ingredient combination (vinyl, hydride, fumed silica)

[0513]

[0514]

[0515]

[0516] Procedure:

[0517] Formulation 83-54 was prepared by a procedure similar to 88-83-V3.

[0518] Andisil VS10,000, Andisil VS165,000, Andisil XL-11 were obtained from Anderson and Associates, Aerosil R8200 was obtained from Evonik, and these four components were mixed by Crisil. RM2051 Thickening Agent and PMX-1184 were obtained from Dow. Gransurf 90 was obtained from Grant. Vitamin-C complex and Vitamin A complex were obtained from DSM. Jeecide CAP-5 was obtained from Jeen. Tween 20 was obtained from Croda. Vitamin-E complex was obtained from TRI-K.

[0519] The second step of the crosslinking component included Formulations 60-148-99, 60-144-San 86-114, and 86-141c shown below.

[0520] Formulation 60-148-99

[0521]

[0522]

[0523] Procedure:

[0524] Combine components 1-6 and mix with 4-bladed 40 mm impeller at 750 RPM for 2 minutes until homogeneous to produce the water phase. In a separate container, mix components 7-10 with 4-bladed 40 mm impeller at 750 RPM for 2 minutes until homogeneous to produce the silicone mixture A. Add components 11 and 12 to the water phase and mix with 4-bladed 40 mm impeller at 750 RPM. Increase the mixing speed to 1000 RPM and mix the mixture until homogeneous and thickened. Add component 13 and stir at 1000 RPM for 1 minute, then homogenize at 25,000 RPM for 5 minutes.

[0525] Formulation 60-144-San

[0526]

[0527] Procedure:

[0528] Carefully blend components 1 and 2 with 4-bladed 40 mm impeller blade at 250 RPM until Carbopol is fully wetted and the mixture is free of white particulates. Add components 3 and 4 with moderate agitation provided by 4-bladed 40 mm impeller at 500 RPM. Add component 5 dropwise with moderate agitation provided by 4-bladed 40 mm impeller at 550 RPM until the mixture is homogeneous and thickened. Add component 6 with moderate agitation provided by 4-bladed 40 mm impeller at 550 RPM, then mix at 1000 RPM for 5 minutes until the mixture is homogeneous.

[0529] Formulations 86-114 and 86-141c

[0530]

[0531]

[0532]

[0533]

[0534] Procedure of 86-114:

[0535] Combine components 1-3 and mix at 750 RPM for two minutes until homogeneous to create the silicone phase. In a separate container, combine components 4-11 and 13 and mix at 750 RPM for 15 minutes until homogeneous to create the water phase. Slowly add the water phase to the silicone phase and mix at 750 RPM. Increase the mixing speed to 2000 RPM and mix the mixture until homogeneous and thickened. Add component 12 and stir at 1000 RPM for 5 minutes. Add component 14 and stir at 1000 RPM for 5 minutes.

[0536] Procedure of 86-141c:

[0537] Combine components 1-4 and mix at 750 RPM for two minutes until homogeneous to create the silicone phase. In a separate container, combine components 5-12 and 14 and mix at 750 RPM for 15 minutes until homogeneous to create the water phase. Slowly add the water phase to the silicone phase and mix at 750 RPM. Increase the mixing speed to 2000 RPM and mix the mixture until homogeneous and thickened. Add component 13 and stir at 1000 RPM for 5 minutes. Add component 15 and stir at 1000 RPM for 5 minutes.

[0538] Example 6: 2 day double blind study to evaluate 2 different formulations for achieving cosmetic benefits on aged skin

[0539] Objective: The purpose of the study was to identify a lead candidate from 2 different formulation candidates for follow-on confirmatory clinical studies. The selection criteria were based on immediate visual improvement in the appearance of fine lines, evenness of skin tone, skin texture and pore appearance, and duration of effect over six hours. An additional purpose was to determine the ease of application of each formulation when applied by the typical user, i.e., self-application.

[0540] Background: This trial was an early development project focused on the use of a polysiloxane-based reactive system for topical human use. At this time, performance evaluation studies have been limited to supervised, restricted use applications. The systems evaluated included a vinyl-terminated polysiloxane, a hydride-functionalized polysiloxane, fumed silica particles, and a platinum catalyst. In these studies, the polysiloxane system was applied to the skin surface and cured by the addition of a platinum catalyst.

[0541] Test Material Composition: The formulation compositions under consideration generally include the following ingredients:

[0542] ■ a vinyl-terminated polysiloxane,

[0543] ■ a hydride-functionalized polysiloxane,

[0544] ■ fumed silica particles,

[0545] ■ a platinum catalyst, and

[0546] ■ commercially available cosmetic ingredients.

[0547] The molecular weights of the polysiloxanes under consideration all exceed 600 Daltons. The polysiloxane compositions evaluated are summarized in the table below. These represent upper concentration ranges of the siloxane and fumed silica materials present in the total formulation. For example, the addition of a 50% level of cosmetic ingredients would result in a 2-fold dilution of each ingredient, such that Composition No. 1 would be 35% vinyl terminated polysiloxane, 15% hydride functional polysiloxane, 0% fumed silica, and 50% commercially available cosmetic ingredients. The platinum catalyst in the final formulation is always present at a concentration of less than 500 ppm. The two treatments tested were Formulations 60-140-1 and 60-140-LX2 and the crosslinking component used was 60-148-99.

[0548] Subject Inclusion:

[0549] Number of Subjects: Approximately 25 subjects were screened for a total of 20 subjects to be enrolled to ensure a minimum of 15 subjects complete the study.

[0550] Informed Consent and Authorization: Each subject was given two copies of the informed consent statement prior to the start of the study. The subject was given the opportunity to have her questions answered to her satisfaction. However, if there were other questions, the subject was given sufficient time at the first visit for the investigator to clarify any outstanding questions and concerns about the study and / or the informed consent prior to signing.

[0551] Subject Identification: The subject was assigned a three-digit number which, when used in conjunction with the clinical study number, uniquely identified each subject in the study. This number belonged to the subject throughout the study.

[0552] Eligibility Criteria: Fitzpatrick Skin Classification is based on the unprotected appearance response of the skin to the first 30 to 45 minutes of sun exposure after a winter without sun. The classification of skin types is as follows:

[0553] I Always sunburn easily; never tans

[0554] II Always sunburn easily; lightly tans

[0555] III Moderately sunburns, gradually tans

[0556] IV Slightly sunburns; always tans

[0557] V Rarely sunburns; completely tans

[0558] VI Never sunburns; deeply pigmented

[0559] Inclusion:

[0560] 1. 30-65 years of age

[0561] 2. Female

[0562] 3. Fitzpatrick skin type I-IV

[0563] 4. Show some visible signs of facial aging, including but not limited to: large pores, fine lines and wrinkles, or poor skin tone / textur

[0564] 5. Willing to cooperate and participate in the study for the duration of the study and to report any adverse symptoms in a timely manner

[0565] 6. Produce little or no erythema at the treatment site due to sun exposure during the treatment period

[0566] 7. Be able to refrain from using the topical skin care products included in the study on the treatment area during the course of the study.

[0567] Exclusion:

[0568] 1. Fitzpatrick skin type V-VI

[0569] 2. Individuals with known history of allergy or sensitivity to the cosmetic study cream ingredients

[0570] 3. Individuals with known genetic allergies, skin diseases or neurodermatitis

[0571] 4. Females known to be pregnant, nursing or planning to become pregnant within 6 months

[0572] 5. Individuals known to be treating for cancer or have a history of cancer

[0573] 6. Individuals with visible sunburn, tanning, scarring, uneven tone / pigmentation, or other skin conditions on the trial area that can affect the trial results

[0574] 7. Any active skin conditions (e.g., tattoos, eczema, psoriasis, rosacea, acne, etc.) that can interfere with clinical assessment

[0575] Study Procedure: Table 2 below outlines the procedures performed at each visit of the study:

[0576] Table 2

[0577]

[0578] Preparation: The two formulations are randomized so that neither the investigator nor the photographer knows the identity of each formulation before any panelists arrive.

[0579] Photography: The panelists were photographed under two different lighting conditions (parallel polarized lighting and orthogonal polarized lighting) and at two different camera angles (90°, 45°) relative to the plane of the face. The panelists were positioned in a facial positioning system to reduce ventral-dorsal rotation and to position the face at approximately the same position relative to the camera each time. The "Photo Setup Capture" instance is mentioned in the "Image Analysis Measurements" section

[0580] Visit 1:

[0581] 1. Upon arrival, the individual receives an evaluation for exclusion / inclusion criteria and is recruited into the study when they meet the requirements

[0582] 2. Upon recruitment, the subject is briefed on the study and the informed consent form and the subject signs after answering all questions about the study adequately (with a witness)

[0583] 3. After signing all paperwork, the subject is assigned the next available subject number

[0584] 4. The subject is tested for both formulations according to the randomization scheme and then applied by the investigator to a small area on the subject's arm and allowed to remain for 5 minutes to determine any sensitivity to the product

[0585] 5. If the panelist is not sensitive to the product, they wash their face with a mild facial cleanser

[0586] 6. After washing the face, a baseline photo of the subject's entire face is taken

[0587] 7. After the baseline photograph, the subject is asked to apply the test material to the entire upper half of their face (below the eyes to the hairline, avoiding the area below the cheekbones), using the fingers for application under supervision

[0588] 8. The panelist is then photographed after 2-5 minutes to obtain the post-application photo

[0589] 9. The panelist is then asked to complete a questionnaire about the test product applied

[0590] 10. The investigator completes an on-site evaluation of the panelist for efficacy against the baseline

[0591] 11. The panelist is then allowed to leave for 6-8 hours and given the following instructions:

[0592] a. Do not scrub or rub the face

[0593] b. Do not shower or wet the face

[0594] c. Apply other products to the face

[0595] d. If any adverse events occur in the application area, the panelist should call the investigator and be evaluated and the film removed.

[0596] 12. Once the panelist returns, take a photograph of them and the panelist and investigator complete the evaluation form

[0597] 13. If a skilled in-house assessor is scheduled for that evening, inform the panelist to wait until the assessment period, at which time the assessor scores the appearance of the panelist against their baseline photograph

[0598] 14. After the assessment, give the panelist the evaluation form to record their impressions and comments on each product

[0599] 15. After the assessment is complete, the panelist is informed to remove the products using make-up remover and do so

[0600] 16. Apply a commercially available skin care moisturiser containing SPF 15 to the panelist's face as a moisturiser

[0601] 17. The panelist is then dismissed

[0602] Visit 2:

[0603] 1. On arrival, the panelist washes their face with a mild facial cleanser

[0604] 2. After washing the face, take a baseline photograph of the whole face of the subject

[0605] 3. After the baseline photograph, give the subject instructions on the method of application of each formulation (see below) and allow each formulation to be applied to the whole of the upper half of their face (switching the side of application compared to the previous visit) according to the randomisation scheme in Appendix A

[0606] 4. Continue the procedure as described in step 7 of visit 1

[0607] Photographic Analysis:

[0608] After the study is complete, the "baseline", "after application" and "6-8 hours later" photographs are compiled into a blinded deck of cards and submitted to a skilled assessor who scores the degree of wrinkling in each photograph using the Griffiths scale shown below:

[0609] ■0-1 : No damage

[0610] ■2-3 : Slight damage

[0611] ■4-5 : Moderate damage

[0612] ■6-7: moderate to severe damage

[0613] ■8-9: severe damage

[0614] The combination card deck is such that the time point of the photograph to be evaluated is unknown. This eliminates any bias towards the expected result from the evaluation. Since the Griffiths score is an absolute score, the difference from baseline is then calculated in the data analysis.

[0615] Results:

[0616] Evaluation Form: A scale of -2, -1, 0, +1, +2 (for significant decrease / increase, some decrease / increase, no decrease / increase, some increase / decrease, and significant increase / decrease) is created for all different parameters evaluated according to the Investigator Evaluation Form. For each formulation, the mean value based on this scale among the panelists is determined along with the standard deviation to give an indication of the performance of each attribute to be evaluated.

[0617] The same scale of -2, -1, 0, +1, +2 is applied according to the Assessor Evaluation Form to obtain the same statistical data on the evaluations contained therein. From these mean values and standard deviations, the confidence in the ability of each individual formulation to affect the parameter under study is determined.

[0618] The Panelist Evaluation Form is based on a scale of -1, 0, +1 for each attribute to be evaluated. The mean value based on this scale for each panelist is determined both after application and after duration to give an indication of the short-term and long-term performance. The trend of this result is evaluated for correlation with the results of the Assessor and Investigator Evaluation Forms.

[0619] Comments on all three forms are tracked and checked for any similarities, since the skilled assessors do not perform the evaluations every week, only the consistency of the efficacy of each formulation for the Investigator and Panelist forms is compared for each week, regardless of which side of the face each formulation is applied to.

[0620] Photographic Analysis: For the post-clinic photograph analysis, the evaluator assigns a Griffiths score to each photograph. The average change in this score from the corresponding baseline photograph gives an indication of the efficacy of each formulation in smoothing fine lines and wrinkles and producing a more youthful appearance for each formulation. These results are compared for correlation with the in-situ assessments.

[0621] Summary of Week 2 Results: As shown in Table 3 below, the durability of 60-140-LX2 is far inferior to that of 60-140-1.

[0622] Table 3

[0623] Formulation Non-Failure % n＝ 60-140-LX2 65.38％ 26 60-140-1 86.84％ 38

[0624] The researchers' assessment of panelists revealed two significant differences between the performance of the two formulations (see Table 2). Figure 3 ) Formulation 60-140-LX2 showed a significantly higher overall improvement in the appearance of forehead wrinkles. Conversely, 60-140-1 showed a significantly higher improvement in the appearance of wrinkles under the eyes. This is significant because it confirms the hypothesis that a softer formulation should be applied to the thinner skin under the eyes to achieve a positive result. Alternatively, because the skin on the forehead is thicker, a harder film can be needed to cause a more significant reduction in wrinkles. According to the researchers' assessment, oil control, fine line reduction, and pore reduction were the top three overall performance attributes.

[0625] The evaluators were able to distinguish differences between the two formulations for three attributes (see Table 3). Figure 4 ) Formulation 60-140-LX2 showed a significantly greater increase in the appearance of younger skin and a natural feel compared to 60-140-1, while formulation 60-140-1 showed a significantly better taut appearance compared to 60-140-LX2. All other attributes showed no significant difference between the two formulations. The top three attributes for the best overall change observed showed that, regardless of formulation, reduced pores and improved fine lines consistently showed the most dramatic improvement compared to baseline.

[0626] The panelist data showed no significant difference between the two formulations tested (see Table 4). Figure 5 ) The highest average score item for 60-140-LX2 was the appearance of the taut attribute. The difference between 60-140-LX2 and 60-140-1 for this attribute was not significant (p ~ 0.24), but it was the most significantly different attribute of those examined below. The sample size was very small for this study, so the difference can not be significantly perceptible without further testing. One hypothesis as to why this attribute was above younger looking, wrinkling, and oil control is that the panelists can have perceived a stronger taut feeling with 60-140-LX2 and therefore scored the formulation higher than 60-140-1. Regardless of this result, the top three attributes for performance were younger looking overall, reduced wrinkling, and oil control. Although pore size was not prominent for the evaluators and researchers among the panelists, this attribute consistently ranked high. This can be because the panelists did not remember their baseline pore size.

[0627] Finally, the evaluators were asked to estimate the age of the panelists at each evaluation. The difference between this age and their actual age was then calculated, and it was found that 60-140-LX2 had a more significant impact on age estimation, -8.7 years, compared to 60-140-1, -7.7 years (see Table 5). Figure 6

[0628] ​The Griffith scores of the panelists were also assessed using the pre- and post- photos. Figure 7 The average Griffith score results from the blinded evaluation of the panelists' photos are shown. For both instances, the average Griffith score decreased by 2.15 points and 1.25 points after application of the formulations 60-140-LX2 and 60-140-1, respectively. This result is consistent with Figure 4 and 5 where the panelists appeared younger after application of the formulations.

[0629] Investigator's Assessment: Significant improvements in the appearance of reduced wrinkles, pores, and shine were observed. According to the Investigator's Assessment, treatment of the upper half of the face of the panelists with the two formulations (60-140-LX2 and 60-140-1) selected from the first week reduced the appearance of fine wrinkles of the panelists. 60-140-LX2 reduced the appearance of fine wrinkles by 100% while 60-140-1 reduced it by 96% (Table 4). These formulations also reduced deep wrinkles, to a lesser extent than fine wrinkles (75% and 67%, respectively).

[0630] Table 4

[0631]

[0632] Among the different types of wrinkles, the 60-140-LX2 and 60-140-1 formulations showed the greatest reduction in the area of wrinkles on the forehead (94% and 93%) and crow's feet (96% and 87%). They also showed a moderate reduction in the wrinkles under the eyes (81% and 79%) along with the forehead frown wrinkles (deep wrinkles of #11), which were only slightly reduced (58% and 31%) (Table 5).

[0633] Table 5

[0634]

[0635] For both treatments, the pores on the forehead appeared to be reduced by 100% and the pores on the cheeks also appeared to be reduced by 50% and 67% after treatment with 60-140-LX2 and 60-140-1, respectively (Table 6).

[0636] Table 6

[0637]

[0638] Both formulations reduced the appearance of shine on the treated skin of the panelists (Table 6).

[0639] Table 7

[0640] Shine? Saw a decrease No decrease or worse From 60-140-LX2 100.00％ 0.00％ 26 60-140-1 95.00％ 5.00％ 40

[0641] All of the aesthetic properties of these two formulations were similar in terms of wrinkle, pore, and shine reduction. However, the mechanical properties showed differences in film integrity and failure, with the harder film showing failure modes such as flaking and cracking (see Tables 8 and 9)

[0642] Table 8

[0643] Formulation Non-Failure % From 60-140-LX2 65.38％ 26 60-140-1 86.84％ 38

[0644] Table 9

[0645] Other Problems Breakouts Flakiness Whitening From 60-140-LX2 26.92％ 11.54％ 34.62％ 26 60-140-1 2.63％ 2.63％ 44.74％ 38

[0646] Formulation 60-140-1 showed greater film durability after forming on the skin surface and only about 13% showed film failure as measured by film cracking and flaking. However, 60-140-LX2 showed greater film failure (35%), indicating poor film durability when the film was formed on the skin resulted in a large amount of film cracking (27%) and flaking (12%). Overall, 60-140-1 was able to provide an "all day" durable film and was the desired skin care treatment that improved the appearance of the skin by reducing wrinkles, pores, and shine.

[0647] Evaluator's Assessment: Evaluator ratings showed a reduction in wrinkles, pores, and shine on the panelists' coated skin. The wrinkle reduction from treatment by 60-140-LX2 and 60-140-1 was similar (Table 10).

[0648] Table 10

[0649]

[0650]

[0651] The evaluators noted a significant reduction in pores (Table 11) and an improvement in oil control (Table 12) in the panelists' skin after treatment. Based on the evaluators' ratings, the panelists' skin tone also improved slightly and the skin appeared taut (Table 11).

[0652] Table 11

[0653]

[0654] Table 12

[0655] Oil Control Improved Group No change or worse From 60-140-LX2 99.00％ 1.00％ 100 60-140-1 98.13％ 1.88％ 160

[0656] While both formulations appeared to give the skin a more youthful appearance, 60-140-LX2 showed greater improvement in producing a youthful appearance (90%) and having a natural feel (86%) compared to the 60-140-1 formulation (73% and 79%, respectively) (Table 13). A surprising observation was also made regarding the tactile feel of the skin treated with these formulations.

[0657] Table 13

[0658]

[0659] The top three descriptors that the evaluators chose to describe the feel of the treated skin were silky, smooth, and / or soft (Table 14)

[0660] Table 14

[0661]

[0662] Example 7: Development of a cleanser for removing body correction compositions

[0663] It was found that commercially available cleansers were not very effective at removing the film formed after application of the body correcting composition of the present application. To evaluate the performance of the cleansers, a film was applied to the facial skin of a volunteer. After 6-8 hours, the cleanser was rubbed onto the film and left on the film for 30 seconds. The subject was then instructed to remove the swelled film by gently wiping it from the skin with a washcloth of given surface roughness. The following commercially available products were tested:

[0664] ■Philosophy Purity Made Simple

[0665] ■Shiseido Benefiance Creamy Cleansing foam

[0666] ■Noxema

[0667] ■Estee Lauder Perfectly Clean Splash Away Foaming Cleanser

[0668] ■Makeup forever sens'eyes

[0669] ■Loreal go 360 clean deep

[0670] ■Clinique Naturally Gentle Eye Makeup Remover

[0671] ■Olay Total Effects 7-in-1 Antiaging Cleanser

[0672] ■Olay Dual Action Cleanser and Pore Scrub

[0673] ■Garnier Skin Renew

[0674] ■Lancome Bi-Facil double action makeup remover

[0675] ■Neutrogena Deep Clean Invigorating Foaming Scrub

[0676] ■Olay Regenerist Daily Regenerating Cleanser

[0677] ■CVS Pharmacy Deep Cleansing Makeup Remover

[0678] ■Neutrogena Ageless essentials Continuous Hydration Cream Cleanser

[0679] ■CVS Cleansing and Makeup Remover

[0680] ■Yes to cucumbers natural glow facial towelettes

[0681] Since none of the foregoing products are effective at removing the film, a cleanser was prepared that disrupts the mechanical integrity of the film and facilitates delivery of the cleanser components into the film. Without being bound by theory, the removal mechanism can be described in four steps, the primary formulation components of each step are shown in parentheses:

[0682] 1. Wetting the film (Silsoft 034, Silsoft ETS, 5CS Polydimethylsiloxane)

[0683] 2. Penetrating the formulation components (Silicone emulsifier, Silicone phase, Glycols, Cremaphor EL)

[0684] 3. Swelling the film (Silsoft 034, Silsoft ETS, Isododecane, 5CS Polydimethylsiloxane)

[0685] 4. Detaching the film from the skin (Glycols, Water)

[0686] Silsoft 034, Silsoft ETS, 5CS Polydimethylsiloxane readily wet the surface of the film. The silicone emulsifier or Cremaphor EL incorporates the aqueous phase into the silicone phase and can facilitate delivery of the film swelling components into the film. Silsoft 034, Isododecane, and Silsoft ETS help to swell the film and mechanically disrupt it. This enables penetration of the aqueous phase, hydration of the skin, and reduction of the film's adhesion to the skin.

[0687] The following Tables 15-17 provide compositions that are effective at removing the film:

[0688] Table 15

[0689] Silicone Phase ]]> ​ w / w gm Silsoft 034 (Caprylyl Polymethylsiloxane) 9.7％ 5 Isododecane 19.4％ 10 Silsoft ETS (Ethyl Trisiloxane) 19.4％ 10 Aerogel VM2270 1.5％ 0.763 Silicone Emulsifier ]]> ​ Shin Etsu KSG 820 3.9％ 2 Shin Etsu KF 6038 3.9％ 2 Aqueous Phase ]]> ​ Propylene Glycol 4.9％ 2.5 Butylene Glycol 4.9％ 2.5 Glycerin 1.9％ 1 MP Diol 7.8％ 4 Deionized Water 19.4％ 10 Neolone PE 0.5％ 0.27 Chronosphere Optical Bright 0.6％ 0.3 Granpowder Nylon 2.1％ 1.1

[0690] Table 16

[0691]

[0692]

[0693] Table 17

[0694]

[0695] Procedure:

[0696] Mix components 1-4 and 9 until a clear dispersion is formed (Phase A). Separately mix compounds 5-8 until a uniform solid dispersion is formed. Then add Phase A to Phase B and mix.

[0697] Example 8: Viscosity Measurements

[0698] The viscosity of a fluid can be measured by many methods known to those skilled in the art. In particular, "The rheology handbook: for users of rotational and oscillatory rheometers By Thomas G. Mezger" or ASTM standards such as ASTM D3835-08, ASTM D2857-95, ASTM D2196-10 and ASTM D2983-09 teach those skilled in the art how to measure the viscosity of a fluid. Exemplary methods also include the following methods:

[0699] Method A

[0700] I. SUMMARY

[0701] The protocol measures viscosity (cP) on a Brookfield viscometer. The protocol can be performed on a variety of formulations including, but not limited to, immediate effects treatments and perfectors.

[0702] II. BACKGROUND

[0703] The viscosity of a formulation is critical to its performance and aesthetics. Also, changes in viscosity over time or upon exposure to stress conditions are important indicators of formulation instability. Therefore, it is important to be able to reproducibly and accurately assess the viscosity of a formulation. The following protocol can be used to measure the viscosity of a formulation having a viscosity of 50 to 300 Pas at a single shear rate.

[0704] III. MATERIALS

[0705] • 2 oz to 8 oz jar filled with the target formulation

[0706] • Brookfield DV-II+ Pro EXTRA viscometer and RV-6 spindle

[0707] • ~5 minutes per sample test

[0708] IV. ANALYTICAL PRECAUTIONS

[0709] • Clean the viscometer geometry prior to use

[0710] • Insert the geometry into the center of the sample to the appropriate depth

[0711] • Ensure that the container is stationary during the test

[0712] V. PROTOCOL

[0713] 5.1 Preparation of the apparatus:

[0714] 1. Turn on the Brookfield DV-II+ Pro EXTRA viscometer by pressing the switch on the back of the instrument. Select "External Mode" by pressing the up arrow key on the instrument control panel.

[0715] 2. Start the Rheocalc software, the shortcut to which can be found on the desktop

[0716] 3. Zero the viscometer by clicking the lightning bolt symbol on the Dashboard tab (the instrument geometry should not be installed)

[0717] 4. Find the RV-6 test geometry and clean with a 50% / 50% IPA / Mineral Spirits mixture, then wipe dry

[0718] 5. Insert the RV-6 geometry by pulling the instrument geometry collet up

[0719] 6. Select the test method by clicking the Test tab and opening the Hold 0.5-RV6-081511.RCP method.

[0720] 5.2 Preparing the Sample:

[0721] 1. No special sample preparation is required, except for a visual inspection to ensure that the sample appears uniform.

[0722] 5.3 Performing the Viscosity Measurement:

[0723] 1. Insert the geometry into a 2 to 8 oz sample under the following conditions:

[0724] i. Make sure the geometry is inserted to the correct measurement height, as indicated by the slice of the geometry's spindle

[0725] ii. Make sure the geometry is centered in the jar

[0726] 2. Adjust the stand to keep the sample and geometry in the proper relative position

[0727] 3. Click the small play button on the Test tab to start the test

[0728] 4. Name the data file appropriately and save the file to an appropriate location

[0729] 5. Allow the test to run to completion, then save your data for subsequent analysis

[0730] 6. To test another sample:

[0731] i. Slide the sample protrusion and remove the sample from the instrument

[0732] ii. Remove the geometry from the instrument and gently wipe all surfaces with a 50% IPA, 50% Mineral Spirit mixture. Dry with a lint free wipe.

[0733] iii. Replace the geometry, return to the Test tab and begin the next test

[0734] 7. After the last test sample is complete, clean the geometry with a 50% IPA, 50% Mineral Spirit mixture, then wipe dry and return to the geometry box.

[0735] VI. Data Analysis

[0736] 1. Open the data file (*.DB) and click on the Output button to obtain an excel file containing the data.

[0737] 2. Position the Viscometer Perfector Template_JL-081511-vl-beta l.xlsx Excel template for data analysis

[0738] 3. Paste the data into the first page

[0739] 4. Record the average viscosity and standard deviation

[0740] 5. Save the template as a new electronic record with a new name referencing the sample being analyzed.

[0741] 1. Repeat the analysis for each data set

[0742] Method B

[0743] I. Overview

[0744] This protocol measures the viscosity (Pas) at 0.5 1 / s, the shear thinning factor (Pa*s^2), and the strain rate of instability. This protocol can be performed on a variety of formulations including, but not limited to, Immediate Effects treatments and the perfector along with any other "cream" or "lotion".

[0745] II. Background

[0746] The viscosity of a formulation and its change is related to the stability of the formulation. Therefore, it is important to be able to reproducibly and accurately evaluate its viscosity properties as a predictor of the stability of the Immediate Effects active prototype. The following protocol can be used to measure the viscosity, the shear thinning factor, and the strain rate of instability.

[0747] III. Materials

[0748] • >1 g of the target formulation

[0749] • Bohlin CVO 100 Rheometer equipped with 20 mm parallel plate geometry

[0750] • Each sample test takes ~ 12 minutes

[0751] IV. Analysis Precautions

[0752] • Cleaning the sides of the geometry is critical for accurate test results

[0753] • Any deviations must be recorded

[0754] V. Procedure

[0755] 5.1 Preparation of the instrument:

[0756] 8. Set up the Bohlin Rheometer

[0757] a. Turn on the instrument

[0758] b. Turn on the temperature controller

[0759] c. Start the Bohlin software

[0760] d. Load the Viscosity Stability Test template

[0761] e. Make sure the geometry and plate are clean

[0762] 9. Install the geometry

[0763] a. Zero the instrument and you are ready to test.

[0764] 10. To test multiple samples simply raise the geometry and clean with a dry wipe, then with a 50% / 50% IPA / Mineral Spirits mixture, and then with a dry wipe again.

[0765] 5.2 Preparation of the sample:

[0766] 1. No special sample preparation is required, except to perform a visual inspection to ensure the sample appears uniform.

[0767] VI. Conducting the Viscosity Measurement

[0768] 7. Place ~ 1 g of the mixed material on the floor of the centering plate, under the geometry

[0769] 8. Lower the geometry to the correct gap (250 um)

[0770] 9. Clean the sides of the geometry with the flat end of the spatula, removing excess material

[0771] 10. Allow the test to run to completion, then save your data for subsequent analysis

[0772] 11. To continue with the next test, raise the geometry and remove the geometry from the instrument. Gently wipe all surfaces clean with a 50% ipa / 50% mineral spirits mixture. Dry with a lint-free wipe.

[0773] 12. Immediately prepare to begin the next cure test

[0774] VII. Data Analysis:

[0775] 2. Set up the following Excel Template for data analysis Viscosity Stability Template 061411-v2

[0776] 3. Paste the appropriate raw instrument data from the Bohlin Viscometry Data File file into the excel document on page 1 (near the left corner) in A:2

[0777] 4. Paste the sample name into the excel document on page 1 in A:1

[0778] 5. Record the calculated "Viscosity at 0.5 1 / s (Pas)" as the Viscosity

[0779] 6. Record the calculated "Shear Thinning Factor (Pa*s^2)" as the Shear Thinning Factor

[0780] 7. Record the calculated "Strain Rate of Instability" as the Strain Stability (scale out of 100)

[0781] 8. Save the completed template as an electronic record with an appropriate file name

[0782] 9. Repeat steps 2 through 7 for the raw data

[0783] Equivalents

[0784] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific polypeptides, nucleic acids, methods, assays, and agents described herein. Such equivalents are considered to be within the scope of this application and encompassed by the following claims.

[0785] The aspects of the application can be summarized as follows:

[0786] Aspect 1. A body correction formulation for application to the skin, comprising:

[0787] a) a reactive enhancing component; and

[0788] b) a crosslinking component;

[0789] wherein the cross-linking component catalyzes in situ cross-linking of the reactive enhancing component to form a body correction film on the skin, and wherein the film has the appearance of natural skin when applied to the body.

[0790] Scheme 2. A two-part body correction formulation for application to skin, comprising:

[0791] a) a reactive enhancing component; and

[0792] b) a cross-linking component;

[0793] wherein the reactive enhancing component and the cross-linking component are prevented from contacting prior to use; and

[0794] wherein the cross-linking component catalyzes in situ cross-linking of the reactive enhancing component to form a body correction film on the skin.

[0795] Scheme 3. A body correction formulation for application to skin, comprising:

[0796] a) a reactive enhancing component; and

[0797] b) a cross-linking component;

[0798] wherein the reactive enhancing component has a viscosity of about 50,000 to 500,000 cSt or cP at 25 °C; and

[0799] wherein the cross-linking component catalyzes in situ cross-linking of the reactive enhancing component to form a body correction film on the skin.

[0800] Scheme 4. A body correction formulation for application to skin, comprising:

[0801] a) a reactive enhancing component; and

[0802] b) a cross-linking component;

[0803] wherein the reactive enhancing component has a vinyl to functional hydride ratio of about 1 : 10 to about 1 : 100;

[0804] wherein the cross-linking component catalyzes in situ cross-linking of the reactive enhancing component to form a body correction film on the skin.

[0805] Scheme 5. The formulation of any one of Schemes 2-4, wherein the reactive enhancing component and the cross-linking component are prevented from reacting with each other prior to use.

[0806] Scheme 6. The formulation of any one of Schemes 1-4, wherein the reactive enhancing component comprises a reactive ingredient and an enhancing ingredient.

[0807] Scheme 7. The formulation of Scheme 6, wherein the reactive ingredient comprises at least one organopolysiloxane and at least one hydride-functional polysiloxane.

[0808] Scheme 8. The formulation of Scheme 7, wherein the organopolysiloxane is a high viscosity organopolysiloxane or a low viscosity organopolysiloxane or a combination thereof.

[0809] Scheme 9. The formulation of Scheme 8, wherein the high viscosity organopolysiloxane has a viscosity of about 100,000 to about 500,000 cSt or cP at 25 °C.

[0810] Scheme 10. The formulation of Scheme 8, wherein the high viscosity organopolysiloxane is selected from the group consisting of: a vinyl-terminated polydimethylsiloxane; a vinyl-terminated diphenylsiloxane-dimethylsiloxane copolymer; a vinyl-terminated polyphenylmethylsiloxane, a vinylphenylmethyl terminated vinylphenylsiloxane-phenylmethylsiloxane copolymer; a vinyl-terminated trifluoropropylmethylsiloxane-dimethylsiloxane copolymer; a vinyl-terminated diethylsiloxane-dimethylsiloxane copolymer; a trimethylsiloxy-terminated vinylmethylsiloxane-dimethylsiloxane copolymer; a silanol-terminated vinylmethylsiloxane-dimethylsiloxane copolymer; a vinyl-terminated vinylmethylsiloxane-dimethylsiloxane copolymer; a vinyl gum; a vinylmethylsiloxane homopolymer; a vinyl T-structure polymer; a monovinyl terminated polydimethylsiloxane; a vinylmethylsiloxane terpolymer; a vinylmethoxysilane homopolymer and combinations thereof.

[0811] Scheme 11. The formulation of Scheme 8, wherein the high viscosity organopolysiloxane is vinyl-terminated.

[0812] Scheme 12. The formulation of Scheme 8, wherein the high viscosity organopolysiloxane is a polydimethylsiloxane.

[0813] Scheme 13. The formulation of Scheme 8, wherein the high viscosity organopolysiloxane has a vinyl weight percent of about 0.05 to about 0.1.

[0814] Scheme 14. The formulation of Scheme 8, wherein the high viscosity organopolysiloxane has a vinyl equivalent per kilogram of about 0.001 to about 0.05.

[0815] Scheme 15. The formulation of Scheme 8, wherein the low viscosity organopolysiloxane has a viscosity of about 1,000 to about 50,000 cSt or cP at 25 °C.

[0816] Scheme 16. The formulation of Scheme 8, wherein the low viscosity organopolysiloxane has a vinyl weight percent of from about 0.01 to about 0.5.

[0817] Scheme 17. The formulation of Scheme 8, wherein the low viscosity organopolysiloxane has a vinyl equivalent per kilogram of from about 0.001 to about 0.1.

[0818] Scheme 18. The formulation of Scheme 8, wherein the low viscosity organopolysiloxane is selected from the group consisting of: a vinyl terminated polydimethylsiloxane; a vinyl terminated diphenylsiloxane-dimethylsiloxane copolymer; a vinyl terminated polyphenylmethylsiloxane, a vinyl phenylmethyl terminated vinyl phenylsiloxane-phenylmethylsiloxane copolymer; a vinyl terminated trifluoropropylmethylsiloxane-dimethylsiloxane copolymer; a vinyl terminated diethylsiloxane-dimethylsiloxane copolymer; a trimethylsiloxy terminated vinylmethylsiloxane-dimethylsiloxane copolymer; a silanol terminated vinylmethylsiloxane-dimethylsiloxane copolymer; a vinyl terminated vinylmethylsiloxane-dimethylsiloxane copolymer; a vinyl gum; a vinylmethylsiloxane homopolymer; a vinyl T-structured polymer; a monovinyl terminated polydimethylsiloxane; a vinylmethylsiloxane terpolymer; a vinylmethoxysilane homopolymer; and combinations thereof.

[0819] Scheme 19. The formulation of Scheme 18, wherein the low viscosity organopolysiloxane is vinyl terminated.

[0820] Scheme 20. The formulation of Scheme 8, wherein the low viscosity organopolysiloxane is vinyl terminated.

[0821] Scheme 21. The formulation of Scheme 8, wherein the low viscosity organopolysiloxane is a vinyl terminated polydimethylsiloxane.

[0822] Scheme 22. The formulation of Scheme 7, wherein the hydride-functionalized polysiloxane has a viscosity of from about 2 to 10,000 cSt or cP at 25 °C.

[0823] Scheme 23. The formulation of Scheme 7, wherein the hydride-functionalized polysiloxane has a SiH content percent of from about 5 to about 75%.

[0824] Scheme 24. The formulation of Scheme 7, wherein the hydride-functionalized polysiloxane has a SiH content of from about 0.5 to about 10 mmol / g.

[0825] Scheme 25. The formulation of Scheme 7, wherein the hydride-functionalized polysiloxane is selected from the group consisting of hydride-terminated polydimethylsiloxane; hydride-terminated polyphenyl-(dimethylhydromethylsiloxy)siloxane; hydride-terminated methylhydrosiloxane-phenylmethylsiloxane copolymer; trimethylsiloxy-terminated methylhydrosiloxane-dimethylsiloxane copolymer; trimethylsiloxy-terminated polymethylhydrosiloxane; polyethylhydrosiloxane, triethylsiloxane, methylhydrosiloxane-phenyl octylmethylsiloxane copolymer; methylhydrosiloxane-phenyl octylmethylsiloxane terpolymer, and combinations thereof.

[0826] Scheme 26. The formulation of Scheme 25, wherein the hydride-functionalized polysiloxane is alkyl-terminated.

[0827] Scheme 27. The formulation of Scheme 25, wherein the hydride-functionalized polysiloxane is trimethylsiloxy-terminated methylhydrosiloxane-dimethylsiloxane copolymer.

[0828] Scheme 28. The formulation of Scheme 7, wherein the hydride-functionalized polysiloxane has at least 2 Si-H units.

[0829] Scheme 29. The formulation of Scheme 28, wherein the hydride-functionalized polysiloxane has at least 3 Si-H units.

[0830] Scheme 30. The formulation of any one of Schemes 1-3, wherein the reactive enhancement component has a vinyl organopolysiloxane to functional hydride molar ratio of about 1:10 to about 1:100.

[0831] Scheme 31. The formulation of Scheme 6, wherein the enhancement ingredient has a surface area of about 100 to about 300 m 2 / g.

[0832] Scheme 32. The formulation of Scheme 6, wherein the enhancement ingredient has an average particle size of about 1 to about 20 pm.

[0833] Scheme 33. The formulation of Scheme 6, wherein the enhancement ingredient is selected from the group consisting of optionally surface-treated mica, zinc oxide, titanium dioxide, aluminum oxide, clay, or silica.

[0834] Scheme 34. The formulation of Scheme 33, wherein the enhancement ingredient is silica.

[0835] Scheme 35. The formulation of Scheme 34, wherein the silica is fumed silica.

[0836] Scheme 36. The formulation of Scheme 35, wherein the fumed silica is surface treated with hexamethyldisilazane.

[0837] Scheme 37. The formulation of Scheme 6, wherein the reactive enhancing component further comprises one or more of a slip agent, a spreadability enhancer, a viscosity modifier, a diluent, a tackiness modifier, an optical modifier, a particulate, a volatile siloxane, an emulsifier, an emollient, a surfactant, a thickener, a solvent, a film former, a humectant, a preservative, and a pigment.

[0838] Scheme 38. The formulation of Scheme 6, wherein the reactive ingredients and enhancing ingredients comprise about 20 to 90% of the reactive enhancing component.

[0839] Scheme 39. The formulation of Scheme 6, wherein the enhancing ingredients are about 2 to about 11% of the reactive enhancing component.

[0840] Scheme 40. The formulation of Scheme 6, wherein the reactive ingredients comprise about 18 to about 50% of the reactive enhancing component.

[0841] Scheme 41. The formulation of any one of Schemes 1-4, wherein the crosslinking component comprises a metal catalyst.

[0842] Scheme 42. The formulation of Scheme 41, wherein the catalyst is a platinum catalyst.

[0843] Scheme 43. The formulation of Scheme 42, wherein the catalyst is selected from the group consisting of platinum carbonyl cyclovinylmethylsiloxane complex, platinum divinyltetramethyldisiloxane complex, platinum cyclovinylmethylsiloxane complex, platinum octanal / octanol complex, and combinations thereof.

[0844] Scheme 44. The formulation of Scheme 41, wherein the catalyst comprises about 1 to about 5% of the crosslinking component.

[0845] Scheme 45. The formulation of Scheme 41, wherein the catalyst comprises about 0.005 to about 0.04% of the crosslinking component.

[0846] Scheme 46. The formulation of Scheme 41, wherein the crosslinking component further comprises one or more of a slip agent, a spreadability enhancer, a viscosity modifier, a diluent, a tackiness modifier, an optical modifier, a particulate, a volatile siloxane, an emulsifier, an emollient, a surfactant, a thickener, a solvent, a film former, a humectant, a preservative, and a pigment.

[0847] Scheme 47. The formulation of Schemes 1-46, wherein the formulation further comprises a cosmetic or therapeutic agent.

[0848] Scheme 48. A body correction film prepared by a method comprising the steps of:

[0849] a) applying a reactive enhancement component to the skin; and

[0850] b) applying a crosslinking component to the reactive enhancement component,

[0851] wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancement component to form a body correction film on the skin.

[0852] Scheme 49. A body shaping film prepared by a method comprising the steps of:

[0853] a) applying a reactive enhancement component to the body; and

[0854] b) applying a crosslinking component to the reactive enhancement component,

[0855] wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancement component to form a body shaping film on the skin.

[0856] Scheme 50. The film according to Scheme 48 or 49, wherein the film is formed in less than 5 minutes.

[0857] Scheme 51. The film according to Scheme 48 or 49, wherein the film has a leather adhesion greater than about 20 N / mm.

[0858] Scheme 52. The film according to Scheme 48 or 49, wherein the film has a Young's modulus of about 0.01 to about 1 MPa.

[0859] Scheme 53. The film according to Scheme 48 or 49, wherein the film has a strain at break of at least about 150%.

[0860] Scheme 54. The film according to Scheme 48 or 49, wherein the film has a hysteresis of less than about 5%.

[0861] Scheme 55. The film according to Scheme 48 or 49, wherein the film has a tack of about 20 N / mm to about 80 N / mm.

[0862] Scheme 56. The film according to Scheme 48 or 49, wherein the film has a thickness of less than about 100 microns.

[0863] Scheme 57. The film according to Scheme 48 or 49, wherein the film has a shrinkage of less than about 1 to about 15%.

[0864] Scheme 58. The film according to Scheme 48 or 49, wherein the film has the appearance of natural skin when applied to the body.

[0865] Scheme 59. The film according to Scheme 48 or 49, wherein the film provides near- youthful elasticity and recoil upon application to the body.

[0866] Scheme 60. A method for correcting a skin defect of a subject's skin comprising applying to the subject's skin a formulation comprising:

[0867] a) a first reactive enhancing component; and

[0868] b) a second crosslinking component;

[0869] wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a film on the skin, thereby correcting a skin defect.

[0870] Scheme 61. A method for protecting a subject's skin comprising applying to the subject's skin a formulation comprising:

[0871] a) a first reactive enhancing component; and

[0872] b) a second crosslinking component;

[0873] wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a film on the skin, thereby protecting the skin.

[0874] Scheme 62. The method according to Scheme 61, wherein the film protects the skin from sun, wind, rain, or environmental toxins.

[0875] Scheme 63. A method for shaping a subject's body comprising applying to the subject's body a formulation comprising:

[0876] a) a first reactive enhancing component; and

[0877] b) a second crosslinking component;

[0878] wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancing component to form a film on the skin, thereby shaping the body.

[0879] Scheme 64. The method according to Scheme 63, wherein the film shapes the body by providing support to soft body tissue.

[0880] Scheme 65. The method according to Scheme 64, wherein the film prevents sagging of soft body tissue.

[0881] Scheme 66. The method of Scheme 64 or 65, wherein the pliable body tissue comprises the skin of the abdomen, buttocks, thighs, neck, eyebrows, jaw, chest, under the arms, and around the eyes.

[0882] Scheme 67. A method for delivering a medicament to a subject comprising applying to the skin of the subject a formulation comprising:

[0883] a) a first reactive enhancement component optionally comprising one or more medicaments; and

[0884] b) a second crosslinking component optionally comprising one or more medicaments;

[0885] wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancement component to form a film on the skin, thereby delivering the medicament to the subject.

[0886] Scheme 68. The method of Scheme 67, wherein the medicament is a cosmetic or therapeutic agent.

[0887] Scheme 69. A body correction composition for application to the body of a subject comprising at least one preselected functional modulating component, wherein the composition forms a body correction film upon application to the body of a subject, and wherein the film has the appearance of natural skin.

[0888] Scheme 70. A body correction composition for targeting a treatment area on the body of a subject comprising at least one preselected treatment specific component, wherein the composition forms a body correction film upon application to the targeted treatment area of the body of a subject, and wherein the film has the appearance of natural skin.

[0889] Scheme 71. A film removal cleanser for removing a body correction film, wherein the film is prepared by a method comprising:

[0890] a) applying a reactive enhancement component to the skin; and

[0891] b) applying a crosslinking component to the reactive enhancement component,

[0892] wherein the crosslinking component catalyzes in situ crosslinking of the reactive enhancement component.

[0893] Scheme 72. A film removal cleanser comprising a film wetting component, a penetrating component, a film swelling component, and a film removing component.

[0894] Scheme 73. The cleanser of Scheme 72, wherein the film wetting component comprises caprylyl methicone, ethyl trisiloxane, or a combination thereof.

[0895] Scheme 74. The cleanser of Scheme 72, wherein the penetrating component comprises a silicone emulsifier, caprylyl methicone, ethyl trisiloxane, or a combination thereof.

[0896] Scheme 75. The cleanser of Scheme 72, wherein the membrane swelling component comprises caprylyl methicone, ethyl trisiloxane, isododecane, or a combination thereof.

[0897] Scheme 76. The cleanser of Scheme 72, wherein the membrane removing component comprises one or more glycols, water, or a combination thereof.

[0898] Scheme 77. The cleanser of Scheme 71 or 72, wherein the cleanser disrupts the mechanical integrity of the membrane.

[0899] Scheme 78. The cleanser of Scheme 71 or 72, wherein the cleanser comprises a silicone phase, an emulsifier system, and an aqueous phase.

[0900] Scheme 79. The cleanser of Scheme 78, wherein the silicone phase comprises caprylyl methicone, isododecane, and ethyl trisiloxane.

[0901] Scheme 80. The cleanser of Scheme 78, wherein the emulsifier phase comprises a silicone emulsifier.

[0902] Scheme 81. The cleanser of Scheme 78, wherein the aqueous phase comprises water, propylene glycol, butylene glycol, glycerin, or a combination thereof.

[0903] Scheme 82. The cleanser of Scheme 79, wherein the silicone phase is about 50% of the cleanser.

[0904] Scheme 83. The cleanser of Scheme 79, wherein the emulsifier phase is about 8% of the cleanser.

[0905] Scheme 84. The cleanser of Scheme 79, wherein the aqueous phase is about 42% of the cleanser.

[0906] Scheme 85. The cleanser of Scheme 71 or 72, wherein the cleanser is formulated as a cosmetic preparation.

[0907] Scheme 86. A method of cleaning a body surface having a body correction membrane, comprising applying an effective amount of a membrane-removing cleanser to the membrane to cause removal of the membrane.

[0908] Scheme 87. A formulation for use in repairing a body correction membrane applied to skin, wherein the formulation comprises

[0909] a) a first reactive enhancing component and

[0910] b) a second cross-linking component

[0911] wherein the cross-linking component catalyzes in situ cross-linking of the reactive enhancing component to form a film on the skin.

[0912] Scheme 88. A method for repairing a body correction film applied to the skin, comprising the steps of

[0913] a) identifying an area of the film in need of repair;

[0914] b) optionally smoothing the edges of the film; and

[0915] c) applying a formulation for repairing the film, wherein the formulation comprises a first reactive enhancing component and a second cross-linking component

[0916] wherein the cross-linking component catalyzes in situ cross-linking of the reactive enhancing component to form a film on the skin, thereby repairing the body correction film.

[0917] Scheme 89. A kit for repairing a body correction film, the kit comprising a formulation comprising

[0918] a) a first reactive enhancing component and

[0919] b) a second cross-linking component

[0920] wherein the cross-linking component catalyzes in situ cross-linking of the reactive enhancing component to form a film on the skin.

[0921] Scheme 90. The kit of Scheme 89, wherein the kit further comprises one or more brushes, one or more swabs, a film-removing cleanser, or a mirror.

[0922] Scheme 91. The kit of Scheme 89, wherein the kit further comprises a finishing formulation.

[0923] Scheme 92. The method of any one of Schemes 1-47 or 87, wherein the formulation further comprises a finishing formulation applied to the film after formation of the film.

[0924] Scheme 93. The method of any one of Schemes 48-59, further comprising a finishing formulation applied to the film after formation of the film.

[0925] Scheme 94. The method of any one of Schemes 60-68 or 88, wherein the method further comprises applying a finishing formulation to the film after formation of the film.

[0926] Scheme 95. The composition of Scheme 70 or 71, wherein the composition further comprises a finishing formulation applied to the film after the film is formed.

[0927] Scheme 96. The formulation of any one of Schemes 1-47, 87, and 92, further comprising a pigment dispersion formulation.

[0928] Scheme 97. The formulation of Scheme 96, wherein the pigment dispersion formulation is applied before or after the reactive enhancement component is applied to the skin.

[0929] Scheme 98. The formulation of Scheme 96, wherein the pigment dispersion formulation is applied before or after the crosslinking component is applied to the skin.

[0930] Scheme 99. The formulation of Scheme 96, wherein the pigment dispersion formulation is applied between the application of the reactive enhancement component to the skin and the application of the crosslinking component to the skin.

[0931] Scheme 100. The film of any one of Schemes 48-59 and 93, further comprising applying a pigment dispersion formulation.

[0932] Scheme 101. The film of Scheme 100, wherein the pigment dispersion formulation is applied before or after the reactive enhancement component is applied to the skin.

[0933] Scheme 102. The film of Scheme 100, wherein the pigment dispersion formulation is applied before or after the crosslinking component is applied.

[0934] Scheme 103. The film of Scheme 100, wherein the pigment dispersion formulation is applied after the reactive enhancement component is applied but before the crosslinking component is applied to the skin.

[0935] Scheme 104. The method of any one of Schemes 60-68, 88, or 94, further comprising the step of applying a pigment dispersion formulation.

[0936] Scheme 105. The method of Scheme 104, wherein the pigment dispersion formulation is applied before or after the reactive enhancement component is applied to the skin.

[0937] Scheme 106. The method of Scheme 104, wherein the pigment dispersion formulation is applied before or after the crosslinking component is applied.

[0938] Scheme 107. The method of Scheme 104, wherein the pigment dispersion formulation is applied after the reactive enhancement component is applied but before the crosslinking component is applied to the skin.

[0939] Scheme 108. The composition of Scheme 70, 71, or 95, further comprising a pigment dispersion formulation.

[0940] Scheme 109. The kit of Scheme 89-91, further comprising a pigment dispersion formulation.

Claims

1. A body correction composition, wherein the composition comprises: a. a reactive enhancing component comprising i. a reactive ingredient comprising at least one vinyl functional organopolysiloxane and at least one hydride functional polysiloxane ingredient; and ii. an enhancing ingredient, wherein the enhancing ingredient is selected from the group consisting of surface treated silica; and b. a crosslinking component comprising a metal catalyst; and wherein said cross-linking component catalyzes cross-linking reactions of said composition to form a film in situ on the body of a subject, characterized in that the formation of the film is substantially complete within five minutes after application to the skin of a subject's body at ambient temperature; and the reactive enhancing component has a vinyl to functional hydride ratio of 1 : 10 to 1 : 100; the reactive ingredient and enhancing ingredient comprise 20 to 90 percent by weight of the reactive enhancing component; wherein the metal catalyst is a platinum catalyst; wherein the at least one vinyl functional organopolysiloxane of the reactive enhancing component has the formula Ha: wherein R 1a’ , R 3a’ , R 4a’ , R 5a’ , R 6a’ , R 8a’ , R 9a’ and R 10a’ are each independently selected from hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxy and p and q are each independently an integer from 10 to 6000; and the vinyl-functional organopolysiloxane is a vinyl-terminated polydimethylsiloxane; and wherein the reactive ingredient comprises at least one hydride functional polysiloxane of the formula III: wherein R 1b , R 2b , R 3b , R 6b , R 7b , and R 8b are each independently C 1-20 alkyl; R 4b , R 5b , R 9b , and R 10b are each independently selected from the group consisting of hydrogen, C 1-20 alkyl, and C 5-10 aryl, wherein at least two of R 4b , R 5b , R 9b , and R 10b are hydrogen; and m and n are each independently an integer from 10 to 6000; and the hydride-functional polysiloxane is a hydridopolymethylsiloxane.

2. The body correction composition of claim 1, wherein the reactive enhancing component has a viscosity of 5,000 to 1,000,000 cSt or cP at 25 °C.

3. The body correction composition of claim 1, wherein the at least one vinyl functional organopolysiloxane of the reactive enhancing component has a viscosity of 110,000 to 450,000 cSt or cP at 25 °C.

4. The body correction composition of claim 1, wherein the at least one hydride functional organopolysiloxane has a viscosity of 30 to 100 cSt or cP at 25 °C.

5. The body correction composition of claim 1, wherein the enhancing ingredient comprises 2 to 11 percent by weight of the reactive enhancing component.

6. The body correction composition of claim 1, wherein the catalyst comprises 0.005 to 0.04 percent of the crosslinking component.

7. The body correction composition of claim 1, wherein the reactive enhancing component and the crosslinking component are prevented from contacting prior to use.

8. The body correction composition of claim 1, wherein the crosslinking component further comprises at least one organopolysiloxane, optionally wherein the organopolysiloxane is an alkenyl functional organopolysiloxane or a vinyl terminated organopolysiloxane.

9. The body correction composition of claim 2, wherein the reactive enhancing component has a viscosity of 200,000 cSt or cP at 25 °C.

10. The body correction composition of claim 2, wherein the reactive enhancing component has a viscosity of 100,000 cSt or cP at 25 °C.

11. The body correction composition of claim 2, wherein the reactive enhancing component has a viscosity of 90,000 cSt or cP at 25 °C.

12. The body correction composition of claim 2, wherein the reactive enhancing component has a viscosity of 80,000 cSt or cP at 25 °C.

13. The body correction composition of claim 2, wherein the reactive enhancing component has a viscosity of 70,000 cSt or cP at 25 °C.

14. The body correction composition of claim 2, wherein the viscosity of the reactive enhancement component is 60,000 cSt or cP at 25°C.

15. The body correction composition of claim 2, wherein the viscosity of the reactive enhancement component is 50,000 cSt or cP at 25°C.

16. The body correction composition of claim 2, wherein the viscosity of the reactive enhancement component is 40,000 cSt or cP at 25°C.

17. The body correction composition of claim 2, wherein the viscosity of the reactive enhancement component is 30,000 cSt or cP at 25°C; or the viscosity of the reactive enhancement component is 20,000 cSt or cP at 25°C.

18. The body correction composition of claim 3, wherein the viscosity of the at least one vinyl functional organopolysiloxane of the reactive enhancement component is 125,000 to 350,000 cSt or cP at 25°C.

19. The body correction composition of claim 3, wherein the viscosity of the at least one vinyl functional organopolysiloxane of the reactive enhancement component is 130,000 to 300,000 cSt or cP at 25°C.

20. The body correction composition of claim 3, wherein the viscosity of the at least one vinyl functional organopolysiloxane of the reactive enhancement component is 135,000 to 250,000 cSt or cP at 25°C.

21. The body correction composition of claim 3, wherein the viscosity of the at least one vinyl functional organopolysiloxane of the reactive enhancement component is 140,000 to 200,000 cSt or cP at 25°C.

22. The body correction composition of claim 3, wherein the viscosity of the at least one vinyl functional organopolysiloxane of the reactive enhancement component is 150,000 to 185,000 cSt or cP at 25°C.

23. The body correction composition of claim 3, wherein the viscosity of the at least one vinyl functional organopolysiloxane of the reactive enhancement component is 165,000 cSt or cP at 25°C.

24. The body correction composition of claim 8, wherein the viscosity of the organopolysiloxane of the crosslinking component is at least 100 cSt or cP at 25°C.

25. The body correction composition of claim 1, wherein the weight percent vinyl of the at least one vinyl functional organopolysiloxane of the reactive enhancement component is 0.01 to 0.

1.

26. The body correction composition of claim 25, wherein the weight percent vinyl of the at least one vinyl functional organopolysiloxane of the reactive enhancement component is 0.02 to 0.

075.

27. The body correction composition of claim 25, wherein the weight percent vinyl of the at least one vinyl functional organopolysiloxane of the reactive enhancement component is 0.025 to 0.

06.

28. The body correction composition of claim 25, wherein the at least one vinyl functional organopolysiloxane of the reactivity enhancing component has a vinyl weight percent of 0.03 to 0.

05.

29. The body correction composition of claim 4, wherein the hydride functionalized polysiloxane has a viscosity of 40 to 50 cSt or cP at 25 °C.

30. The body correction composition of claim 4, wherein the hydride functionalized polysiloxane has a viscosity of 45 cSt or cP at 25 °C.

31. The body correction composition of claim 4, wherein the hydride functionalized polysiloxane has a viscosity of 50 cSt or cP at 25 °C.

32. The body correction composition of claim 1, wherein the hydride functionalized polysiloxane is selected from the group consisting of: hydride terminated polydimethylsiloxane; hydride terminated polyphenyl-(dimethylhydromethylsiloxy)siloxane; hydride terminated methylhydrosiloxane-phenylmethylsiloxane copolymer; trimethylsiloxy terminated methylhydrosiloxane-dimethylsiloxane copolymer; trimethylsiloxy terminated polymethylhydrosiloxane; polyethylhydrosiloxane, triethylsiloxane, methylhydrosiloxane-phenyl octylmethylsiloxane copolymer; methylhydrosiloxane-phenyl octylmethylsiloxane terpolymer; and combinations thereof.

33. The body correction composition of claim 1, wherein the hydride functionalized polysiloxane has a percent SiH content of 3 to 45%.

34. The body correction composition of claim 33, wherein the hydride functionalized polysiloxane has a percent SiH content of 5 to 40%.

35. The body correction composition of claim 33, wherein the hydride functionalized polysiloxane has a percent SiH content of 10 to 35%.

36. The body correction composition of claim 1, wherein the hydride functionalized polysiloxane has a SiH content of 0.5 to 10 mmol / g.

37. The body correction composition of claim 36, wherein the hydride functionalized polysiloxane has a SiH content of 1 to 9 mmol / g.

38. The body correction composition of claim 36, wherein the hydride functionalized polysiloxane has a SiH content of 2 to 8 mmol / g.

39. The body correction composition of claim 36, wherein the hydride functionalized polysiloxane has a SiH content of 3 to 7 mmol / g.

40. The body correction composition of claim 1, wherein the hydride functionalized polysiloxane is alkyl terminated.

41. The body correction composition of claim 40, wherein the hydride functionalized polysiloxane is trimethylsiloxy terminated methylhydrosiloxane-dimethylsiloxane copolymer.

42. The body correction composition of claim 1, wherein the hydride functionalized polysiloxane has at least 2 Si-H units.

43. The body correction composition of claim 42, wherein the hydride functionalized polysiloxane has at least 3 Si-H units.

44. The body correction composition of claim 42, wherein the hydride-functionalized polysiloxane has 8 Si-H units.

45. The body correction composition of claim 1, wherein the surface area of ​​the reinforcing component is 100 to 300 m². 2 / g.

46. The body correction composition of claim 45, wherein the surface area of the reinforcing element is 110 to 250 m2 / g. 2 / g.

47. The body correction composition of claim 45, wherein the surface area of the reinforcing element is 120 to 225 m 2 / g.

48. The body correction composition of claim 1, wherein the reinforcing component has an average particle size of 1 to 20 μιη.

49. The body correction composition of claim 1, wherein the silica is fumed silica.

50. The body correction composition of claim 49, wherein the fumed silica is surface treated with hexamethyldisilazane.

51. The body correction composition of claim 1, wherein the platinum catalyst is selected from the group consisting of platinum carbonyl cyclovinylmethyl siloxane complex, platinum divinyltetramethyldisiloxane complex, platinum cyclovinylmethyl siloxane complex, platinum octanal / octanol complex, and combinations thereof.

52. The body correction composition of claim 6, wherein the catalyst comprises 0.02% of the crosslinking component.

53. The body correction composition of claim 6, wherein the catalyst comprises 0.025% of the crosslinking component.

54. The body correction composition of claim 1, wherein the reactive reinforcing component further comprises one or more diluents.

55. The body correction composition of claim 1, wherein the reactive reinforcing component further comprises a volatile siloxane.

56. The body correction composition of claim 1, wherein the composition, the reactive reinforcing component, and / or the crosslinking component further comprises one or more additives.

57. The body correction composition of claim 56, wherein the one or more additives are selected from the group consisting of emulsifiers, and the emulsifiers are selected from the group consisting of alkyl dimethicone, alkyl dimethicone, amodimethicone, sulfodimethicone, phosphodimethicone, borodimethicone, halodimethicone, fluorodimethicone, chlorodimethicone, bromodimethicone, charged dimethicone, and combinations thereof.

58. The body correction composition of claim 1, wherein the reactive reinforcing component further comprises 10,000 cSt vinyl terminated polydimethylsiloxane.

59. The body correction composition of claim 1, wherein the crosslinking component further comprises a vinyl terminated organopolysiloxane.

60. A body correction film for non-therapeutic purposes made by a method comprising the steps of: a) applying the reactive-enhancing component in the composition of any one of claims 1-59 to the skin of the subject; and b) applying the crosslinking component of the composition of any one of claims 1-59 to the skin of a subject; wherein the crosslinking component catalyzes a crosslinking reaction to form a film in situ on the subject's body, characterized in that the formation of the film is substantially complete within five minutes after application to the skin of the subject's body at ambient temperature.

61. The film of claim 60, wherein the film has a leather adhesion greater than 20 N / mm.

62. The film of claim 61, wherein the film has a Young's modulus of 0.01 to 1 MPa.

63. The film of claim 62, wherein the strain at break is at least 150%.

64. The film of claim 63, wherein the film has a hysteresis of less than 5%.

65. The film of claim 64, wherein the film has a tack of 20 N / mm to 80 N / mm.

66. The film of claim 65, wherein the film has a thickness of less than 100 microns.

67. The film of claim 66, wherein the film has a shrinkage of less than 1 to 15%.

68. A kit comprising: a. a reactivity enhancing component of the body correction composition of any one of claims 1-59; b. a crosslinking component of the body correction composition of any one of claims 1-59.

69. The kit of claim 68, further comprising instructions for use.

70. A formulation for application to skin comprising: a. a reactivity enhancing component comprising i. a reactive ingredient comprising at least one organopolysiloxane and at least one hydride functional polysiloxane; and ii. an enhancing ingredient, wherein the enhancing ingredient is selected from the group consisting of surface treated silica; and b. a crosslinking component comprising at least one catalyst; wherein the crosslinking component facilitates a reaction to form a film in situ on the skin; and the reactivity enhancing component has a vinyl to functional hydride ratio of 1:10 to 1:100; the reactive ingredient and enhancing ingredient comprise 20 to 90 wt% of the reactivity enhancing component; wherein the catalyst is a platinum catalyst; wherein the at least one vinyl functional organopolysiloxane of the reactivity enhancing component has the formula Ha: wherein R 1a’ , R 3a’ , R 4a’ , R 5a’ , R 6a’ , R 8a’ , R 9a’ and R 10a’ are each independently selected from hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxy and p and q are each independently integers from 10 to 6000; and the vinyl-functional organopolysiloxane is a vinyl-terminated polydimethylsiloxane; and wherein the reactive ingredient comprises at least one hydride functional polysiloxane of formula III: wherein R 1b , R 2b , R 3b , R 6b , R 7b , and R 8b are each independently C 1-20 alkyl; R 4b , R 5b , R 9b , and R 10b are each independently selected from hydrogen, C 1-20 alkyl, and C 5-10 aryl, wherein at least two of R 4b , R 5b , R 9b , and R 10b are hydrogen; and m and n are each independently an integer from 10 to 6000; and the hydride-functional polysiloxane is a hydridopolymethylsiloxane.

Images